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ABSTRACT
Limitations in current model systems for researching bone repair have 
hampered the development of alternative clinical therapies. This thesis aimed 
to develop and validate an ex vivo rat mandible model, to investigate specific 
molecular and cellular processes involved in bone repair. Maintenance of cell 
and tissue architecture and viability was shown within mandible slices 
cultured for up to 21 days, both intact and fractured. Autoradiographic studies 
showed that resident cells were actively synthesising and secreting proteins, 
and cells of the osteoblast lineage were shown to survive throughout the 
culture period. The model was responsive to exogenously added growth 
factors TGF-p1 and BMP-2, with increased cellular migration / proliferation 
and expression of bone matrix proteins observed. A second model system, 
an in vitro bone slab cell culture system, demonstrated that endogenous 
growth factors could be released from the matrix of bone by chemicals such 
as EDTA, calcium hydroxide, and sodium hydroxide. Different growth factor 
release kinetics were observed with each treatment, and released growth 
factors were capable of actively influencing the behaviour of osteogenic cells. 
Pre-treatment of mandible slices with these chemical treatments yielded 
similar results, with an observed increase in cell number, proliferation, and 
bone matrix protein expression. The ex vivo mandible model developed 
within this study may represent an ideal system for investigating specific 
processes of bone repair, as well as a promising alternative to in vivo testing 
of novel clinical therapeutics.
IV
CONTENTS
CHAPTER 1 
INTRODUCTION
Contents Page
GENERAL INTRODUCTION 1
1.1 Bone Biology 4
1.1.1 General Bone Composition and Organisation 4
1.1.2 Bone Structure and Types 5
1.1.3 Embryonic Bone Formation 8
1.1.4 Post-natal Bone Remodelling 9
1.2 Bone Repair 10
1.2.1 Primary / Direct Healing 11
1.2.2 Secondary / Indirect Healing 11
1.2.3 Osteoblasts and their Role in Bone Repair and Remodelling 13
1.2.4 Osteoclasts and their Role in Bone Repair and Remodelling 16
1.2.5 Osteocytes and their Role in Bone Repair and Remodelling 21
1.2.6 Signals Involved in Bone Repair and Remodelling 23
1.2.6.1 Transforming Growth Factor Beta 24
1.2.6.2 Bone Morphogenetic Proteins 27
1.2.6.3 Platelet Derived Growth Factor 30
1.2.6.4 Vascular Endothelial Growth Factor 31
1.2.6.5 Fibroblast Growth Factors and Insulin-like
Growth Factors 32
V
1.2.6.6 Wnts 33
1.2.6.7 Sonic Hedgehog 34
1.2.7 Major Transcription Factors Involved in Bone Repair 35
1.2.8 Major Proteins Expressed in Bone Repair 37
1.2.8.1 Type I Collagen 38
1.2.8.2 Osteopontin 39
1.2.8.3 Osteocalcin 41
1.2.8.4 Osteonectin 42
1.2.8.5 Bone Sialoprotein 43
1.2.8.6 Alkaline Phosphatase 43
1.2.9 Impaired Bone Healing 44
1.3 Biomimetic Matrices 45
1.3.1 Clinical Treatments: Bone Autograft and Allograft 47
1.3.2 Clinical Treatments: Growth Factor Therapy 48
1.4 Modelling of Bone Repair 50
1.4.1 Current Models 50
1.4.2 Ex Vivo Modelling 51
1.5 Aims 53
VI
CHAPTER 2 
ORGAN CULTURE OF INTACT AND FRACTURED RAT
MANDIBLE SLICES
2.1 Introduction 54
Section A - Establishment of optimal conditions for the organ culture of intact 
rat mandible slices
2.2 Materials and Methods 56
2.2.1 Preparation of tissue culture reagents 56
2.2.2 Organ culture of intact mandible slices 57
2.2.3 Histological examination 60
2.2.4 Cell viability assessment 61
2.2.5 Tritiated proline pulse chase 61
2.2.6 Immunohistochemistry 64
2.3 Results 67
2.3.1 Histology and viability of intact mandible slices 67
2.3.1.1 Uncultured intact mandible slices 67
2.3.1.2 24 hour culture of intact mandible slices 69
2.3.1.3 7 day culture of intact mandible slices 73
2.3.1.4 14 day culture of intact mandible slices 76
2.3.1.5 21 day culture of intact mandible slices 79
2.3.2 Synthetic and secretory activity of intact mandible slices 83
2.3.2.1 7 day culture of radiolabelled intact mandible slices 83
2.3.2.2 14 day culture of radiolabelled intact mandible
slices 83
VII
2.3.3 Immunohistochemical characterisation 88
2.3.3.1 PCNA immunolocalisation 88
2.3.3.2 Alkaline phosphatase immunolocalisation 88
2.3.3.3 Osteopontin immunolocalisation 89
2.4 Discussion 93
Section B - Organ culture of fractured mandible slices
2.5 Materials and Methods 101
2.5.1 Organ culture of fractured mandible slices 101
2.5.2 Histological examination 101
2.5.3 Cell viability assessment 102
2.5.4 Tritiated proline pulse chase 102
2.5.5 Immunohistochemistry 102
2.6 Results 104
2.6.1 Histology and viability of fractured mandible slices 104
2.6.1.1 24 hour culture of fractured mandible slices 106
2.6.1.2 7 day culture of fractured mandible slices 108
2.6.1.3 14 day culture of fractured mandible slices 110
2.6.1.4 21 day culture of fractured mandible slices 112
2.6.2 Synthetic and secretory activity of fractured mandible slices 115
2.6.2.1 7 day culture of radiolabelled fractured mandible
slices 115
2.6.2.2 14 day culture of radiolabelled fractured mandible
slices 115
2.6.3 Immunohistochemical characterisation 120
2.6.3.1 PCNA immunolocalisation 120
VIII
2.6.3.2 Alkaline phosphatase immunolocalisation 120
2.6.3.3 Osteopontin immunolocalisation 121
2.7 Discussion 128
CHAPTER 3
GROWTH FACTOR STIMULATION OF THE EX VIVO FRACTURED
MANDIBLE MODEL
3.1 Introduction 132
3.2 Materials and Methods 135
3.2.1 Cellular stimulation of fractured mandible slices with TGF-p1 135
3.2.2 Cellular stimulation of fractured mandible slices with BMP-2 136
3.2.3 Histological examination 136
3.2.4 Immunohistochemistry 137
3.3 Results 139
3.3.1 Histology of TGF-p1 and BMP-2 stimulated mandible slices 139
3.3.2 Immunohistochemical characterisation of stimulated cells 145
3.3.2.1 PCNA immunolocalisation 145
3.3.2.2 Osteopontin immunolocalisation 150
3.3.2.3 Bone sialoprotein immunolocalisation 155
3.4 Discussion 160
IX
CHAPTER 4 
GROWTH FACTOR EXPOSURE FROM BONE SURFACES BY CHEMICAL
TREATMENT MODALITIES
4.1 Introduction 165
4.2 Materials and Methods 168
4.2.1 Preparation of tissue culture reagents 168
4.2.2 Preparation and chemical treatments of bone slabs 168
4.2.3 Immunogold labelling of released TGF-01 from bone surfaces 169
4.2.4 Isolation and culture of bone marrow stromal cells 170
4.2.5 Visualisation of cellular cytoskeleton 171
4.2.6 Immunocytochemical characterisation of cells 172
4.3 Results 174
4.3.1 Immunogold labelling of released TGF-p1 from bone surfaces 174
4.3.1.1 EDTA treated bone surfaces 174
4.3.1.2 Calcium hydroxide treated bone surfaces 174
4.3.1.3 Citric acid treated bone surfaces 175
4.3.1.4 Sodium hydroxide treated bone surfaces 176
4.3.2 Immunocytochemical characterisation of cultured cells 182
4.3.2.1 Cells cultured on untreated surfaces 182
4.3.2.2 Cells cultured on EDTA treated surfaces 182
4.3.2.3 Cells cultured on Ca(OH)2 treated surfaces 183
4.4 Discussion 189
X
CHAPTER 5
STIMULATION OF THE EX VIVO MANDIBLE MODEL WITH CHEMICALLY
RELEASED ENDOGENOUS GROWTH FACTORS
5.1 Introduction 198
5.2 Materials and Methods 201
5.2.1 Preparation and chemical treatment of fractured
mandible slices 201
5.2.2 Histological examination 201
5.2.3 Immunohistochemistry 202
5.3 Results 203
5.3.1 Histology of pre-treated mandible slices 203
5.3.2 Immunohistochemical characterisation of pre-treated
mandible slices 206
5.3.2.1 PCNA immunolocalisation 206
5.3.2.2 Osteopontin immunolocalisation 206
5.3.2.3 Bone sialoprotein immunolocalisation 207
5.4 Discussion 214
CHAPTER 6 
GENERAL DISCUSSION
GENERAL DISCUSSION 220
REFERENCES 227
XI
INDEX OF TABLES
Table Page
Table 2.1: Immunohistochemistry primary antibodies. 66
Table 4.1: Immunocytochemistry antibodies. 173
INDEX OF FIGURES
Figure Page
Figure 1.1: Cortical bone structure. 7
Figure 1.2: Trabecular bone structure. 7
Figure 1.3: Osteoblast differentiation. 14
Figure 1.4: Osteoclast differentiation. 17
Figure 2.1: Preparation of mandibles. 57
Figure 2.2: Base type cultures. 59
Figure 2.3: Trowel type cultures. 59
Figure 2.4: Histology of uncultured mandible slices. 68
Figure 2.5: Acridine orange / vital dye staining of an uncultured 
mandible slice. 68
Figure 2.6: Histology of 24 hour base type culture. 70
Figure 2.7: Histology of 24 hour Trowel type culture. 70
Figure 2.8: Acridine orange / ethidium bromide vital dye staining of 
a mandible slice cultured for 24 hours in base type culture. 71
Figure 2.9: Acridine orange / ethidium bromide vital dye staining of 
a mandible slice cultured for 24 hours in Trowel type culture. 71
XII
Figure 2.10: Acridine orange / ethidium bromide vital dye staining of 
a mandible slice cultured for 4 days in base type culture. 72
Figure 2.11: Acridine orange / ethidium bromide vital dye staining of 
a mandible slice cultured for 4 days in Trowel type culture. 72
Figure 2.12: Histology of 7 day base type culture. 74
Figure 2.13: Histology of 7 day Trowel type culture. 74
Figure 2.14: Acridine orange / ethidium bromide vital dye staining of 
a mandible slice cultured for 7 days in base type culture. 75
Figure 2.15: Acridine orange / ethidium bromide vital dye staining of 
a mandible slice cultured for 7 days in Trowel type culture. 75
Figure 2.16: Histology of 14 day base type culture. 77
Figure 2.17: Histology of 14 day Trowel type culture. 77
Figure 2.18: Acridine orange / ethidium bromide vital dye staining 
of a mandible slice cultured for 14 days in base type culture. 78
Figure 2.19: Acridine orange / ethidium bromide vital dye staining 
of a mandible slice cultured for 14 days in Trowel type culture. 78
Figure 2.20: Histology of 21 day base type culture. 80
Figure 2.21: Histology of 21 day Trowel type culture. 80
Figure 2.22: Acridine orange / ethidium bromide vital dye staining 
of a mandible slice cultured for 21 days in base type culture. 81
Figure 2.23: Acridine orange / ethidium bromide vital dye staining 
of a mandible slice cultured for 21 days in Trowel type culture. 81
Figure 2.24: Average cell numbers per 100pm2 area within the 
periodontal ligament after 7, 14 or 21 days of culture. 82
XIII
Figure 2.25: Average cell numbers per 100pm2 area within the 
pulp after 7, 14 or 21 days of culture. 82
Figure 2.26: Tritiated proline radiolabelled mandible slices cultured 
for 7 days. 85
Figure 2.27: Radiolabel false positive controls. 85
Figure 2.28: Tritiated proline radiolabelled mandible slices cultured 
for 14 days. 86
Figure 2.29: Radiolabel false positive controls. 86
Figure 2.30: Average number of silver grains per 100pm2 area 
within the periodontal ligament after 7 or 14 days of culture. 87
Figure 2.31: Average number of silver grains within the predentine 
after 7 or 14 days of culture. 87
Figure 2.32: PCNA immunohistochemistry. 90
Figure 2.33: Alkaline phosphatase immunohistochemistry. 91
Figure 2.34: Osteopontin immunohistochemistry. 92
Figure 2.35: Histology of uncultured fractured mandible slices. 105
Figure 2.36: Acridine orange / vital dye staining of an uncultured 
fractured mandible slice. 105
Figure 2.37: Fractured mandible slices cultured for 24 hours. 107
Figure 2.38: Acridine orange / vital dye staining of a fractured 
mandible slice cultured for 24 hours. 107
Figure 2.39: Acridine orange / vital dye staining of a fractured 
mandible slice cultured for 4 days. 107
Figure 2.40: Fractured mandible slices cultured for 7 days. 109
XIV
Figure 2.41: Acridine orange / vital dye staining of a fractured 
mandible slice cultured for 7 days.
Figure 2.42: Fractured mandible slices cultured for 14 days.
Figure 2.43: Acridine orange / vital dye staining of a fractured 
mandible slice cultured for 14 days.
Figure 2.44: Fractured mandible slices cultured for 21 days.
Figure 2.45: Acridine orange / vital dye staining of a fractured 
mandible slice cultured for 21 days.
Figure 2.46: Average cell number per 100pm2 area within the PDL 
after 7, 14 or 21 days of culture.
Figure 2.47: Average cell number per 100pm2 area within the pulp 
after 7, 14 or 21 days of culture.
Figure 2.48: Tritiated proline radiolabelled fractured mandible 
slices cultured for 7 days.
Figure 2.49: Radiolabel false positive controls.
Figure 2.50: Tritiated proline radiolabelled fractured mandible slices 
cultured for 14 days.
Figure 2.51: Radiolabel false positive controls.
Figure 2.52: Average number of silver grains per 100pm2 area within 
the PDL of fractured mandible slices after 7 or 14 days of culture. 
Figure 2.53: Average number of silver grains per 100pm2 area within 
the PDL of fractured mandible slices after 7 or 14 days of culture. 
Figure 2.54: PCNA immunohistochemistry within fractured mandible 
slices.
109
111
111
113
113
114 
114
117
117
118 
118
119
119
122
XV
Figure 2.55: Number of PCNA positive cells within 100pm2 areas of 
PDL in fractured mandible slices cultured for 7 or 14 days. 123
Figure 2.56: Alkaline phosphatase immunohistochemistry within 
fractured mandible slices. 124
Figure 2.57: Number of alkaline phosphatase positive cells within 100pm2 
areas of PDL in fractured mandible slices cultured for 7 or 14 days. 125
Figure 2.58: Osteopontin immunohistochemistry within fractured 
mandible slices. 126
Figure 2.59: Number of osteopontin positive cells within 100pm2 areas 
of PDL in fractured mandible slices cultured for 7 or 14 days. 127
Figure 3.1: Mandible slices cultured for 7 days following stimulation 
with TGF-pi with agarose beads. 141
Figure 3.2: Mandible slices cultured for 7 days following stimulation 
with BMP-2 with agarose beads. 142
Figure 3.3: Average cell numbers within 100pm2 areas of PDL in 
fractured mandible slices stimulated with TGF-p1. 143
Figure 3.4: Average cell numbers within 100pm2 areas of PDL 
in fractured mandible slices stimulated with BMP-2. 144
Figure 3.5: PCNA immunohistochemistry within TGF-p1 
stimulated cultures. 146
Figure 3.6: PCNA immunohistochemistry within BMP-2 
stimulated cultures. 147
Figure 3.7: Number of PCNA positive cells within 100pm2 areas 
of PDL in fractured mandible slices stimulated with TGF-p1. 148
XVI
Figure 3.8: Number of PCNA positive cells within 100pm2 areas 
of PDL in fractured mandible slices stimulated with BMP-2. 149
Figure 3.9: Osteopontin immunohistochemistry within TGF-p1 
stimulated cultures. 151
Figure 3.10: Osteopontin immunohistochemistry within BMP-2 
stimulated cultures. 152
Figure 3.11: Number of osteopontin positive cells within 100pm2 
areas of PDL in fractured mandible slices stimulated with TGF-pi. 153
Figure 3.12: Number of osteopontin positive cells within 100pm2 
areas of PDL in fractured mandible slices stimulated with BMP-2. 154
Figure 3.13: BSP immunohistochemistry within TGF-p1 stimulated 
cultures. 156
Figure 3.14: BSP immunohistochemistry within BMP-2 
stimulated cultures. 157
Figure 3.15: Number of BSP positive cells within 100pm2 areas of 
PDL in fractured mandible slices stimulated with TGF-p1. 158
Figure 3.16: Number of BSP positive cells within 100pm2 areas 
of PDL in fractured mandible slices stimulated with BMP-2. 159
Figure 4.1: Immunogold labelling of TGF-p1 released from bone 
surfaces treated with 17% EDTA. 177
Figure 4.12 Immunogold labelling of TGF-pi released from bone 
surfaces treated with 0.02M Ca(OH)2. 178
Figure 4.3: Immunogold labelling of TGF-pi released from bone 
surfaces treated with 10% citric acid. 179
XVII
Figure 4.4: Immunogold labelling of TGF-p1 released from bone
surfaces treated with 0.2M NaOH. 180
Figure 4.5: Number of TGF-pi labelled immunogold particles
per 20pm2 area of treated bone surface. 181
Figure 4.6: Immunocytochemical characterisation of cells
cultured on untreated bone slabs. 185
Figure 4.7: Immunocytochemical characterisation of cells
cultured on bone slabs treated with 17% EDTA. 186
Figure 4.8: Immunocytochemical characterisation of cells
cultured on bone slabs treated with 0.02M Ca(OH)2. 187
Figure 4.9: Average number of phalloidin stained cells cultured on
bone surfaces left untreated, treated with EDTA, or treated with
Ca(OH)2. 188
Figure 4.10: Average % positive nuclei for alkaline phosphatase
or osteopontin expression on bone surfaces left untreated, treated
with EDTA, or treated with Ca(OH)2. 188
Figure 5.1: Fractured mandible slices cultured for 7 days following
pre-treatment with 17% EDTA or 0.02M Ca(OH)2. 204
Figure 5.2: Average cell numbers within 100pm2 areas of PDL in fractured
mandible slices treated with 17% EDTA or 0.02M Ca(OH)2. 205
Figure 5.3: PCNA immunohistochemistry of fractured mandible slices
treated with 17% EDTA or 0.02M CA(OH)2. 208
Figure 5.4: Number of PCNA positive cells within 100pm2 areas of
PDL in fractured mandible slices treated with 17% EDTA or
0.02M Ca(OH)2. 209
XVIII
Figure 5.5: Osteopontin immunohistochemistry of fractured 
mandible slices treated with 17% EDTA or 0.02M Ca(OH)2. 210
Figure 5.6: Number of osteopontin positive cells within 100pm2 
areas of PDL in fractured mandible slices treated with 17% EDTA 
or 0.02M Ca(OH)2. 211
Figure 5.7: BSP immunohistochemistry of fractured mandible slices 
treated with 17% EDTA or 0.02M Ca(OH)2. 212
Figure 5.8: Number of BSP positive cells within 100pm2 areas of 
PDL in fractured mandible slices treated with 17% EDTA or 
0.02M Ca(OH)2. 213
XIX
ABBREVIATIONS
3H T ritiated
ABC Avidin and Biotinylated horseradish peroxidase
macromolecular Complex 
aFGF Acidic Fibroblast Growth Factor
ALKs Activin Receptor-Like Kinases
ANOVA Analysis of Variance
bFGF Basic Fibroblast Growth Factor
BMP Bone Morphogenetic Proteins
BSA Bovine Serum Albumin
BSP Bone Sialoprotein
Ca(OH)2 Calcium Hydroxide
C 02 Carbon Dioxide
Co-Smad Common mediator Smad
DAB 3,3'-Diaminobenzidine
DMEM Dulbecco’s Modified Eagle’s Medium
DNA Deoxyribonucleic Acid
ECM Extracellular Matrix
EDTA Ethylenediaminetetraacetic acid
ELISA Enzyme-Linked Immunosorbent Assay
FDA Food and Drug Administration
FGF Fibroblast Growth Factor
FITC Fluorescein Isothiocyanate
GAG Glycosaminoglycan
XX
H&E Haematoxylin & Eosin
IGF Insulin-like Growth Factor
IL-1 lnterleukin-1
IL-6 lnterleukin-6
IMS Industrial Methylated Spirit
LAP Latency-Associated Peptide
LTBP Latent TGF-p Binding Protein
MAPK Mitogen-Activated Protein Kinase
M-CSF Macrophage Colony-Stimulating Factor
NaOH Sodium Hydroxide
NF-kB Nuclear Factor Kappa B
NSAID Non-Steroidal Anti-Inflammatory Drug
OPG Osteoprotegerin
PBS Phosphate-Buffered Saline
PCNA Proliferating Cell Nuclear Antigen
PDGF Platelet-Derived Growth Factor
PDL Periodontal Ligament
RANK Receptor Activator of Nuclear Factor k  B
RANKL Receptor Activator of Nuclear Factor k  B ligand
ROS Reactive Oxygen Species
R-Smad Receptor-regulated Smad
SEM Scanning Electron Microscopy
SIBLING Small Integrin-Binding Ligand, N-linked Glycoprotein
SLC Small Latent Complex
SPARC Secreted Protein, Acidic and Rich in Cysteine
XXI
TBS Tris-Buffered Saline
TGF-p Transforming Growth Factor-(3
TNAP Tissue Non-specific Alkaline Phosphatase
TNF-cx Tumour Necrosis Factor-a
TRAFs Tumour Necrosis Factor Receptor-Associated Factors
TRAP Tartrate-Resistant Acid Phosphatase
UV Ultraviolet
VEGF Vascular Endothelial Growth Factor
a-MEM Alpha-modified Minimum Essential Medium
XXII
CHAPTER 1
INTRODUCTION
Bone repair involves a complex cascade of biological events initiated in 
response to injury or trauma, and the process ultimately results in optimal 
repair and restoration of function to the bone. It is a recovery process unlike 
any other tissue regeneration, and the process recapitulates the development 
and growth of bones observed in the embryo (Zimmermann et al. 2005). In 
the majority of cases, intramembranous and endochondral ossification lead 
to normal and natural bone healing, but there are many clinical situations 
where repair processes are impaired. Examples can be seen in fracture non­
unions (Kloen et al. 2002; Trippel et al. 1996), non-healing sockets after tooth 
extraction, and patients suffering from diseases such as osteonecrosis (Reid 
2008), osteoporosis (Namkung-Matthai et al. 2001; Tang et al. 2008), and 
diabetes. Diabetic patients often show significantly reduced bone healing 
capabilities, and patients are reported to have a higher failure rate of dental 
implants due to a reduced capability for osseointegration (Valero et al. 2007). 
Other contributory factors such as smoking, certain medications, and 
infection can also result in poor healing (Hayda et al. 1998).
There are a limited number of therapies in clinical practice, with treatments 
mostly used to aid normal bone healing, or being best suited in healing small 
defects in maxillofacial surgery and (to a lesser extent) orthopaedic surgery. 
These therapies are used infrequently, if at all, in the conditions described
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above where healing is impaired. There is much interest in refining and 
developing treatments, and in particular expanding therapies so that they 
may be used in conditions with impaired bone healing. The current gold 
standard is the use of bone autograft and allograft as materials for skeletal 
repair and regeneration (Stevenson 1998). These materials have several 
drawbacks, including limits in bone availability and infection-associated 
problems (Cancedda et al. 2007). Research into alternative therapies has 
focused on the many bone-inducing proteins present in bone (Urist 1965), 
particularly the bone morphogenetic proteins (BMPs), a group of growth 
factors known to be potent inducers of bone formation (Bilic et al. 2006; 
Boden et al. 2000; Friedlaender et al. 2001; Jones et al. 2006). Problems 
currently associated with this field of clinical treatment are related to the large 
supraphysiological doses of growth factor required to elicit a therapeutic 
response in humans.
The development of alternative therapies is hampered by the research model 
systems currently available for studying bone repair processes. In vitro 
models use one or two cell types at the most (Jiang et al. 2005; Jung et al. 
2005), and are unable to recapitulate the spatial arrangement of cells in vivo. 
As such, in vitro models can be severely limiting. In vivo models have been 
developed in a variety of animals (Lu and Rabie 2003; Mark et al. 2004; 
Pearce 2007; Petite et al. 2000) and have yielded considerable information 
on repair processes. However, such models are extremely expensive, 
requiring large numbers of animals, it can be difficult to obtain clear data due 
to systemic influences, and there are ethical implications involved in
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undertaking in vivo work. One solution to the problems currently associated 
with modelling of bone repair may be to utilise ex vivo organ culture models, 
where cells and tissues are cultured in situ. Ex vivo models have significant 
advantages, as cells and tissue can be cultured in the same spatial 
arrangement as would be found in the in vivo situation, while systemic 
influences are removed. Furthermore, animal numbers can be significantly 
reduced, allowing for cheaper and more ethically sound experimentation.
An ex vivo tooth slice model, developed by Sloan et al. (1998) has been used 
successfully instead of traditional in vitro and in vivo models to investigate a 
range of dental repair processes (Gongalves et al. 2007; Murray et al. 2000; 
Sloan and Smith 1999). The tooth slice model also provided a basis for 
development of an ex vivo rat mandible model to investigate the effects of 
externally applied forces on the dentine-pulp complex (Dhopatkar et al. 
2005). This thesis aims to further develop this ex vivo model for investigating 
specific processes of bone repair. The model will enable the investigation of 
many bone repair pathways by examining cellular proliferation, migration, 
and differentiation, as well as the role that specific growth factors play in 
repair (Lieberman et al. 2002). In conjunction with the mandible model, a 
bone slab cell culture model will also be developed, to demonstrate proof of 
principle that growth factors can be chemically released from bone matrix, 
and that release of such molecules can have profound effects on cell 
behaviour. The development of such models may be invaluable in the search 
for ways to improve and enhance the initial stages of bone repair in patients 
where normal healing does not occur.
3
1.1 BONE BIOLOGY
1.1.1 General Bone Composition and Organisation
Bone is a dynamic, highly organised tissue, providing a rigid structure for 
supporting the body, attachment points for muscles and tendons, acting as a 
reservoir of mineral ions, and producing a vast array of humoral cell types 
(Ng et al. 1997; Totora and Grabowski 2003). The components of bone can 
be divided into cellular and acellular categories. The cellular components 
form the living part of bone tissue and are involved in maintaining both 
structure and function of the tissue. The acellular components are 
synthesised by osteoblast cells secreting an organic matrix, which is 
subsequently mineralised. This mineralised bone matrix provides the 
structure of the tissue, and is also involved in providing a reservoir of mineral 
ions which can be accessed as required (Roberts and Hartsfield 2004).
The extracellular matrix (ECM) of bone is comprised predominantly of type I 
collagen (approximately 90%), as well as a number of non-collagenous 
proteins including osteonectin, osteopontin, osteocalcin, bone sialoprotein, 
and the small proteoglycans decorin and biglycan (Nanci 1999; Waddington 
et al. 2003; Young et al. 1992). Non-collagenous proteins interact within a 
framework of type I collagen, allowing accumulation of calcium and 
phosphate ions and subsequent formation of hydroxyapatite crystal which 
provides an organic framework and gives bone many of its structural
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properties. The proteins contained within the matrix can specifically interact 
with bone cells embedded within the ECM, controlling processes such as 
survival, proliferation, and differentiation (Schonherr and Hausser 2000). The 
ECM also acts as a reservoir for a variety of cytokines and growth factors, via 
proteoglycans and other proteins that bind secreted growth factors and 
immobilise them within the matrix, enabling the generation of rapid and highly 
localised signals when required (Hauschka et al. 1986; Ramirez and Rifkin 
2003; Schonherr and Hausser 2000; Taipale and Keski-Oja 1997). 
Interaction of cells with the ECM is therefore fundamental to cellular 
differentiation and function and may be critical in bringing about rapid healing 
of damaged bone (Green et al. 1995).
1.1.2 Bone Structure and Types
There are several types of bone, depending on the conditions under which it 
is produced and also the state of maturity. Mature lamellar bone has an 
orderly, organised structure, comprising of many collagen fibres running 
parallel to other fibres in the same layer (Nanci 1999), and provides structural 
strength and high mineral content (Weiner et al. 1999). Lamellar bone can 
further be divided into two structural types depending on the location and 
environment under which it was synthesised: cortical (or compact) bone, and 
trabecular (or spongy) bone. Cortical bone is rigid and dense, and comprises 
80% of skeletal tissue, being found in the walls of bone shafts and on 
external bone surfaces (Ng et al. 1997). It consists of closely packed osteons
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(also known as haversian systems), each one consisting of a central 
haversian canal surrounded by concentric rings of matrix known as lamellae 
(Weiner and Traub 1992). The blood vessels of the bone are contained within 
the haversian canals, and interconnect with blood vessels on the surface of 
the bone via vascular Volkmann’s canals (Figure 1.1). Trabecular bone, 
located internal to cortical bone and at the end of long bones, has a more 
porous, lightweight structure, and is composed of trabeculae (thin plates) 
separated by marrow spaces (Figure 1.2). The bone marrow space contains 
mesenchymal stem cells, capable of differentiating into cells of the 
osteoblastic lineage, and as such plays a crucial role in bone repair 
(Beresford 1989; Krebsbach et al. 1999). Trabecular bone has a very high 
surface to volume ratio, making it ideal for easy storage and release of 
calcium and phosphate ions (Buckwalter et al. 1995). The periosteum is the 
outer layer of cortical and trabecular bone (Figure 1.2), within which reside 
the stem cells and progenitors which are ultimately responsible for the 
formation of cells involved in bone repair processes (Malizos and 
Papatheodorou 2005).
During initial stages of bone repair, rapid bone synthesis is required to bridge 
the gap left by an injury. Thus an immature bone, known as woven bone, is 
formed first, in order to restore structural integrity to the injured tissue (Kalfas 
2001). This immature bone consists of intertwined mineralised collagen fibres 
that are orientated in many different directions, and also contains a relatively 
higher proportion of osteocytes than mature bone (White and Folkens 
2000b). As such, woven bone is relatively weak and not optimal for providing
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structural strength. In order to provide structural strength, woven bone is 
slowly remodelled into mature lamellar bone over time (Nanci 1999).
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1.1.3 Embryonic Bone Formation
Embryonically, bone development or osteogenesis occurs via two distinct 
mechanisms, depending on the environment in which it occurs. 
Intramembranous ossification occurs where bones ossify by apposition on 
tissue within an embryonic connective tissue membrane. Endochondral 
ossification occurs where bone formation is preceded by cartilage precursors, 
and is the mechanism by which most bones in the skeleton develop (White 
and Folkens 2000a). The molecular and cellular processes involved in 
embryonic bone formation, and subsequent remodelling, may provide 
valuable information on the molecular and cellular processes involved in 
bone repair (Ferguson et al. 1999), as there are a number of proteins 
expressed during bone repair that are known to play important roles in 
embryonic bone development (Vortkamp et al. 1998).
At the onset of skeletal development, undifferentiated mesenchymal cells 
condense at sites where skeletal bones will eventually form (Zelzer and 
Olsen 2003). In endochondral ossification the cells within these 
condensations differentiate into chondrocytes, a cell type specific of cartilage 
(Karsenty 2001). These cells further differentiate into hypertrophic 
chondrocytes, which are gradually surrounded by a calcified extracellular 
matrix, facilitating invasion of blood vessels from the perichondrium (Wagner 
and Karsenty 2001). This blood vessel invasion stimulates apoptosis of 
hypertrophic chondrocytes, and osteoblasts (also originating from 
mesenchymal cells) begin to differentiate and deposit osteoid, the type I
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collagen-rich extracellular matrix of bone. Any remaining chondrocytes reside 
in the growth plate, a narrow zone that together with the osteoblasts 
coordinates longitudinal bone growth (Wagner and Karsenty 2001).
Intramembranous ossification is a process responsible for development of 
the flat bones, in particular the facial bones, the cranial bones which form the 
sides and roof of the neurocranium, the mandible and the clavicle (Dixon et 
al. 1997). During this process, the cells within mesenchyme condensations 
differentiate directly into the bone-forming osteoblasts, without forming a 
cartilage precursor, and synthesise osteoid (Kronenberg 2003). Development 
of the mandible, the bone which forms the basis of the ex vivo model to be 
developed in this thesis, forms by the processes of intramembranous 
ossification described above, although it is preceded by the development of 
Meckel’s cartilage, thought to initiate and regulate the growth of the primary 
ossification centre of the mandible (Frommer and Margolies 1971).
1.1.4 Post-natal Bone Remodelling
Following birth, and into adult life, processes of growth and remodelling 
within bones result in the formation of a skeleton which is well adapted for 
functions of movement, support, blood cell production, and calcium 
homeostasis (Zelzer and Olsen 2003). Bone constantly needs to adapt, to 
facilitate growth within young bones, to respond to environmental stresses, or 
to stimulate repair processes when damaged. All of these adaptations are
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brought about by the control and coordination of two opposing processes: 
bone formation, coordinated by osteoblasts, and bone resorption, 
coordinated by osteoclasts. Together these cells orchestrate remodelling 
processes throughout the skeleton, a process important in the repair of 
damaged bone (Macdonald and Gowen 1993). Bone remodelling involves 
the localised removal of aged bone by osteoclasts and replacement with 
newly formed bone by osteoblasts. It is a complex process, requiring 
interactive cellular activity between osteoblasts and osteoclasts, and is 
regulated by a wide range of biochemical and mechanical factors. 
Remodelling processes occur continuously throughout life, to prevent 
accumulation of older bone, which is densely mineralised and therefore more 
brittle than younger bone. Remodelling also occurs to repair microdamage in 
order to maintain its strength, to adapt to mechanical stresses, and to 
metabolise minerals stored within its matrix (Ott 2002).
1.2 BONE REPAIR
Unlike other tissue regeneration, which results in fibrous scarring, the 
process of bone repair involves a complete regeneration of bone with no 
formation of scar tissue, and ultimately results in optimal skeletal repair 
accompanied by restoration of skeletal function (Einhorn 1998). The process 
of bone repair can be divided histologically into direct (primary) healing, and 
indirect (secondary) healing.
10
1.2.1 Primary I Direct Healing
Primary (or direct) bone healing occurs where there is rigid internal fixation 
resulting in anatomic reduction of the bone fragments, and decreased 
intrafragmentary strain that ensures the stability of this reduction (Dimitriou et 
al. 2005). The cortex directly attempts to re-establish itself, in order to restore 
mechanical continuity, by establishing new haversian systems throughout the 
cortical bone. This is achieved by the formation of ‘cutting cones’, discrete 
remodelling units composed of bone-resorbing osteoclasts which tunnel 
through the cortical bone, and which can infiltrate directly into the opposite 
bone fragment (McKibbin 1978). These cutting cones provide access for the 
penetration of blood vessels, accompanied by vascular endothelial cells and 
perivascular mesenchymal cells (osteoprogenitor cells that will become 
osteoblasts) and together are able to re-establish the haversian systems 
(Einhorn 1998). There is very little or no periosteal response during primary 
fracture healing, so no callus formation is observed (Dimitriou et al. 2005). 
Since the process of primary bone healing requires extremely high stability of 
fracture reduction, it is in practice the rarest type of repair. Secondary, or 
indirect, healing is far more common (Phillips 2005).
1.2.2 Secondary I Indirect Healing
Secondary, or indirect, healing involves both intramembranous and 
endochondral ossification. The initial stage in secondary healing involves the
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formation of an injury-induced haematoma, and inflammation occurs. The 
haematoma has inherent osteogenic potential (Mizuno et al. 1990), with 
degranulated platelets in the haematoma releasing growth factors such as 
transforming growth factor-p (TGF-p) and platelet-derived growth factor 
(PDGF) which act initially to recruit mesenchymal stem cells, inflammatory 
cells and macrophages to the site of injury, In addition, TGF-p promotes 
recruitment and differentiation of osteoblast progenitors (Barnes et al. 1999). 
Pro-inflammatory cytokines, including interleukin-1 (IL-1), interleukin-6 (IL-6), 
and tumour necrosis factor-a (TNF-a), are released which recruit 
inflammatory cells, fibroblasts, and osteoblasts (Dimitriou et al. 2005). The 
potent angiogenic stimulator vascular endothelial growth factor (VEGF) is 
released, and this is followed by release of the bone morphogenetic proteins 
(BMPs), key regulators of bone formation (Gerstenfeld et al. 2003).
Callus formation begins at the periphery of the site of bone injury. Committed 
osteoprogenitors present in the periosteum stimulate intramembranous 
ossification at the periphery. Towards the centre, a soft cartilaginous callus is 
formed by chondrocytes synthesising a matrix with a high concentration of 
type II collagen fibrils, and deposition of calcium hydroxyapatite crystals into 
this matrix allows mineralisation of the cartilage (Phillips 2005). Invasion of 
blood vessels into this matrix recruits osteoblast progenitors, which undergo 
proliferation and differentiation into osteoblasts and, together with cartilage- 
resorbing chondroclasts, convert the soft cartilaginous callus into immature 
woven bone via endochondral ossification (Einhorn 1998). Bone remodelling 
is the final stage in the secondary bone healing cascade, and functions to
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replace the immature woven bone with lamellar bone, through the coupled 
action of the bone-resorbing osteoclasts and the bone-forming osteoblasts 
(Schell et al. 2006).
1.2.3 Osteoblasts and their Role in Bone Repair and Remodelling
Osteoblasts originate from multipotent stem cells derived from the embryonic 
connective tissue mesenchyme. Mesenchymal stem cells are 
undifferentiated, self-renewing cells found predominantly in the bone marrow 
but also in the periosteum and connective tissues (Bielby et al. 2007). Being 
multipotent, they are capable of differentiating into several cell types, namely 
osteoblasts, chondrocytes, adipocytes, and myoblasts (Pittenger et al. 1999; 
Prockop 1997). Osteoblasts are found on bone surfaces, usually in a single 
layer, and are responsible for bone formation, participating in both embryonic 
skeletal development and post-natal bone remodelling, as well as playing an 
essential role in bone repair (Mackie 2003).
Osteoblast differentiation is regulated by a complex system of growth factors 
(Lieberman et al. 2002). The intracellular signals conveyed by these growth 
factors in turn influence the expression of an array of transcription factors and 
proteins (Hughes et al. 2006) (Figure 1.3). These transcription factors and 
proteins can be considered to be biomarkers of osteoblast differentiation, and 
in vitro techniques can exploit expression of these biomarkers to assess the 
behaviour of cells in vivo or ex vivo (Kartsogiannis and Ng 2004; Yang and
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Karsenty 2002). Numerous growth factors exert their influences on different 
stages of the differentiation pathway, inducing intracellular signalling 
processes that in turn affect the expression of transcription factors within the 
cells. Runx2/Cbfa1 and Osterix, for example, are transcription factors that are 
essential for osteoblast differentiation, inducing expression of many 
osteoblast proteins, including osteocalcin and bone sialoprotein (Kim et al.
2004). Bone morphogenetic protein-2 (BMP-2) is capable of inducing 
expression of these transcription factors, via the upstream regulators Msx-2 
and Dlx-5, which are involved in upregulating the expression of Osterix and 
Runx2 respectively (Kim et al. 2004; Matsubara et al. 2008). It is the 
transcription factor TAZ, however, expressed early in the pathway, that 
specifies the osteoblastic cell fate of mesenchymal stem cells (Hong et al.
2005).
Mesenchymal stem cells osteoprogenitor cells Pre Osteoblast Osteoblast
Osterix
BMPs
PDGF
«GFR
Figure 1.3. Osteoblast differentiation. A host of growth factors act temporally 
and spatially to drive the stages of differentiation. Intracellular growth factor 
signalling influences expression of transcription factors which in turn induce 
expression of osteoblastic proteins. (Adapted from Hughes et al., 2006).
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Upon recruitment to the bone surfaces, mesenchymal stem cells give rise to 
osteoprogenitors, highly proliferative cells with a finite lifespan that are 
committed to the osteoblast lineage (Aubin and Heersche 2000). 
Osteoprogenitors further differentiate into pre-osteoblasts, which have a 
more limited proliferative capacity and begin to resemble the mature 
osteoblast. This differentiation is associated with a change in morphology, so 
that the cells take on the cuboidal shape associated with mature osteoblasts, 
and expression of a number of cell surface markers associated with a mature 
phenotype, such as osteopontin, alkaline phosphatase and bone sialoprotein, 
although the cells do maintain a limited ability to proliferate (Mackie 2003). 
Pre-osteoblasts themselves differentiate into fully mature, functional 
osteoblasts, synthesising and secreting bone matrix. In vitro experiments 
performed using rat calvaria cells have suggested that osteoprogenitor / pre­
osteoblasts must transit though approximately 9-10 population doublings in 
vitro before reaching terminal differentiation into mature osteoblasts, marked 
by acquisition of a cuboidal shape and arrest of cellular proliferation (Malaval 
et al. 1999).
During bone remodelling and repair, mesenchymal stem cells are recruited to 
the site of injury. Numerous growth and transcription factors, detailed later in 
sections 1.2.6 and 1.2.7, stimulate the proliferation and differentiation of 
these cells, until a population of fully mature, active osteoblasts are present 
at the site of trauma (Bielby et al. 2007). As differentiation occurs, the 
osteoblasts begin to secrete bone matrix proteins. The most abundant of 
these proteins is type I collagen, but non-collagenous proteins are also
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secreted (fully described in section 1.2.8) (Macdonald and Gowen 1993). The 
synthesis and secretion of this osteoid is initially unmineralised, but 
osteoblast secretion of proteins such as alkaline phosphatase, bone 
sialoprotein, osteonectin, and osteocalcin stimulate calcification of this 
osteoid (Mackie 2003; Whyte 1994). Initially, this mineralised bone matrix 
takes the form of immature woven bone, but over time this is remodelled into 
stronger lamellar bone, by osteoblasts working in conjunction with 
osteoclasts (Tsiridis et al. 2007).
1.2.4 Osteoclasts and their Role in Bone Repair and Remodelling
Osteoclasts are an essential component of bone repair, removing damaged 
and necrosed tissue, and resorbing the irregular woven bone callus in the 
remodelling stage, allowing subsequent osteoblast formation of mature 
lamellar bone (Schindeler et al. 2008). Osteoclasts are large, multinucleated 
cells created by the differentiation of monocyte / macrophage haemopoietic 
progenitor cells, found in the bone marrow (Schell et al. 2006). These 
osteoclast precursors migrate from the bone marrow to the bone surfaces, 
where they proliferate, differentiate into mononuclear preosteoclasts, and 
fuse with each other to form multinucleated mature osteoclasts, with around 
10-20 individual cells fusing to form each osteoclast (Boyle et al. 2003; 
Roodman 1999; Suda et al. 1992) (Figure 1.4).
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Figure 1.4. Differentiation of haematopoietic precursor cells into mature 
osteoclasts, via the actions of the osteoblast-derived factors macrophage 
colony-stimulating factor (M-CSF) and receptor for activation of nuclear factor 
kappa B ligand (RANKL). Differentiation is associated with expression of 
phenotypic markers such as tartrate-resistant acid phosphatase (TRAP), 
calcitonin receptor (CTR) and the (33 integrin, which mediate osteoclast 
migration, attachment, and differentiation. Osteoprotegerin (OPG) is a 
soluble decoy receptor for RANKL and inhibits osteoclast differentiation 
(Adapted from Boyle et al., 2003).
The differentiation of osteoclasts is dependent on the presence of M-CSF 
and RANKL. These factors drive proliferation and differentiation of osteoclast 
precursors, and induce expression of genes that characterise the osteoclast 
lineage; TRAP, cathepsin K, CTR, and the (33 integrin (Lacey et al. 1998). 
Mature osteoclasts are responsible for the resorption of mineralised bone 
matrix, which they achieve by tightly adhering to bone surfaces via integrins 
(Crippes et al. 1996; Helfrich et al. 1996). Adherence of mature osteoclasts to 
a bone surface forms a resorption pit, into which the cells secrete protons
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and osteolytic enzymes (Chambers 2000; Macdonald and Gowen 1993). 
TRAP is one such enzyme, and has been used extensively as a marker for 
terminally differentiated osteoclasts (Angel et al. 2000). The exact role of 
TRAP in osteoclasts is not fully understood, but TRAP knock-out mice show 
decreased resorptive activity of osteoclasts (Hayman et al. 1996). It has been 
suggested that TRAP dephosphorylates osteopontin and bone sialoprotein, 
proteins involved in promoting osteoclast attachment, thus TRAP may 
regulate osteoclast attachment to these proteins and osteoclast migration on 
the bone surface (Ek-Rylander et al. 1994). TRAP has also been implicated 
in generation of hydroxyl radicals, iron transport, and as a growth factor for 
haematopoietic and osteoblast cells (Ljusberg et al. 2005; Sheu et al. 2003). 
Activation of TRAP is thought to be mediated through cathepsin K, a 
protease secreted into the acidic microenvironment of the resorption lacunae, 
facilitating matrix degradation through its proteolytic activity (Drake et al. 
1996; Ljusberg et al. 2005; Saftig et al. 1998). Negative regulation of bone 
resorption is brought about through the actions of the peptide hormone 
calcitonin, which signals through its cognate receptor abundantly present on 
osteoclasts (Quinn et al. 1999). Calcitonin inhibits the motility, cytoplasmic 
spreading, and bone resorption abilities of osteoclasts, preventing bone 
resorption when required (Lee et al. 1995; Nicholson et al. 1986).
In bone remodelling and repair, osteoclasts function to clear away damaged 
and necrosed tissue at the site of injury. Resorption of this tissue facilitates 
release of growth factors bound within the bone matrix, including TGF-(31 and 
BMPs (Dallas et al. 2002). Release and activation of these molecules
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initiates intracellular signalling cascades, which ultimately promote the 
recruitment and proliferation of mesenchymal stem cells / osteoprogenitors to 
the site of injury, and stimulates osteoblast differentiation of these cells. This 
provides a population of cells at the site of injury capable of laying down 
newly formed bone matrix. To stimulate remodelling of the newly formed 
bone, osteoblasts produce local signalling molecules that play a role in 
osteoclast differentiation. The maturation of macrophages into osteoclasts in 
vitro requires the presence of bone marrow stromal cells, or their osteoblastic 
progeny (Udagawa et al. 1990). These cells produce M-CSF and RANKL, 
essential for osteoclast differentiation (Quinn et al. 1998; Teitelbaum 2000). 
M-CSF is a secreted product, and binds to its sole receptor, c-Fms, present 
on early osteoclast precursors (Kodama et al. 1991; Stanley et al. 1997). 
Binding of M-CSF initiates dimerization and activation of the receptor tyrosine 
kinase, leading firstly to autophosphorylation of the receptor (Stanley et al.
1997). This leads to propagation of downstream signals via binding of 
proteins to the phosphorylated receptor sites that stimulate proliferation and 
survival of osteoclast progenitors (Ross 2006; Stanley et al. 1997). M-CSF 
alone, however, is not sufficient to cause differentiation of osteoclasts from 
their precursors. It is a secreted product, and osteoclast differentiation 
requires contact between osteoclast precursors and bone marrow stromal 
cells or osteoblasts. It is therefore the role of RANKL, expressed on the 
surface of committed osteoblast progenitors, to stimulate the differentiation of 
osteoclast progenitors into fully mature osteoclasts (Lemaire et al. 2004; 
Yasuda et al. 1998). RANKL binds to the RANK receptor present on the 
surface of haemopoietic monocyte progenitors, bringing the two cell types
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into contact with each other. This binding initiates recruitment of tumour 
necrosis factor receptor-associated factors (TRAFs) to the intracellular 
domain of RANK, activating intracellular signalling cascades. These include 
stimulation of NF-KB, mitogen-activated protein kinase (MAPK) pathways via 
Jnk, Erk and p38, and the Akt/protein kinase B pathway (Darnay et al. 1998; 
Feng 2005). Stimulation of these pathways regulates the fusion of osteoclast 
precursors, and their survival and differentiation into mature osteoclasts, 
activating bone resorption (Blair et al. 2007; Burgess et al. 1999; Nakagawa 
et al. 1998). M-CSF and RANKL therefore work synergistically to induce 
osteoclast differentiation, with M-CSF driving proliferation of osteoclast 
progenitors, and RANKL initiating differentiation of this expanded population 
(Quinn et al. 1998).
Unregulated resorption of bone can lead to severe disease states, and so 
osteoclast differentiation is tightly regulated via OPG, expressed by stromal 
cells and osteoblasts (Burgess et al. 1999; Lacey et al. 1998; Vega et al.
2007). OPG blocks the formation of mature osteoclasts by acting as a soluble 
decoy receptor for RANKL, preventing its binding to RANK and inhibiting 
osteoclast differentiation (Roodman 1999). Transgenic mice overexpressing 
OPG show a marked reduction in trabecular osteoclasts, although osteoclast 
precursor numbers remain at normal levels (Simonet et al. 1997). OPG 
therefore serves to regulate bone density by modulating the differentiation of 
osteoclasts from haemopoietic precursors, rather than affecting the 
proliferative phase. OPG is secreted by osteoblasts in response to 
osteogenic signals, including TGF-p1 (Centrella et al. 1994; Takai et al.
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1998; Thirunavukkarasu et al. 2001; Udagawa et al. 2000). TGF-(31 may 
inhibit survival and differentiation of osteoclasts not only by inducing OPG, 
but also by suppressing osteoblast expression of RANKL (Quinn et al. 2001). 
TGF-(31 is sequestered within the bone matrix, and its release during 
osteoclastic bone resorption stimulates OPG expression and suppresses 
RANKL, inhibiting further formation and activity of osteoclasts and ultimately 
inhibiting bone resorption (Dallas et al. 2002; Taipale and Keski-Oja 1997; 
Thirunavukkarasu et al. 2001). Through their ability to secrete M-CSF / 
RANKL and OPG, osteoblasts play a crucial role in both activation and 
inhibition of bone resorption, creating a complex feedback system where 
bone formation follows bone resorption and completes a bone remodelling 
cycle. Therefore, the coordination between osteoblasts and osteoclasts 
allows the initial and rapid production of woven bone at the site of bone injury 
or trauma, creating a temporary structure which can be broken down 
gradually and replaced with a stronger, functional structure. However, the 
coordinated activities of the osteoblasts and osteoclasts are reliant on a third 
cell type within the bone system, the osteocyte (Knothe Tate et al. 2004).
1.2.5 Osteocvtes and their Role in Bone Repair and Remodelling
Osteocytes coordinate bone remodelling processes by osteoblasts and 
osteoclasts, by acting as mechanosensors that can respond to mechanical 
strain and microdamage to signal bone resorption / formation. Osteocytes are 
terminally differentiated osteoblasts that have become embedded in the
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mineralised matrix of bone. Active osteoblasts have a limited lifespan of 
approximately 3 months, after which time their fate varies, either undergoing 
programmed cell death (apoptosis), transforming into inactive bone-lining 
cells, or differentiating into osteocytes (Jilka et al. 1998; Manolagas 2000). 
The selection of osteoblasts for terminal differentiation to osteocytes is 
influenced by a variety of factors, including the position of the cell and the 
presence of local signalling factors (Manolagas 2000). Osteocytes are by far 
the most abundant cellular component within mammalian bone, and their 
lifespan of approximately 25 years greatly exceeds that of the osteoblast 
(Knothe Tate et al. 2004). Once embedded within the bone matrix, the cells 
cease secretory activity and undergo several phenotypic changes, including 
a decrease in cell body size, and a reduction in secretory organelles (Knothe 
Tate et al. 2004). The osteocytes also develop a meshwork of filamentous 
cellular processes that extend into the surrounding bone tissue, running 
along the bone canaliculi, and connect the osteocytes to other cell types 
(Kamioka et al. 2001; Noble et al. 2003). The connections established 
between osteocytes and surrounding bone cells allow them to regulate bone 
mass (Franz-Odendaal et al. 2006). Osteocytes are thought to respond to 
mechanical strain and microdamage to signal processes of bone resorption 
or formation, through communication between each other and other bone 
cells within the tissue, via gap junctions at the end of the cellular processes, 
and through their contact with the bone marrow (Kamioka et al. 2001). 
Osteocytes can respond to an increase in mechanical loading by producing a 
number of molecules involved in osteogenesis, such as osteocalcin, and 
insulin-like growth factor I (IGF-I), known to increase proliferation and
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differentiation of osteoblasts, ultimately leading to an upregulation of bone 
formation (Kawata and Mikuni-Takagaki 1998). Osteocytes can also undergo 
apoptotic cell death in response to microdamage to the bone, releasing 
prostaglandins or cytokines which can initiate resorption of the damaged 
bone by osteoclasts (Sims and Gooi 2008; Verborgt et al. 2002). In this way, 
osteocytes maintain the balance between bone formation and resorption, and 
increase local repair mechanisms in response to perceived bone damage 
(Tomkinson et al. 1997).
1.2.6 Signals Involved in Bone Repair and Remodelling
The differentiation of bone cells, and the processes of bone formation and 
resorption, are controlled by systemic signals acting though local signalling 
molecules and growth factors. These molecules act in synergy to recruit 
progenitor cells to sites of bone injury, to stimulate their proliferation, and to 
bring about their differentiation into mature bone cells capable of initiating 
repair processes. The interactions between this ‘cocktail’ of factors is 
complex. The way in which these factors interact and influence each other is 
pivotal to understanding repair processes, and to determine the molecular 
and cellular events associated with clinical situations of impaired bone 
healing.
23
1.2.6.1 Transforming Growth Factor Beta
TGF-p plays a major role in repair processes in bone, stimulating migration 
and proliferation of osteoprogenitors (Barnes et al. 1999). There are five 
known isoforms of TGF-p (TGF-pi through to TGF-P5), and the isoform TGF- 
P1 is especially prevalent in bone and platelets (Assoian et al. 1983; 
Janssens et al. 2005; Lieberman et al. 2002). TGF-P is secreted by bone 
cells in a latent dimeric complex, consisting of TGF-p plus its propeptide, 
termed latency-associated peptide (LAP) (Saharinen et al. 1999). The 
association between the TGF-p1 LAP and the growth factor itself, in the 
small latent complex (SLC), prevents signalling through the TGF-P receptors, 
keeping the growth factor in an inactive form (Annes et al. 2004). An 
additional protein, the latent TGF-p binding protein (LTBP-1), promotes 
binding of the TGF-p complex to the ECM, through covalent cross-linking to 
ECM proteins via tissue transglutaminase (Annes et al. 2004; Dallas et al. 
2002; Todorovic et al. 2005). This matrix storage of growth factor allows for 
the generation of rapid and highly localised signals when required, which 
may be critical to bring about rapid healing of damaged bone tissue (Taipale 
and Keski-Oja 1997; Todorovic et al. 2005). TGF-p release from the matrix in 
response to bone damage is generally brought about through osteoclast 
activity, capable of releasing latent TGF-p through cleavage of LTBP-1 
(Dallas et al. 2002). The release of the mature TGF-p 25kDa homodimer 
from this latent complex is required to activate TGF-p, to exert effects on 
target cells. Osteoclasts themselves are able to activate TGF-p, possibly via
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the acidic environment created by secretion of protons into the resorption 
lacunae (Bonewald et al. 1997). Active TGF-p acts through transmembrane 
serine/threonine kinase receptors present at the cell surface, classified as 
type I (activin receptor-like kinases, ALKs) or type II receptors (Derynck and 
Feng 1997; Janssens et al. 2005). Ligand binding induces the formation of a 
heteromeric receptor complex, where receptor II phosphorylates receptor I 
via its constitutively active serine/threonine kinase domain, activating the 
receptor and initiating intracellular signalling cascades (Massague 1998). The 
Smad proteins (a family of transcription factors) play a central role in the 
propagation of signals from activated TGF-p receptors (Janssens et al. 2005; 
Massague 2000; Miyazawa et al. 2002). Receptor-regulated Smads (Smad2 
and Smad3 in the case of TGF-p signalling) are phosphorylated and 
activated by the type I receptor, to form heteromeric complexes with a 
common mediator Smad, or Co-Smad, Smad4 (Shi and Massague 2003). 
These Smad complexes translocate to the nucleus to regulate target gene 
expression in conjunction with other nuclear co-factors. TGF-p can also 
induce transcription of inhibitory Smads (Smad6 and Smad7), forming a 
negative feedback loop by antagonising TGF-p signalling, either by 
competing with the R-Smads, or by inducing targeted degradation of the 
receptors (Massague 2000; Wrana and Attisano 2000). Although Smad 
proteins are critical in mediating the TGF-p signalling pathway, TGF-P can 
also activate Smad-independent signalling cascades, including the Erk, JNK, 
and p38 MAPK pathways, although some of these pathways also regulate 
Smad activation (Derynck and Zhang 2003).
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Release of TGF-p at a site of bone injury stimulates chemotactic recruitment 
of mesenchymal stem cells and osteoprogenitors from the bone marrow and 
periosteum, and increases their proliferation (Barnes et al. 1999). There is 
also evidence that TGF-P promotes the early stages of differentiation within 
these cells, increasing levels of type I collagen synthesis and inducing 
expression of Runx2 (Bostrom and Asnis 1998; Janssens et al. 2005). 
Studies performed on TGF-p null mice have demonstrated a lack of 
proliferation and differentiation amongst the osteoprogenitor population within 
these mice with consequential dramatic effects on matrix deposition and 
mineralisation, with subsequent impaired longitudinal growth and slow 
mineralisation (Atti et al. 2002). It has also been demonstrated that these 
TGF-p null mice display reduced elasticity of the bones, and lack material 
integrity of the long bones when compared to wild-type littermates (Geiser et 
al. 1998). However, during later stages of osteoblast differentiation, TGF-p 
has been observed to suppress the expression of Runx2, as well as 
osteocalcin, thereby acting to inhibit the later stages of osteoblast maturation 
(Janssens et al. 2005). It appears, therefore, that the role of TGF-p in 
response to bone injury is to recruit local mesenchymal stem cells and 
osteoprogenitors to the site of injury, stimulate their proliferation, and induce 
some early differentiation stages, thereby providing an expanded pool of 
committed osteoblasts at the site of injury. Other growth factors, such as the 
BMPs, then take responsibility for the later differentiation stages into fully 
mature, active osteoblasts capable of bone repair. TGF-pi also plays a role 
in regulating osteoclast differentiation, although the osteoclast response to 
TGF-p1 may depend on the differentiation state (Filvaroff et al. 1999). TGF-
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(31 inhibits early differentiation in osteoclast precursors, through either OPG 
expression or suppression of RANKL (Chenu et al. 1988; Quinn et al. 2001), 
but in contrast TGF-(31 stimulates bone resorption by mature osteoclasts, 
possibly through upregulation of prostaglandins, potent stimulators of 
osteoclast differentiation (Tashjian et al. 1985). Through its actions on both 
bone formation and resorption, TGF-(31 plays a critical role in repair 
processes.
1.2.6.2 Bone Morphogenetic Proteins
The BMPs belong to the TGF-(3 superfamily, and were identified by Urist 
(1965). The BMPs are key regulators of bone induction, maintenance and 
repair, and regulate growth and differentiation of cells of the chondroblast 
and osteoblast lineage (Sakou 1998; Tsiridis et al. 2007; Wozney 1992). 
Several of the BMPs have also been shown to independently induce ectopic 
bone formation, a unique ability among growth factor families (Katagiri and 
Takahashi 2002; Wozney and Rosen 1998). Members of the BMP family play 
a critical role in repair processes in bone, due to their ability to differentiate 
mesenchymal stem cells and osteoprogenitors into mature, fully functional 
osteoblasts. A study by Cheng and colleagues (2003) demonstrated that 
BMP-2, 6, and 9 exhibit the greatest ability among the BMP family members 
to induce early and late osteogenic markers, as well as matrix mineralisation, 
with other members such as BMP-4 and 7 stimulating differentiation of later, 
committed osteoblasts (Cheng et al. 2003a).
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There are over 20 identified and characterised BMP family members which 
can be further divided into groups based on their structure and function 
(Biase and Capanna 2005; Cheng et al. 2003a). BMPs are synthesised 
within bone cells as precursor forms and are sequestered within the ECM, 
providing an easily accessible reservoir of these growth factors which can be 
released at times of bone resorption (Mackie 2003). The released BMPs are 
proteolytically cleaved at the carboxy-terminal region to release the mature 
protein, which undergoes dimerization to form the active protein (Sakou
1998).
BMPs influence osteoblast differentiation by signalling through a serine- 
threonine receptor kinase pathway to stimulate the expression of many 
osteoblast proteins. This pathway, although similar to the TGF-p signalling 
pathway, involves different type I and type II receptors, with BMPs binding to 
three distinct type I receptors (ALK2, ALK3, and ALK6) and three distinct type 
II receptors (type II BMP receptor, type II activin receptor, and type MB activin 
receptor) (Derynck and Feng 1997; Miyazono et al. 2005). Intracellular 
signalling occurs in a similar way to TGF-p signalling (Kawabata et al. 1998), 
with downstream signalling occurring via phosphorylation of the R-Smads 1, 
5, and 8 (Dijke et al. 2003), which translocate to the nucleus (together with 
the common mediator Smad 4) and regulate transcription of target genes 
such as Runx2 (Phimphilai et al. 2006). Runx2 is involved in the 
transcriptional activation of many osteoblast marker genes by interacting with 
BMP-activated Smads in the nucleus (Barnes et al. 1999; Ducy et al. 1997;
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Lieberman et al. 2002). Regulation of Runx2 expression is probably mediated 
via BMP-induced expression of Dlx5, a homeobox gene that positively 
regulates later stages of osteoblast differentiation, and stimulates matrix 
mineralisation, via osteocalcin and alkaline phosphatase upregulation 
(Miyama et al. 1999). BMPs have also been shown to induce expression of 
Msx2, another homeobox gene that promotes osteoblast differentiation by 
inducing expression of the transcription factor Osterix, which in turn 
upregulates osteocalcin and alkaline phosphatase within osteoblasts 
(Matsubara et al. 2008; Tu et al. 2006). BMP signalling can also be 
antagonised, and therefore controlled, by inhibitory Smads (Smad6 and 
Smad7), or by numerous BMP antagonists including noggin and chordin, 
which bind to the BMPs and prevent further signalling (Etsuko 2006).
The presence of BMPs around a site of bone injury may indicate the 
differentiation state of the cells present within the area, depending on which 
BMPs are expressed. Expression of the early BMPs 2, 6, and 9, may indicate 
the presence of mesenchymal stem cells or early osteoprogenitors around 
the site, whereas the expression of the later BMPs, 4 and 7, may indicate the 
presence of more committed osteoblasts (Cheng et al. 2003a).
29
1.2.6.3 Platelet Derived Growth Factor
In bone repair processes, PDGF is one of the first factors to be released 
around the site of injury, from degranulating platelets within the haematoma 
and from surrounding inflammatory macrophages (Barnes et al. 1999; 
Bolander 1992; Simmons 1985). PDGF has been shown to play a role in 
stimulating both migration and proliferation of mesenchymal stem cells and 
osteoblasts, thus providing a population of osteoblast cells at the site of injury 
(Graves and Cochran 1990; Rasubala et al. 2003; Ross et al. 1986). In 
regards to osteoblast differentiation, it has been demonstrated that PDGF 
inhibits the differentiation of osteoblasts, by decreasing the expression of 
alkaline phosphatase, osteocalcin, and type I collagen in vitro (Yu et al. 
1997). Therefore the functions of PDGF as it relates to osteoblast function in 
bone repair appears to be the recruitment of osteoprogenitors to the site of 
injury, and stimulation of proliferation of these cells. It has also been 
demonstrated that PDGF can stimulate osteoclast bone resorption, by 
inducing expression of prostaglandins (Habenicht et al. 1986; Ross et al. 
1986; Tashjian et al. 1982). Thus PDGF may play a role in mediating bone 
remodelling processes during injury, due to its capability of influencing both 
bone formation and resorption.
The effects of PDGF on mesenchymal stem cells and osteoblasts are similar 
to those brought about by TGF-(3, and several reports have shown that TGF- 
(3 and PDGF actually work in synergy to promote migration and growth of
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osteoblasts (Kells et al. 1995). In osteoblast cell cultures it has been reported 
that TGF-p is capable of inducing the expression of PDGF (Rydziel et al. 
1992). This emphasises the need for a ‘cocktail’ of growth factors to work 
synergistically to bring about bone repair processes.
1.2.6.4 Vascular Endothelial Growth Factor
VEGF promotes vascular development and adult angiogenesis (Breier and 
Risau 1996; Ferrara et al. 2003; Senger et al. 1997). Angiogenesis is critical 
for successful osteogenesis, since the vasculature is responsible for 
delivering oxygen, nutrients, soluble factors and cells to the bone tissue 
(Carano and Filvaroff 2003; Hsiong and Mooney 2006; Kanczler and Oreffo 
2008). Endothelial cells are the primary target of VEGF, but it has also been 
shown that VEGF is involved in modulating recruitment, survival, and activity 
of osteoblasts (Midy and Plouet 1994; Street et al. 2002). VEGF has been 
reported to directly stimulate the chemotactic migration of primary human 
osteoblasts, as well as inducing their differentiation (Mayr-wohlfart et al. 
2002; Orlandini et al. 2006). Many osteoinductive growth factors induce 
expression of VEGF, including TGF-p, BMPs and PDGF (Brogi et al. 1994; 
Carano and Filvaroff 2003; Deckers et al. 2002; Saadeh et al. 1999). VEGF 
has also been shown to function synergistically with BMP-4 to induce bone 
formation (Peng et al. 2002). The synergistic activity that VEGF appears to 
have with many other growth factors makes it an interesting candidate for 
possible clinical treatments (Ferrara 2004), with studies showing that delivery
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of recombinant VEGF (Street et al. 2002), or adenovirus-delivered VEGF 
(Tarkka et al. 2003) promotes blood vessel formation and ossification in 
rodent models of bone damage.
1.2.6.5 Fibroblast Growth Factors and Insulin-like Growth Factors
Fibroblast growth factors (FGFs) play critical roles in mediating angiogenesis 
and mitogenesis of mesenchymal cells (Baird and Walicke 1989; Friesel and 
Maciag 1995; Ornitz and Itoh 2001). FGF-1 (acidic FGF) and FGF-2 (basic 
FGF) are the most abundant, expressed in many tissues including bone 
matrix (Baird and Walicke 1989; Hauschka et al. 1986). FGFs are expressed 
by osteoblasts (Canalis et al. 1988), and can be detected in early stages of 
bone repair (Bolander 1992). The exact function of FGFs in osteoblast 
differentiation is unclear, with effects depending on the maturation of the cell 
(Debiais et al. 1998). It has been reported that FGFs increase proliferation of 
early immature osteoprogenitors and prevent apoptosis, increasing the pool 
of committed osteoblastic cells at the site of injury (Mansukhani et al. 2000). 
As these cells further differentiate in response to other factors, FGFs induce 
apoptosis of these cells, perhaps functioning to control the number of 
osteoblasts that undergo terminal differentiation (Mansukhani et al. 2000). 
These differentiation-dependent effects of FGF signalling on osteoblast 
apoptosis are likely to be important in controlling the rate of differentiation 
and ultimately osteogenesis.
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Insulin-like growth factors (IGFs) play critical roles in skeletal development 
(Lieberman et al. 2002). IGFs are expressed by bone cells (Trippel 1998), 
although they are also sequestered in the bone matrix (Bautista et al. 1991). 
IGFs can stimulate osteoblast proliferation and differentiation, particularly the 
later stages, by upregulating Osterix (Celil and Campbell 2005; Hughes et al. 
2006; McCarthy et al. 1989). IGF expression can be increased by both BMP- 
2 (Canalis and Gabbitas 1994) and TGF-p1 (Okazaki et al. 1995), although it 
has also been reported that TGF-p1, along with FGF-2 and PDGF, can 
suppress expression in several in vitro models (Gangji et al. 1998). The 
specific actions of the IGFs in bone repair are not fully elucidated, but may 
indicate the presence of late-stage differentiation osteoblasts around the site 
of a bone injury.
1.2.6.6 Wnts
In terms of bone repair, Wnt signalling appears to be involved in mediating 
only the early osteoblast differentiation stages, inducing expression of early 
markers Runx2 and alkaline phosphatase, but not inducing osteocalcin 
expression, associated with mature osteoblasts (Gaur et al. 2005; Gong et al. 
2001; Rawadi et al. 2003). Wnts are a group of over 19 secreted, lipid 
modified glycoproteins that regulate a variety of cellular activities such as 
proliferation, migration, and gene expression (Moon et al. 2002). They are 
known to be important in the development and patterning of the skeleton 
(Greco et al. 1996), but also actively partake in adult bone repair, where they
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stimulate osteoblast precursor growth as well as early differentiation events 
(Rawadi et al. 2003; Ross et al. 2000; Westendorf et al. 2004).
Induction of the Wnt proteins themselves appears to be under the regulation 
of the TGF-p family, most notably BMP-2, which has been shown to induce 
Wnt signalling in vitro (Bain et al. 2003), and may be required for BMP2- 
induced expression of alkaline phosphatase within osteoblasts (Rawadi et al. 
2003). The exact nature of the interaction between BMPs and Wnts is not yet 
clear, and neither is the exact role that Wnts play in osteoblast differentiation 
and bone repair. However Wnt activity present around a site of bone injury 
would indicate BMP activity, strongly indicating the presence of differentiating 
osteoblasts and therefore bone formation.
1.2.6.7 Sonic Hedgehog
Members of the hedgehog family of signalling molecules play central roles in 
the control of pattern formation and cellular proliferation during development 
(Hammerschmidt et al. 1997; Perrimon 1995). Sonic hedgehog is involved in 
regulation of skeletal formation (Spinella-Jaegle et al. 2001) and in vitro can 
induce osteoblast differentiation within osteogenic precursors and 
osteoblasts (Nakamura et al. 1997). Sonic hedgehog has also been shown to 
increase the commitment of mesenchymal stem cells to the osteoblastic 
lineage, and inhibits adipocyte differentiation of these cells (Spinella-Jaegle 
et al. 2001). It has also been shown to act synergistically with BMP-2 during 
osteoblast differentiation (Nakamura et al. 1997; Spinella-Jaegle et al. 2001;
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Yuasa et al. 2002), although the precise nature of the interaction is not yet 
elucidated.
1.2.7 Major Transcription Factors Involved in Bone Repair
In bone repair, growth factors exert transcriptional regulation via transcription 
factors which initiate signalling cascades within target cells, shifting their 
differentiation towards the osteoblast lineage, and away from pathways 
towards other cell lineages.
TAZ, upregulated by BMP-2, is involved in stimulating differentiation of 
mesenchymal stem cells into osteoprogenitors, and also suppresses the 
formation of adipocytes (Hong et al. 2005). TAZ stimulates osteoblast 
differentiation by acting as a specific transcriptional coactivator of Runx2 (Cui 
et al. 2003; Kanai et al. 2000), essential for osteoblast differentiation and 
ultimately repair processes in bone (Ducy and Karsenty 1995; Ducy et al. 
1997; Perinpanayagam et al. 2006). TAZ is thought to bind to Runx2 in the 
cytoplasm, and therefore may play a role in its nuclear translocation, where 
transcriptional activation can then occur (Cui et al. 2003). Runx2 is able to 
stimulate the differentiation of cells down an osteoblastic lineage by binding 
to promoter regions within a number of osteoblast-related genes, such as 
osteocalcin, osteopontin, type I collagen, and bone sialoprotein, and inducing 
expression of these proteins (Ducy et al. 1997). Komori and colleagues 
(1997) demonstrated the absolute requirement for Runx2 expression in bone
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formation processes, as Runx2 knockout mice exhibit complete lack of bone 
formation and die at birth without breathing, probably due to the lack of 
ossification of the ribs (Komori et al. 1997). Examination of osteoblasts from 
within these Runx2 knockout mice embryos demonstrate that maturational 
arrest occurs within these cells at an early stage of osteoblast differentiation, 
as the cells express osteonectin, an early marker of differentiation, but 
express only low levels of alkaline phosphatase, and barely detectable levels 
of the later markers osteopontin and osteocalcin. This indicates that Runx2 
plays a critical role in the differentiation of early, immature osteoblasts.
Expression of Runx2 can also be induced via the BMP2-activated Dlx5 
transcription factor, a homeobox gene involved in stimulating later phases of 
the osteoblast differentiation pathway, activating expression of proteins such 
as alkaline phosphatase and osteocalcin (Kim et al. 2004). Msx2 is another 
homeobox transcription factor induced by BMP-2 which is associated with 
stimulation of osteoblast differentiation, and suppression of adipocyte 
differentiation (Cheng et al. 2003b; Ichida et al. 2004). BMP2-stimulated 
expression of Msx2 in turn induces expression of Osterix, another 
transcription factor absolutely required for the differentiation of osteoblasts 
that upregulates osteocalcin and alkaline phosphatase (Cheng et al. 2003b; 
Matsubara et al. 2008; Tu et al. 2006). Osterix knockout mice develop a 
similar phenotype to Runx2 knockout mice (Komori et al. 1997), whereby a 
complete lack of osteoblast differentiation results in the arrest of both 
intramembranous and endochondral ossification, leading to an entire lack of 
skeletal development (Nakashima et al. 2002). Interestingly, however, Runx2
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expression was observed in the Osterix knockout mice, at a level comparable 
to normal wild type mice, suggesting that Osterix is not required for 
expression of Runx2. Within the Runx2 knockout mice, no expression of 
Osterix could be detected, suggesting that Osterix acts downstream of 
Runx2, and that Osterix expression requires the presence of Runx2, which 
has been demonstrated to bind to the Osterix promoter and stimulate 
transcription (Nakashima et al. 2002; Nishio et al. 2006).
The signalling pathways involved in regulating bone repair are complex. As 
such the growth factors and the transcription factors described here are by 
no means the only factors involved in the osteoblast differentiation process, 
and many of these signalling pathways are still to be fully elucidated. 
However, the factors described here are well documented to be significantly 
involved in the differentiation of cells down an osteoblast lineage, and many 
of them can be detected by various qualitative and quantitative techniques. 
As such they are established indicators of osteoblast activity, and therefore 
bone formation, and they enable a picture of cellular activity to be established 
when examining repair processes in bone.
1.2.8 Major Proteins Expressed in Bone Repair
The many growth and transcription factors responsible for driving repair 
processes in bone ultimately regulate production of proteins within target 
cells. This coordinated secretion dictates functionality of bone repair, and
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secreted proteins can be biomarkers for monitoring repair processes. These 
proteins drive both osteoblast and osteoclast differentiation, thus regulating 
processes of bone formation and resorption, essential for repair and 
remodelling. Although each protein has specific roles in bone repair, they 
work synergistically in order to coordinate aspects of the process. The 
temporal specificity of proteins in the cellular differentiation pathways make 
them ideal indicators of cellular behaviour around a site of bone injury.
1.2.8.1 Type I Collagen
Type I collagen is the major protein found within the bone matrix, comprising 
around 90% of the organic phase, and is secreted by osteoblasts as they 
differentiate from their precursors (Buckwalter et al. 1995; Kalfas 2001; 
Seyedin and Rosen 1990). Structurally, each type I collagen molecule is 
comprised of three helical polypeptide subunits, together forming a triple 
helix, and these collagen helices associate to form fibrils, which may then 
further associate to form bundled collagen fibres (Allori et al. 2008). The 
network of these type I collagen fibres provide the structure onto which bone 
mineral is deposited (Baht et al. 2008). This is a highly organised process, in 
which hydroxyapatite mineral is first deposited into gaps between each 
collagen subunit, which provide nucleation sites for the mineral and allow the 
process to progress so that eventually mineral deposits occupy all of the 
available space within the fibrils (Buckwalter et al. 1995). The exact 
mechanism of bone mineral formation is not yet elucidated, although one
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proposed mechanism involves the binding of a protein nucleator to the 
collagen, perhaps one of the acidic ECM proteins known to be modulators of 
mineral formation, such as the phosphoprotein bone sialoprotein (Baht et al.
2008).
As well as representing a structural element of the matrix essential for 
mineralisation, collagen type I also actively contributes to the regulation of 
cellular activities involved in bone repair and remodelling processes (Ramirez 
and Rifkin 2003). Collagen type I is able to interact with both osteoblasts and 
osteoclasts via cell surface integrins, promoting cell attachment to the bone 
matrix (Clover et al. 1992; Helfrich et al. 1996; Xiao et al. 1998), and is also 
capable of chemotactically attracting osteoclast precursors (Malone et al. 
1982). Collagen is then able to modulate the activity of the cells, by 
influencing morphology, proliferation, and signal transduction, thus 
influencing processes of both bone formation and resorption (Green et al. 
1995).
1.2.8.2 Osteopontin
Osteopontin is a phosphorylated glycoprotein found within the bone matrix 
and concentrated at cement (renewal) lines; it is both aspartic-acid rich and 
highly phosphorylated, resulting in a highly acidic protein (Giachelli and Steitz 
2000). It is this highly acidic character, and the presence of a number of 
putative calcium binding motifs, that enable osteopontin to bind large
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amounts of calcium and interact with hydroxyapatite crystals with high 
affinity, suggesting a role for regulating mineral deposition in bone (Giachelli 
et al. 1995). It is also able to be crosslinked by transglutaminase, enabling 
binding to other ECM components such as type I collagen and osteocalcin, 
thus adding physical strength to the matrix and enabling accumulation of 
osteopontin within the ECM (Denhardt and Noda 1998). The primary role of 
osteopontin is thought be as a cell attachment protein due to a number of cell 
adhesive domains found within its structure, which include RGD domains, 
anchoring osteoblasts and osteoclasts to bone during repair processes 
(Denhardt and Noda 1998; Reinholt et al. 1990; Ross et al. 1993). As well as 
being contained within the bone matrix, expression of osteopontin has been 
demonstrated by several cell types, including osteoblasts and osteoclasts, as 
well as their respective progenitors (Denhardt and Noda 1998; Merry et al. 
1993; Yamate et al. 1997). Expression of osteopontin subsequently 
influences activity of the cells themselves, stimulating intracellular signalling 
pathways that modify cell behaviour and gene expression and influencing 
bone remodelling (Denhardt and Guo 1993; Miyauchi et al. 1991). 
Osteopontin expression within cells around a site of bone injury is indicative 
that osteoblast progenitors have migrated into the site and differentiated into 
osteoblasts.
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1.2.8.3 Osteocalcin
Osteocalcin (bone Gla protein / y-carboxyglutamate protein) is the most 
abundant non-collagenous protein within the bone matrix (Lian and 
Gundberg 1988). Osteoblasts are the only cell type to synthesise osteocalcin, 
and it is considered to be the most specific protein to bone (Ducy et al. 1997). 
The protein is released as a 10kD precursor (Pan and Price 1985) and Gla 
residues are post-translationally synthesised within the protein and can bind 
calcium. This enables tight binding of osteocalcin to hydroxyapatite, 
facilitating protein accumulation within the matrix (Kudo et al. 1998; Lian and 
Friedman 1978). The majority of osteocalcin is incorporated into the bone 
matrix, although it can also be released into the blood circulation where it can 
function as an indicator of bone turnover (Polak-Jonkisz and Zwolinska 1998; 
Price and Nishimoto 1980). The exact functions of osteocalcin are as yet not 
fully elucidated, but the ability of the protein to bind calcium suggests a role in 
mediating matrix mineralisation (Lian and Gundberg 1988). Osteocalcin has 
been shown to be a potent chemoattractant for mesenchymal stem cells, 
osteoblasts, osteoclasts, and their precursors, indicative of a role in bone 
repair and remodelling processes (Lucas et al. 1988; Malone et al. 1982). 
There is a high correlation between circulating serum levels of osteocalcin 
and bone formation, with elevated levels observed in situations of new bone 
formation or increased bone turnover (Lian and Gundberg 1988; Taniguchi et 
al. 2003). Thus osteocalcin both accumulated within the bone matrix, and 
released into circulation by osteoblasts near a site of bone injury, could
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chemotactically attract both osteoblasts and osteoclasts to the site, coupling 
formation and resorption processes, critical for repair and remodelling (Lucas 
et al. 1988).
1.2.8.4 Osteonectin
Osteonectin, also known as SPARC (Secreted Protein, Acidic and Rich in 
Cysteine), is a calcium-binding glycoprotein that is expressed within areas of 
bone remodelling and repair (Alford and Hankenson 2006). Osteonectin is 
able to bind to ECM components, including collagen and hydroxyapatite, thus 
contributing to the organisation of the matrix, and may be involved in 
regulating cell proliferation and cell-matrix interactions (Brekken and Sage 
2000; Young et al. 1992). Mice deficient in osteonectin have been shown to 
have significantly lower numbers of both osteoclasts and osteoblasts, leading 
to a dramatic decrease in bone formation and development of a low-turnover 
osteoporosis-like phenotype (Delany et al. 2000; Delany et al. 2003). 
Osteonectin present within the bone matrix may stimulate stromal cell 
differentiation towards the osteoblastic lineage, at the expense of 
adipogenesis (Bradshaw and Sage 2001; Delany et al. 2003). Osteonectin 
also appears to provide a survival function for osteogenic cells, particularly in 
times of stress (Bradshaw and Sage 2001), and may be critical for survival of 
cells during bone damage, to enable repair.
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1.2.8.5 Bone Sialoprotein
Bone sialoprotein (BSP) is an acidic phosphoprotein expressed in abundance 
by osteoblasts and present at high levels within mineralised bone tissues 
(Ganss et al. 1999). It is a member of the mineralised tissue-associated 
SIBLING (Small Integrin Binding Ligand, N-linked Glycoprotein) family 
(Fisher et al. 2001). BSP contains motifs that enable interaction of the protein 
with multiple binding partners, including collagen, matrix metalloproteinases, 
hydroxyapatite, and integrins (Baht et al. 2008; Fisher et al. 2001; Oldberg et 
al. 1988; Wuttke et al. 2001). This diverse binding ability leaves the exact role 
of BSP still unknown, although in regards to bone repair it is thought to be 
involved with the onset of mineralisation (Baht et al. 2008; Chen et al. 1994), 
and play a role in promoting osteoblast differentiation, particularly the later 
stages (Gordon et al. 2007).
1.2.8.6 Alkaline Phosphatase
The human alkaline phosphatases are a group of membrane-bound 
glycoproteins that are expressed throughout the body in four isoforms; three 
of these isoenzymes are expressed in a tissue-specific distribution and are 
thus called intestinal, placental, and germ cell (McKenna et al. 1979; Schar et 
al. 1997). The fourth isoenzyme, tissue non-specific alkaline phosphatase 
(TNAP), is ubiquitous, but expressed abundantly in liver, kidney, and bone 
(Moss 1992; Schar et al. 1997). This bone-expressed alkaline phosphatase
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enzyme is involved in biomineralisation (Robison 1923), cleaving ester bonds 
of pyrophosphates, potent inhibitors of hydroxyapatite crystal growth (Whyte 
1994), and releasing inorganic phosphate into the matrix (Houston et al.
2004). In terms of bone repair alkaline phosphatase is known to be 
expressed on the surface of osteoblast progenitors and osteoblasts 
themselves, and is a widely accepted marker of differentiating osteoblasts 
(Kim et al. 2004). BMP-2 has been shown to induce expression of alkaline 
phosphatase (Rawadi et al. 2003; Yamaguchi et al. 1991), and serum levels 
of the enzyme have been shown to be elevated during fracture healing 
(Taniguchi et al. 2003).
1.2.9 Impaired Bone Healing
Through the actions of the cells, proteins, growth factors, and transcription 
factors detailed above, the complex processes involved in bone repair will 
often lead to normal and natural healing of the injured bone. However, there 
are many clinical situations where repair processes are impaired. Examples 
of impaired bone healing can be seen in fracture non-unions (Kloen et al. 
2002; Marsh 1998), non-healing sockets after tooth extraction, and patients 
suffering from diseases such as osteonecrosis, caused by reduced blood 
flow to the bones (Reid 2008), osteoporosis, where bone mineral density is 
reduced (Namkung-Matthai et al. 2001; Tang et al. 2008), and diabetes, 
where patients often show significantly reduced bone healing capabilities 
(Gandhi et al. 2005; Loder 1988; Macey et al. 1989). Other factors can also 
contribute to poor healing, such as smoking (Hollinger et al. 1999), infection
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at the site of injury, and the use of certain medications, including non­
steroidal anti-inflammatory drugs (NSAIDs) (Simon et al. 2002; Zhang et al. 
2002).
Current clinical therapies for bone injury are mostly used to aid normal bone 
healing processes, or to heal small defects. The therapies are used 
infrequently, if at all, in conditions where normal bone healing does not occur, 
or occurs at a significantly reduced rate. There is therefore much interest in 
refining and developing such treatments, and in particular expanding 
therapies so that they may be used in conditions where healing is impaired.
1.3 BIOMIMETIC MATRICES
Biomaterials are now commonplace in modern clinical approaches towards 
bone tissue engineering and regeneration (Axelrad et al. 2007; Finkemeier 
2002; Mahendra and Maclean 2007). Such materials are osteoconductive 
scaffolds that passively facilitate bone repair by providing a physical three- 
dimensional matrix to facilitate attachment of cells and subsequent repair of 
damaged bone, although they may also be used in cell-based therapies to 
deliver transplanted cells to a site of injury. Interest has also focused on 
coupling these scaffolds with exogenous growth factors, or utilising those 
contained endogenously within the bone matrix, actively inducing bone 
formation via osteoinduction.
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Both synthetic and natural polymers have been extensively investigated for 
possible uses as biomaterials in tissue regeneration. Biological materials 
from natural sources have the advantages of being biologically recognisable, 
can present receptor-binding ligands, and are susceptible to cell-triggered 
proteolytic degradation and remodelling. Such natural matrices include 
collagen, hyaluronan, and Bio-Oss®, a natural osteoconductive bovine bone 
substitute used primarily to fill bone defects in periodontal and maxillofacial 
surgery (Benke et al. 2001). Natural matrices provide structural scaffolds that 
can resist both tensile and compressive stresses, via the protein fibrils and 
hydrated network respectively (Lutolf and Hubbell 2005). The biophysical 
properties of natural ECMs can also influence cellular functions, as cells can 
sense mechanical properties of their environment, and convert these 
mechanical signals into chemical signals. However, significant disadvantages 
are associated with them, including problems of purification, immunogenicity 
and transmission of pathogens (Lutolf and Hubbell 2005). Synthetic materials 
may overcome the problems involved with biological materials, as they 
attempt to mimic properties of biological ECM material without the side 
effects outlined above. For example, micro- and nano-fibrillar synthetic 
materials attempt to recreate the fibrillar architecture of natural ECM 
components, whereas hydrogels attempt to mimic the hydrated network. 
Hydrogels are of particular interest, as they can be synthesised in gentle 
enough conditions for the presence of cells, allowing cell entrapment within 
the structure for possible delivery to an injury site (Hennink and van Nostrum 
2002).
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Biomaterials that can actively induce bone formation in an osteoinductive 
manner are ultimately more successful than those which function as a 
passive scaffold. The addition of exogenous bioactive molecules to 
biomaterials, or an ability to release bioactive factors already present within 
the bone matrix, may increase the potential of biomaterials in bone tissue 
regeneration therapies.
1.3.1 Clinical Treatments: Bone Autograft and Allograft
Current clinical treatments of bone injury commonly see the use of bone 
autograft (bone taken directly from the patient) or bone allograft (bone 
derived from biopsies from other patients or cadavers) as materials to aid in 
the processes of skeletal repair and regeneration (Finkemeier 2002). Bone 
grafts can enhance healing where repair does not occur normally, but the use 
of autografts and allografts has many associated problems. Both types of 
bone graft are dependent on the surrounding environment to provide cells 
and a blood supply, as well as mechanical stability, and therefore the 
success of a bone graft in enhancing bone repair is greatly influenced by the 
environment in which it is placed (Stevenson 1998). Infection at the site of a 
graft is also common. The usefulness of autogenous bone is often limited by 
the amount of material that is available, the necessity of a second operation, 
and the risk of complications at the donor site (Salkeld et al. 2001). Allograft 
bone is often the preferred choice for grafting material, as it has a less limited 
supply, and large structural restorations are possible. However, allograft has 
a much smaller osteoinductive capacity when compared to autograft, and a
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limited capacity to incorporate with host bone (Heiple et al. 1963). Another 
problem is that allograft is often highly sterilised to reduce pathogen 
contamination, which can lead to a severe loss of the osteoinductive activity 
of the material (Lutolf et al. 2003). The problems associated with bone grafts 
continue to drive the development of new and improved clinical methods for 
bone regeneration, particularly in situations where repair processes are 
impaired.
1.3.2 Clinical Treatments: Growth Factor Therapy
Research into alternative therapies has focused on the many bone-inducing 
proteins present in bone (Urist 1965). Natural ECM modulates tissue repair 
by binding, storing, and releasing these bioactive growth factors to elicit local 
signalling responses as required (Hauschka et al. 1986; Taipale and Keski- 
Oja 1997). Several strategies to engineer the release of growth factors from 
biomimetic matrices have been presented over the years (Luginbuehl et al. 
2004; Malafaya et al. 2002). Animal models have been utilised to investigate 
the effects of exogenous growth factors on repair, with studies demonstrating 
that addition of TGF-(3 can increase callus formation and strength, and bone 
formation, either on its own or in conjunction with IGF-1 (Lee et al. 2006; 
Schmidmaier et al. 2004; Srouji et al. 2004). Studies have also demonstrated 
that recombinant bFGF can promote fracture healing, and prevent non-union 
(Kawaguchi et al. 2001; Nakamura et al. 1998). Particular attention has 
focused on the BMPs, potent inducers of bone formation. Recombinant
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BMPs have the ability to heal critical sized bone defects in a number of 
animal species when combined with a carrier of collagen, demineralised 
bone matrix, biodegradable polymers, or hydroxyapatite (Kang et al. 2004). 
Recombinant BMP-2 and BMP-7 are now commercially available, and 
research has focused on their delivery into the site of injury using a 
biomimetic scaffold or carrier (Gautschi et al. 2007). Successful clinical trials 
using growth factor therapy have led to the FDA-approval of both BMP-2 and 
BMP-7 for clinical use in the treatment of non-union in long bones 
(Friedlaender et al. 2001; Govender et al. 2002) and in the induction of spinal 
fusion (Boden et al. 2000; Vaccaro et al. 2003).
Problems currently associated with this field of clinical treatment are related 
to the massive milligram doses of growth factor required to elicit a therapeutic 
response in humans, which is in stark contrast to the natural situation (Reddi 
1998). These problems may be due in part to the treatments containing a 
single growth factor. This is very different to an in vivo situation, where a 
whole plethora of growth factors work synergistically, activating a complex 
network of signalling pathways and stimulating optimal repair (Hughes et al. 
2006; Lieberman et al. 2002; Lutolf and Hubbell 2005). It may be that clinical 
treatments that allow for the sequential delivery of multiple growth factors will 
show more success at clinically treating bone injury (Richardson et al. 2001).
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1.4 MODELLING OF BONE REPAIR
1.4.1 Current Models
The development of alternative clinical therapies for bone injury to overcome 
some of the current associated limitations is hampered by research models 
currently available for studying bone repair. In vitro models use only a single 
cell system, or at most two in the case of organotypic models. Single cell 
systems typically involve the isolation of primary osteoblasts or osteoclasts, 
or their respective progenitors, or the use of established bone cell lines, to 
investigate the behaviour of these cells in response to varying treatments. 
This might involve the addition of exogenous growth factors (Abdelmagid et 
al. 2007; Canalis and Lian 1988; Itonaga et al. 2004; Yamaguchi et al. 1996) 
or treatment with vitamins (Matsumoto et al. 1991; Shi et al. 2007). 
Organotypic in vitro models co-culture two different cell types, examples 
being the co-culture of osteoblasts with chondrocytes to investigate the 
biological integration of cartilage grafts with subchondral bone (Jiang et al. 
2005), or the co-culture of osteoblasts and haematopoietic stem cells to 
investigate physical interactions between the cell types (Jung et al. 2005). 
While such in vitro models can provide information on the behaviour of single 
cell types in response to varying factors, or the influence of one cell type on 
another in the case of organotypical models, the information they can yield is 
limited as they are unable to recapitulate the spatial arrangement of cells in 
vivo. In vivo models of bone repair have been developed in a variety of
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animals (Lu and Rabie 2003; Mark et al. 2004; Pearce 2007; Petite et al. 
2000) and are often critical sized defect models developed in the calvaria, 
mandible or femur (Fini et al. 2005; Schmitz and Hollinger 1986). While they 
have yielded considerable information on bone repair, in vivo models also 
have limitations and problems. They are expensive, requiring large numbers 
of animals, with a typical ethos of one animal equalling one experiment. It 
can also be difficult to obtain clear data from in vivo model systems due to 
the intrinsic systemic influences, which although important for modulating 
repair processes can often confuse and cloud the underlying molecular 
mechanisms. There are also the ethical ramifications associated with in vivo 
work. Ex vivo models may have significant advantages over the models 
above, as cells and tissue are in the same spatial arrangement as in vivo, 
while systemic influences are removed. Furthermore, multiple experiments 
can be carried out on single animals, reducing animal numbers and 
experimental costs.
1.4.2 Ex Vivo Modelling
In 1998, Sloan and colleagues developed an ex vivo tooth slice model (Sloan 
et al. 1998), with the aim of developing a novel system to investigate dentine 
repair processes, overcoming some of the problems associated with in vitro 
and in vivo models. The model, using cultured rat incisor slices, has been 
used successfully to investigate a wide range of dental repair processes 
(Sloan et al. 2000a; Sloan et al. 2000b; Sloan and Smith 1999), including the 
study of angiogenesis within the pulp (Gonpalves et al. 2007) and
51
assessment of the cytotoxicity of commonly used dental materials (Murray et 
al. 2000). The model also provided a basis for the development of another ex 
vivo model; a mandible slice organ culture model (Dhopatkar et al. 2005). 
This model was developed to investigate the effects of externally applied 
forces on the dentine-pulp complex, as a means of modelling orthodontic 
forces. This thesis aims to develop this ex vivo mandible slice model for 
investigating bone repair processes. Cells are more likely to survive and 
proliferate within mandible slices, since the mandible contains bone cells 
present within both the endosteum and the trabecular bone, as opposed to 
cortical bone slices where cells only reside within the endosteum. Also the 
use of a Trowel type culture system enables natural perfusion of the bone 
tissue, promoting cellular survival and viability within the system. The 
periodontal ligament (PDL) within the mandibular tissue aids the fracturing 
process, ensuring attachment of bone. Use of mandible slices, with the 
presence of both bone and dental tissue, also allows greater flexibility of the 
model for future development, such as a model for inflammatory-mediated 
bone loss in periodontal disease.
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1.5 AIMS
This thesis aims to:
• Develop and validate a reproducible and quantitative ex vivo rat mandible 
fracture model that can be used to investigate specific molecular and 
cellular processes of bone repair;
• Investigate cellular responses by looking at proliferation, migration, and 
differentiation of cell types present within the model, in particular 
investigating cellular responses of the osteoblasts and their progenitors;
• Investigate the role that growth factors play in repair and regeneration, in 
particular cellular responses to these growth factors within the model;
• Develop a reproducible bone slab cell culture model to work in 
conjunction with the mandible model;
• Use the bone slab model to demonstrate release of bioactive molecules 
from bone matrix, and their effects on primary bone marrow stromal cells.
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CHAPTER 2
ORGAN CULTURE OF INTACT AND FRACTURED RAT MANDIBLE
SLICES
2.1 INTRODUCTION
As discussed in the introduction to this thesis, a major limiting factor towards 
understanding optimal repair processes, and refining and developing 
therapeutic approaches, is the lack of a suitable model system for studying 
aspects of bone repair and regeneration. In vitro models use a single cell 
system, for example the culture of bone marrow stromal cells (Yamaguchi et 
al. 1996), or at the most two cell types in the case of organotypical models, 
such as the co-culture of osteoblasts and haematopoietic stem cells to 
investigate physical interactions between the two cell types (Jung et al.
2005). The information such in vitro cell culture systems yield is limiting, as 
they cannot recapitulate the complex interactions that occur in vivo between 
the many cell types present in bone. Neither can such model systems 
recapitulate the spatial arrangement of cells in vivo. In vivo models of bone 
repair have been developed in a number of animals (Pearce 2007; Petite et 
al. 2000), and while they have yielded considerable information on processes 
taking place in bone repair, these models can also be limiting. Experiments 
are extremely costly, requiring large numbers of animals, and results can be 
somewhat ambiguous due to the complex systemic influences which, 
although Important for modulating bone repair processes, can often confuse
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and cloud the underlying molecular mechanisms. There are also the ethical 
ramifications involved in undertaking such in vivo work, especially 
considering the large numbers of animals that are often used in such 
experiments.
An attractive alternative to the more limiting in vitro and in vivo model 
systems may be ex vivo organ culture models. Such models involve the 
culturing of both cells and tissues in situ, in the same spatial arrangement 
that they would be found in vivo, but the systemic influences that often hinder 
in vivo experimentation are removed. Furthermore, the cost of experiments 
can be significantly reduced, as one animal can yield many experiments, as 
opposed to the one animal, one experiment policy often adopted in in vivo 
work. An ex vivo tooth slice model, involving the culture of rat incisor slices, 
has been developed (Sloan et al. 1998), and used successfully in the 
investigation of dental repair processes (Gonpalves et al. 2007; Murray et al. 
2000). This thesis chapter aims to build on this tooth slice model, by 
developing, refining, and characterising a quantitative ex vivo fractured rat 
mandible slice model, to investigate the processes involved in bone repair. 
Cellular behaviour within the model will be assessed by analysing 
morphology, proliferation, differentiation, and protein synthesis, to determine 
if mandible slices (both intact and fractured) can be cultured ex vivo while 
maintaining the viability and behaviour of the cells and tissues. The 
development of such a model may be invaluable in the search for ways to 
improve and enhance the initial stages of bone repair in patients, particularly 
where normal healing does not occur.
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CHAPTER TWO
SECTION A: 
ESTABLISHMENT OF OPTIMAL CONDITIONS FOR THE ORGAN 
CULTURE OF INTACT RAT MANDIBLE SLICES
2.2 MATERIALS AND METHODS
2.2.1 Preparation of tissue culture reagents 
Washing Medium
Washing medium of Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma 
Chemical Co Ltd, UK) was prepared containing 1% concentration of a 
penicillin / streptomycin / amphotericin solution (containing 10,000 units of 
penicillin, 10mg/ml of streptomycin, and 25pg/ml amphotericin B) (Invitrogen, 
UK) and 200mM L-glutamine (Invitrogen, UK).
Culture Medium
Culture medium of DMEM (Sigma Chemical Co Ltd, UK) was prepared 
containing 10% heat inactivated foetal calf serum (FCS) (Invitrogen, UK), 1% 
concentration of a penicillin / streptomycin / amphotericin solution (containing 
10,000 units of penicillin, 10mg/ml of streptomycin, and 25pg/ml amphotericin 
B) (Invitrogen, UK), 0.15mg/ml of ascorbic acid (Invitrogen, UK), and 200mM 
L-glutamine (Invitrogen, UK).
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Embedding medium for culture of mandible tissue
Embedding medium was prepared by adding 10ml of culture medium to 1% 
low melting point agar (agarose type VII) (Sigma Chemical Co Ltd) which had 
been previously sterilised by autoclaving.
2.2.2 Organ culture of intact mandible slices
Mandibles were dissected from 28 day old male Wistar rats, freshly sacrificed 
by CO2 asphyxiation. Soft tissue was removed with a sterile scalpel blade, 
and the mandible placed into sterile washing medium. After removal of the 
condyle, ramus, and molars with a segmented diamond-edged rotary saw, 
sections of mandible approximately 2mm thick were cut using the rotary saw 
cooled with washing medium at 4°C (Figure 2.1). Sterility of the disc was 
achieved by washing with 70% ethanol and distilled water prior to use. 
Mandible slices were placed immediately into fresh washing medium.
Incisor Molars Condyle
s
tv  ; - .13^
Ramus
2mm slices through 
mandible body
Figure 2.1: Preparation of mandibles.
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Two different culture methods were used for the organ culture of the intact 
mandible slices: base type cultures; and Trowel type cultures (Begue-Kirn et 
al. 1992; Sloan et al. 1998). For base type cultures, the intact mandible slices 
were transferred from the washing media into individual wells of a plastic 24- 
well plate (Greiner Bio-One, UK), and 2ml of culture media added to each 
well (Figure 2.2). For Trowel type cultures, the intact mandible slices were 
transferred from the washing media into individual wells of a plastic 96-well 
plate (Greiner Bio-One, UK) and embedded in 100pl sterile molten 
embedding media. Slices were left at room temperature for 10 min until semi­
solid, after which time the embedded mandible slices were transferred from 
the multiwell dish to a sterile 25mm diameter Millipore filter (mixed esters of 
cellulose acetate and nitrate). With the aid of a plastic ring support, the 
Millipore filter was floated on the surface of 2ml of culture medium in Trowel 
type cultures (Trowell 1959) in individual wells of a plastic 24-well plate 
(Greiner Bio-One, UK) (Figure 2.3). Mandible slices in both base and Trowel 
type cultures were incubated at 37°C, in a humidified atmosphere of 5% CO2 
in air, for 7, 14, or 21 days.
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Individual well 
of 24-well plate
Culture
medium
Mandible
slice
Figure 2.2: Base type culture.
Mandible slice embedded 
in agar media
Millipore filter 
floated on plastic 
ring support
Individual well of 
24-well plate
Culture medium
Figure 2.3: Trowel type culture.
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2.2.3 Histological examination
Following culture, mandible slices were fixed in 10% (w/v) neutral buffered 
formalin at room temperature for 24 hrs. Slices were then demineralised in 
10% (w/v) formic acid at room temperature for 72 hrs, while being gently 
agitated. Mandible slices were processed through a series of 70, 90, and 
100% graded alcohols, cleared through xylene, and taken to molten paraffin 
wax (Raymond Lamb, UK) on an automatic tissue processer (Shandon 
Pathcentre). Slices were embedded in paraffin wax in a metal mould prior to 
sectioning. Sections of 7pm thickness were cut on a rotary microtome (Leica) 
at different levels throughout the tissue and mounted onto glass SuperFrost 
microscope slides (Fisher Scientific Ltd, UK). In order to improve adhesion of 
sections to the slides, sections were dried in an oven at 65°C. Sections were 
then rehydrated by taking to xylene, a series of graded alcohols, and water. 
Sections were stained with haematoxylin, washed and blued in Scott’s tap 
water, and differentiated in 1% acid alcohol. After a further wash in tap water, 
sections were stained with eosin, washed in tap water again, and finally 
dehydrated through alcohol and cleared with xylene. Sections were mounted 
under a coverslip with DPX mounting medium (Raymond Lamb, UK), and 
examined on an Olympus AX40 light microscope. Photographs were taken 
using a Nikon DXM digital camera and ACT-1 imaging software. Cell 
numbers were automatically counted using Image ProPlus software within 
100pm2 areas of the PDL and the pulp of haematoxylin and eosin (H&E) 
stained mandible sections. 100pm2 areas within five random fields of view 
were counted per section. PDL and pulp cell counts were obtained for 7, 14,
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and 21 day cultures (n=12 for each time point), cultured in base and Trowel 
type cultures, and standard errors of the mean were calculated. Mean values 
were analysed using one-way analysis of variance (ANOVA) and Tukey’s 
post hoc test, to analyse differences between the cell numbers in different 
culture types and culture periods.
2.2.4 Cell viability assessment
At the end of a culture period, culture media was removed from each well, 
and mandible slices in Trowel type cultures were removed from the filters and 
placed onto the base of the well. 2ml of acridine orange / ethidium bromide 
solution (100pg/ml in DMEM prepared from 2.5mg/ml and 10mg/ml stock 
solutions respectively, Sigma Chemical Co, UK) was added to each culture, 
and incubated for 5 s. Mandible slices were then washed briefly in 2ml 
phosphate buffered saline (PBS) before being placed onto a microscope 
slide and examined immediately under UV light using an Olympus AX70 
fluorescence microscope. Viable cells actively extruded ethidium bromide 
and exhibited green fluorescence, whereas non-viable cells fluoresced red. 
Photographs were taken using a Nikon DXM digital camera and ACT-1 
imaging software.
2.2.5 Tritiated proline pulse chase
Cellular secretion of collagen can be shown by incorporation of tritiated 
proline (Kameyama 1975; Weinstock and Leblond 1974). Proline is an amino
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acid essential for the synthesis of collagen, and to a much lesser extent other 
proteins. Therefore the addition of a radiolabelled proline enables the 
visualisation of protein secretion.
Freshly prepared mandible slices were placed into individual wells of a plastic 
96-well dish (Greiner Bio-One, UK). 100pl of embedding media containing 
0.37MBq of 3H proline (Amersham, UK; L -  [5 3H] proline, specific activity 
925GBq/mmol; 25Ci/mmol) was added to each well, using a dedicated 
radioactive tray and sterile disposable pipettes to prevent contamination. 
Once semi-solid, slices were transferred into Trowel type culture containing 
2ml of culture media with 0.185MBq of 3H proline / ml of media. Slices were 
cultured at 37°C in 5% CO2 in air in a humidified incubator for 48 hrs. After 48 
hrs, culture media was removed, and replaced with fresh working media 
containing no radiolabel. Cultures were continued for up to 7 or 14 days. 
Control cultures were prepared in the absence of radiolabel within the 
embedding or working media. Mandible slices were placed into individual 
wells of a plastic 96-well plate, into which 100pl of embedding media was 
added and left to solidify. Once semi-solid, the embedded slices were 
transferred into Trowel type cultures containing 2ml of culture media. The 
control slices were cultured at 37°C in 5% CO2 in air in a humidified incubator 
for 7 or 14 days.
After a culture period of 7 or 14 days, slices were processed, embedded, and 
cut into 7pm sections (described in 2.2.3). Sections were dewaxed in xylene 
for 5-10 min, hydrated in industrial methylated spirit (IMS) for 5 min and left to
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air-dry before autoradiography was carried out in a light-tight darkroom using 
a photographic safelight to provide suitable illumination. All glassware was 
washed in 90% ethanol, followed by distilled water, prior to use. A glass 
dipping chamber containing molten LM-1 nuclear emulsion (Amersham, UK) 
was placed into a 45°C water bath. Experimental slides containing the 
histological sections of cultured tissue were dipped vertically into the dipping 
chamber for 5 s, withdrawn at a steady rate, and excess liquid removed from 
the back of the slide. Slides were placed face-up on an ice block, to gel the 
emulsion, for 5-10 min. Following this, slides were placed into a light-tight box 
and left at room temperature for 1-2 hrs to allow the slides to dry. Silica gel 
was placed into the box to provide a dry atmosphere and the slides were left 
in the dark at 4°C for 12 days to expose. Control slides were prepared to 
assess for false-positive signals, by dipping and exposing slides from 
unlabelled control cultures. To assess for false-negative signals, slides of 
sections incorporating radiolabel were dipped in nuclear emulsion and then 
exposed to the light for a few seconds. Control slides were exposed as 
previously described.
After a 12 day exposure, the slides to be developed were placed into 
Phenisol developing solution (Ilford Photo, UK; diluted 1:4 with distilled water) 
for 5 min with gentle agitation, under darkroom conditions. Slides were then 
placed into 0.5% (w/v) acetic acid stop solution for 1 min with gentle 
agitation, before being transferred into 30% (w/v) sodium thiosulphate fixing 
solution for 4 min, again with gentle agitation. Under light conditions, slides 
were soaked in fixing solution for a further 4 min, and then washed in gently
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running tap water (at room temperature) for 15 min. Slides were washed 
twice in distilled water (10ml/slide) for 15 min, and then counterstained with 
H&E (as described in 2.2.3).
The number of silver grains deposited were automatically counted within 
100pm2 areas of the PDL matrix, or within the predentine, of radiolabelled 
mandible sections, using Image ProPlus software. Silver grain numbers were 
also calculated within similar areas in unlabelled control cultures. 100um2 
areas within five random fields of view were counted per section. PDL and 
predentine grain counts were obtained for 7 and 14 day cultures (n=10 for 
each time point), cultured in base and Trowel type cultures, and standard 
errors of the mean were calculated. Mean values were analysed using one­
way ANOVA and Tukey’s post hoc test, to analyse silver grain deposition 
over the culture period.
2.2.6 Immunohistochemistrv
Immunohistochemical staining was carried out on mandible slices cultured in 
Trowel type cultures for 7 or 14 days. Following histological fixation, 
demineralisation, processing and embedding of mandible slices (as 
described in 2.2.3), 7pm thick sections were cut on a rotary microtome at 
different levels throughout the tissue and mounted onto glass SuperFrost 
microscope slides (Fisher Scientific Ltd, UK). Sections were dried overnight 
in an oven at 65°C prior to immunolocalisation, in order to improve adhesion 
of sections to the slides.
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Sections were deparaffinised and hydrated by washing with xylene for 5-10 
min, IMS for 5 min, and rinsing in distilled water for 5 min. Sections were then 
incubated in 3% hydrogen peroxide solution for 10 min to quench 
endogenous peroxidase activity and washed in tris-buffered saline (TBS) 
buffer for 2x 2.5 min. The staining for proliferating cell nuclear antigen 
(PCNA), an indicator of cellular proliferation, and osteopontin and alkaline 
phosphatase, markers of osteoblast differentiation, was carried out using a 
Vectastain ABC peroxidase kit (Vector Laboratories Ltd). The kit included 
normal horse serum for blocking, a universal biotinylated secondary antibody 
and the ABC’ reagent -  a preformed avidin and biotinylated horseradish 
peroxidase macromolecular complex. The horseradish peroxidase is 
visualised by the development of a peroxidase substrate that produces a 
colour.
Sections were blocked using the normal horse serum diluted in TBS (50pl 
serum in 5ml TBS) for 20 min. Excess serum was wiped from the slides and 
sections incubated for 1 hr with the appropriate primary antibody, diluted 
appropriately in TBS / 1% bovine serum albumin (BSA) (Table 2.1). For 
negative controls, a non-immunogenic IgG isotype control antibody (Sigma 
Chemical Co; diluted to working concentration of primary antibody) was used 
instead of the primary, as well as exclusion of the primary antibody and 
replacement with TBS.
Following primary antibody incubation, sections were washed for 2x 2.5 min 
in TBS buffer and then incubated for 30 min with the universal biotinylated
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secondary antibody. Following a further TBS buffer wash, sections were 
incubated for 30 min with the VECTASTAIN ‘ABC’ reagent followed by 
incubation in DAB peroxidase substrate solution (Vector Laboratories) for 2-5 
min. Sections were rinsed in tap water, and counterstained with 0.1% light 
green for 1 min. Finally sections were dehydrated in IMS for 5-10 min, 
cleared in xylene for 5-10 min, and glass coverslips applied using DPX 
mounting medium (Raymond Lamb, UK). Sections were examined under an 
Olympus AX70 light microscope, and photographs taken using a Nikon DXM 
digital camera and ACT-1 imaging software.
Antibody Source of 
antibody
Isotype Source / 
species 
reactivity
Clone
ID
Antibody
Dilution
PCNA Santa Cruz 
Biotech
igG Monoclonal 
mouse anti-rat
PC10 1:20
Osteopontin Kind gift from 
Larry Fisher 
(Fisher et al. 
1995)
igG Monoclonal 
mouse anti­
human
LF-
124
1:250
Alkaline
Phosphatase
Santa Cruz 
Biotech
IgG Polyclonal 
rabbit anti­
human
H-300 1:50
Table 2.1: Immunohistochemistry primary antibodies.
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2.3 RESULTS
2.3.1 Histology and viability of intact mandible slices
2.3.1.1 Uncultured intact mandible slices
Studies were first performed on mandible slices that had not been cultured. 
H&E histology performed on these slices showed maintenance of 
architecture throughout the tissue, with the pink eosin staining highlighting 
intact bone, dentine and PDL (Figure 2.4). Morphological analysis of cells 
within all areas of the tissue indicated intact, viable cells with darkly stained, 
round nuclei. Cell types observed included osteoblasts and osteocytes within 
the bone, bone marrow stromal cells, PDL cells, odontoblasts and pulp cells. 
All cell types were observed to be residing within the appropriate areas of the 
tissue, where they would be found in vivo. Acridine orange / ethidium 
bromide vital dye staining of the surface of slices prior to culture showed 
significant cell death throughout the tissue (Figure 2.5). Since H&E histology 
demonstrated healthy viable cells further into the tissue, this may indicate 
surface damage due to the slicing procedure.
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Figure 2.4: Histology of uncultured mandible slices, showing maintenance of 
tissue and cells of the bone (B), periodontal ligament (PDL), dentine (D), and pulp
(P).
Figure 2.5: Acridine orange / ethidium bromide vital dye staining of an uncultured 
mandible slice showing bone (B), periodontal ligament (PDL), dentine (D), and pulp
(P).
68
2.3.1.2 24 hour culture of intact mandible slices
Intact mandible slices were prepared from 28 day old male Wistar rats and 
placed into either base type culture or Trowel type culture for 24 hours. H&E 
histology performed on base type cultures after this 24 hour period showed 
maintenance of tissue architecture within all areas, including the bone, 
dentine, and PDL, as indicated by the pink eosin stain highlighting these 
intact structures (Figure 2.6). Morphological analysis of cells within the tissue 
indicated the presence of intact, viable cells with darkly stained, round nuclei. 
Mandible slices cultured in Trowel type appeared morphologically very similar 
to those cultured in base type, with maintenance of tissue and cell 
morphology observed throughout the tissue (Figure 2.7). Generally, the 
morphological appearance of the tissues and cells closely paralleled that of 
the uncultured control mandible slices. Acridine orange / ethidium bromide 
vital dye staining of the surface of slices in both base type cultures (Figure 
2.8) and Trowel type cultures (Figure 2.9) demonstrated significant cell 
death, although again the H&E stains indicated healthy viable tissue further 
into the mandible slice. Taken together these results demonstrated that the 
observed cell death was present on the surface only, probably due to 
damage from the slicing procedure, indicating that the surface damage had 
not been resolved after 24 hours. Acridine orange / ethidium bromide staining 
of intact mandible slices after 4 days in culture, however, showed significantly 
improved cell viability, with the vast majority of cells across the surface of the 
tissue fluorescing green (Figures 2.10 and 2.11), indicating resolution of 
surface damage.
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Figure 2.6: Histology of 24 hour base type culture showing maintenance of cell 
and tissue architecture of the bone (B), periodontal ligament (PDL), dentine (D), 
and pulp (P).
Figure 2.7: Histology of 24 hour Trowel type culture showing maintenance of cell 
and tissue architecture of the bone (B), periodontal ligament (PDL), dentine (D), 
and pulp (P).
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Figure 2.8: Acridine orange / ethidium bromide vital dye staining of a mandible 
slice cultured for 24 hours in base type culture, showing bone (B), periodontal 
ligament (PDL), pulp (P) and dentine (D).
B
Figure 2.9: Acridine orange / ethidium bromide vital dye staining of a mandible 
slice cultured for 24 hours in Trowel type culture, showing bone (B), periodontal 
ligament (PDL), pulp (P) and dentine (D).
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Figure 2.10: Acridine orange / ethidium bromide vital dye staining of a mandible 
slice cultured for 4 days in base type culture, showing bone (B), periodontal 
ligament (PDL), pulp (P) and dentine (D).
Figure 2.11: Acridine orange / ethidium bromide vital dye staining of a mandible 
slice cultured for 4 days in Trowel type culture, showing bone (B), periodontal 
ligament (PDL), pulp (P) and dentine (D).
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2.3.1.3 7 day culture of intact mandible slices
After 7 days in base type cultures, H&E histology showed maintenance of 
architecture across the mandibular tissue, and was comparable to the 
uncultured and 24 hour cultured mandible slices (Figure 2.12). Cells in all 
areas appeared with darkly stained round nuclei and were observed to be 
morphologically similar to uncultured controls. Tissue and cell architecture 
appeared to be maintained to a slightly higher degree in Trowel type cultures 
(Figure 2.13). Acridine orange / ethidium bromide vital dye staining indicated 
a high level of cellular viability maintained throughout the tissue, in both base 
type cultures (Figure 2.14) and Trowel type cultures (Figure 2.15). The 
majority of cells exhibited green fluorescence, with only a few cells 
fluorescing red, and viability was comparable to slices cultured for 4 days.
Automated cell counts performed on H&E stained sections of base type 
cultures using Image ProPlus software calculated an average number of 91 ±
3.1 cells per 100pm2 area within the PDL, and an average number of 132 ± 
3.3 cells per 100pm2 area within the pulp. The same cell counts performed 
on Trowel type cultures calculated an average of 102 ± 5.4 cells per 100pm2 
area within the PDL, and an average number of 133 ± 2.8 cells per 100pm2 
area within the pulp (Figures 2.24 and 2.25). Statistical analysis showed no 
significant differences in cell numbers between base and Trowel type 
cultures, either in the PDL or the pulp (p>0.05).
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Figure 2.12: Histology of 7 day base type culture. Maintenance of cell and tissue 
architecture can be observed throughout the bone (B), periodontal ligament 
(PDL), dentine (D) and pulp (P).
Figure 2.13: Histology of 7 day Trowel type culture. Maintenance of cell and 
tissue architecture can be observed throughout the bone (B), periodontal 
ligament (PDL), dentine (D) and pulp (P).
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Figure 2.14: Acridine orange / ethidium bromide vital dye staining of a mandible 
slice cultured for 7 days in base type culture, showing bone (B), periodontal 
ligament (PDL), pulp (P) and dentine (D).
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Figure 2.15: Acridine orange / ethidium bromide vital dye staining of a mandible 
slice cultured for 7 days in Trowel type culture, showing bone (B), periodontal 
ligament (PDL), pulp (P) and dentine (D).
PDL
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2.3.1.4 14 day culture of intact mandible slices
Maintenance of tissue architecture was observed throughout mandible slices 
after 14 days in base type culture, and was comparable to the 7 day cultured 
mandible slices (Figure 2.16). Cells within the slices demonstrated darkly 
stained, round nuclei, and were morphologically similar to 7 day cultures. 
Similar results were observed with mandible slices in Trowel type cultures, 
with maintenance of cell and tissue architecture throughout the tissue, 
although as with the 7 day cultures, maintenance of tissue architecture 
appeared to be better within these Trowel type cultures (Figure 2.17). There 
did appear to be a slight decrease in cell numbers in the 14 day cultures, 
when compared with the 7 day cultures, and this was confirmed with 
automated cell counting (Figure 2.24 and 2.25). Within base type cultures, 
there were an average of 79 ±1.4 cells per 100pm2 area of the PDL, and 126 
± 6.3 cells per 100pm2 area of the pulp. Trowel type cultures had an average 
number of 89 ± 2.2 cells per 100pm2 area of the PDL, and 129 ± 3 cells per 
100pm2 area of the pulp. However, statistical analysis did not show this slight 
decrease in cell number to be significant (p>0.05). Also, acridine orange / 
ethidium bromide vital dye staining indicated high cellular viability across the 
tissue in both base type cultures (Figure 2.18) and in Trowel type cultures 
(Figure 2.19), indicating that although cell numbers had slightly decreased, 
the vast majority of the population remaining were still highly viable. Viability 
appeared to be higher within the Trowel type cultures when compared with 
the base type cultures, and there were slightly higher cell numbers within 
Trowel type cultures, although this was not shown to be significant (p>0.05).
76
  4 v *  *‘ , /<«if V. V *■*'.' ?•!.•■ *•*••'<»■»•
! w $ t ?  v ‘••/•' •
r s>v p.pv ; ;*••
*■• J 2 S S #  >**-> •.,.. .-.-
v*;.- ■*.*
'  ,#  • . . : • ■ •• ■ -.•__£__ «L^____ 1
v ' / - M l
i  \r . * •_ -v ^-,vv'* -
» f ' £  W - ' ;
. V ^ r r ' , -  . ' -  • ; .  «
» * 777X + * ‘ * i  „ <  '
5S
Figure 2.16: Histology of 14 day base type culture. Maintenance of cell and tissue 
architecture can be observed throughout the bone (B), periodontal ligament 
(PDL), dentine (D) and pulp (P).
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Figure 2.17: Histology of 14 day Trowel type culture. Maintenance of cell and 
tissue architecture can be observed throughout the bone (B), periodontal 
ligament (PDL), dentine (D) and pulp (P).
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Figure 2.18: Acridine orange / ethidium bromide vital dye staining of a mandible 
slice cultured for 14 days in base type culture, showing bone (B), periodontal 
ligament (PDL), pulp (P) and dentine (D).
Figure 2.19: Acridine orange / ethidium bromide vital dye staining of a mandible 
slice cultured for 14 days in Trowel type culture, showing bone (B), periodontal 
ligament (PDL), pulp (P) and dentine (D).
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2.3.1.5 21 day culture of intact mandible slices
After 21 days of culturing, maintenance of cell and tissue architecture could 
still be observed throughout both base type cultures (Figure 2.20) and Trowel 
type cultures (Figure 2.21). Tissue structure was well preserved and cells still 
appeared morphologically intact with round, darkly stained nuclei. Slices in 
Trowel type cultures appeared to demonstrate slightly better maintenance of 
tissue architecture and cellular viability. Results were comparable with 7 and 
14 day cultures, although cell numbers again appeared to have decreased. 
This was confirmed with automated cell counting (Figure 2.24 and 2.25), and 
statistical analysis confirmed that there were significant differences in cell 
numbers within the 21 day cultures, when compared to the 7 day cultures 
(p<0.001). This was shown in both base and Trowel type cultures, within both 
the PDL and the pulp. Within base type cultures, automated cell counts 
calculated an average of 47 ± 2.6 cells per 100pm2 area of the PDL, and 105 
± 2.5 cells per 100pm2 area of the pulp. Trowel type cultures had an average 
of 53 ± 1.2 cells per 100pm2 area of the PDL, and 107 ± 4 cells per 100pm2 
area of the pulp. However, despite this decrease in cell number, acridine 
orange / ethidium bromide vital dye staining indicated high cellular viability 
across the tissue in both base type cultures (Figure 2.22) and in Trowel type 
cultures (Figure 2.23). This indicated that a highly viable population of cells 
were still present after 21 days in culture. Viability appeared to be higher 
within the Trowel type cultures when compared with the base type cultures, 
as indicated by the presence of fewer dead cells, although there was no 
significant difference in cell numbers between the types of culture.
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Figure 2.20: Histology of 21 day base type culture. Maintenance of cell and tissue 
architecture can be observed throughout the bone (B), periodontal ligament 
(PDL), dentine (D) and pulp (P).
PDL'*
Figure 2.21: Histology of 21 day Trowel type culture. Maintenance of cell and 
tissue architecture can be observed throughout the bone (B), periodontal 
ligament (PDL), dentine (D) and pulp (P).
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Figure 2.22: Acridine orange / ethidium bromide vital dye staining of a mandible 
slice cultured for 21 days in base type culture, showing bone (B), periodontal 
ligament (PDL), pulp (P) and dentine (D).
Figure 2.23: Acridine orange / ethidium bromide vital dye staining of a mandible 
slice cultured for 21 days in Trowel type culture, showing bone (B), periodontal 
ligament (PDL), pulp (P) and dentine (D).
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Figure 2.24: Average cell numbers per 100pm2 area within the 
periodontal ligament after 7, 14 or 21 days of culture.
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Figure 2.25: Average cell numbers per 100pm2 area within the 
pulp after 7, 14 or 21 days of culture.
*** p<0.001
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2.3.2 Synthetic and secretory activity of intact mandible slices
2.3.2.1 7 day culture of radiolabelled intact mandible slices
After a 48 hr exposure to tritiated proline, and subsequent 7 day culture, 
mandible slices exhibited deposition of silver grains throughout the tissue, 
indicative of protein secretion (Figure 2.26). In particular, high densities of 
silver grains could be observed within and surrounding the cells of the PDL, 
within the matrix of both the PDL and the bone, and within the predentine of 
the dentine-pulp complex. Unlabelled but exposed control cultures, assessing 
for false-positive signals, demonstrated minimum silver grain deposition 
within the tissue, and the small amount that could be observed did not follow 
any distinctive deposition patterns (Figure 2.27). Automated counts of silver 
grains within both the PDL matrix (Figure 2.30) and the predentine (Figure 
2.31) showed significant increases (p<0.001) in 7 day cultures exposed to 
tritiated proline when compared with unlabelled control cultures.
2.3.2.2 14 day culture of radiolabelled intact mandible slices
After extension of the culture period to 14 days after exposure to a 48 hr 
pulse of tritiated proline, mandible slices again exhibited deposition of silver 
grains throughout the tissue (Figure 2.28). In contrast to 7 day cultures, 
higher densities of silver grains appeared to be deposited within the matrix of 
the PDL, and less associated with the actual cells of the PDL. There also 
appeared to be a higher density of silver grains within the predentine of 14
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day cultures, when compared with 7 day cultures. Unlabelled but exposed 
control cultures, assessing for false-positive signals, exhibited minimum 
deposition of silver grains within the tissue (Figure 2.29). The small amount 
of deposition that could be observed within these control cultures did not 
follow any distinctive deposition patterns, and was comparable to 7 day 
control cultures.
Automated counts of silver grains showed significant increases (p<0.001) in 
14 day cultures exposed to tritiated proline, when compared with unlabelled 
control cultures, both within the PDL matrix (Figure 2.30) and the predentine 
(Figure 2.31). Comparisons between 7 day cultures and 14 day cultures 
revealed significantly higher silver grain numbers within the PDL matrix of 14 
day cultures (p<0.001). There was also a slightly higher increase in silver 
grains within the predentine of 14 day cultures when compared with 7 day 
cultures, but this increase was not shown to be significant.
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Figure 2.26: Tritiated proline radiolabelled mandible slices cultured for 7 days. 
Silver grains can be seen within the cells and matrix of the periodontal ligament 
(PDL), and within the predentine (PD) of the dentine-pulp complex.
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Figure 2.27: Radiolabel false positive controls. Mandible slices cultured for 7 
days with no addition of radiolabel to the culture.
Figure 2.28: Tritiated proline radiolabelled mandible slices cultured for 14 days. 
Silver grains can be seen within the cells and matrix of the periodontal ligament 
(PDL), and within the predentine (PD) of the dentine-pulp complex.
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Figure 2.29: Radiolabel false positive controls. Mandible slices cultured for 14 
days with no addition of radiolabel to the culture.
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Figure 2.30: Average number of silver grains per 100 pm2 area 
within the periodontal ligament after 7 or 14 days of culture.
*** p<0.001
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Figure 2.31: Average number of silver grains within the 
predentine after 7 or 14 days of culture.
*** p<0.001
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2.3.3 Immunohistochemical characterisation
2.3.3.1 PCNA immunolocalisation
Cells exhibiting positive expression for the proliferation marker PCNA could 
be observed within the PDL, and bone marrow space, within mandible slices 
cultured for both 7 days (Figure 2.32A) and 14 days (Figure 2.32B). No
expression could be detected within the cells of the pulp or within non­
proliferating osteocytes. Negative controls either replaced the primary 
antibody with a non-immune IgG control (Figure 2.32C), or omitted the 
primary antibody (Figure 2.32D), and showed only the methyl green
counterstain.
2.3.3.2 Alkaline phosphatase immunolocalisation
Expression of the osteoblast differentiation marker, alkaline phosphatase, 
could be observed within some cells of the PDL, bone marrow spaces, and 
some osteocytes within the mandibular bone, in mandible slices cultured for 
both 7 days (Figure 2.33A) and 14 days (Figure 2.33B). There was no 
detectable expression within the pulp. Negative controls, where the primary 
antibody was replaced with a non-immune IgG control (Figure 2.33C) or 
where it was omitted (Figure 2.33D), showed only the methyl green
counterstain.
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2.3.3.3 Osteopontin immunolocalisation
Osteopontin is a protein thought to be involved in cell adhesion and matrix 
mineralisation. It is expressed by a variety of cell types, including 
osteoprogenitors, osteoblasts and osteoclasts, as well as being localised to 
the mineralised bone matrix, especially concentrated at cement lines 
(Giachelli and Steitz 2000). Expression of this protein could be detected in 
mandible slices cultured for both 7 days (Figure 2.34A) and 14 days (Figure 
2.34B). Expression was localised to cells within the PDL and bone marrow 
spaces. The pattern of expression was similar to that observed for 
immunolocalisation of alkaline phosphatase, with immunopositivity identified 
within cells of the PDL and bone marrow spaces. Negative controls either 
replaced the primary antibody with a non-immune IgG control (Figure 2.34C), 
or omitted the primary antibody (Figure 2.34D), and these controls showed 
only the methyl green counterstain.
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Figure 2.32: PCNA immunohistochemistry. Positive cellular expression 
(examples indicated by arrows) can be observed within cells of the periodontal 
ligament (PDL) and bone marrow (BM) within (A) 7 day cultures and (B) 14 day 
cultures. Negative controls using (C) a non-immune IgG or (D) omitting the 
primary antibody exhibit only the methyl green counterstain.
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Figure 2.33: Alkaline phosphatase immunohistochemistry. Positive cellular 
expression (examples indicated by arrows) can be observed within some cells of 
the periodontal ligament (PDL) and bone marrow (BM), and some osteocytes, 
within (A) 7 day cultures and (B) 14 day cultures. Negative controls using (C) a 
non-immune IgG or (D) omitting the primary antibody exhibit only the methyl 
green counterstain.
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Figure 2.34: Osteopontin immunohistochemistry. Positive cellular expression 
(examples indicated by arrows) can be observed within some cells of the 
periodontal ligament (PDL) and bone marrow (BM), within (A) 7 day cultures and 
(B) 14 day cultures. Negative controls using (C) a non-immune IgG or (D) 
omitting the primary antibody exhibit only the methyl green counterstain.
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2.4 DISCUSSION
This study has demonstrated the successful establishment of an ex vivo rat 
mandible culture model. Culture conditions have demonstrated that intact rat 
mandible slices can be successfully cultured for up to 21 days, with 
maintenance of tissue architecture, cellular morphology, and viability during 
this time. Cells have been shown to be actively synthesising and secreting 
matrix during the culture period and expression of typical in vivo proliferation 
markers and bone markers have been demonstrated within the various cell 
types.
Mandibles that had been initially sliced but not cultured, and mandible slices 
cultured for 24 hours, showed significant cell deajh across their surfaces. 
This was most likely due to initial surface damage caused by the slicing 
procedure, as histological stains indicated healthy viable tissue deeper into 
the mandible slice. However, 4 day cultures demonstrated significantly 
improved cellular viability, suggesting that after this time period the surface 
damage had been resolved, perhaps by apoptosis or necrosis of the cells 
and tissue being sloughed off to reveal healthy viable tissue underneath. In 
base type cultures these cells are likely to be sloughed off into the 
surrounding media, but in Trowel type cultures it is likely that these cells 
remain within the agar plug. After 4 days mandible slices remained highly 
viable for up to 21 days in culture, with very little observed decrease in 
cellular viability across the time period. Automated cell counts of these 
mandible slices did, however, reveal a decrease in cell numbers across the
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culture period, although the decrease was only statistically significant after 21 
days of culture. Such a decrease in cell number is probably due to cell death 
within the PDL and pulp across the extended time in culture, a problem often 
encountered during the culture of cells and tissues (Arden and Betenbaugh 
2004). There are a number of reasons for this decrease in cell number. 
Programmed cell death will occur due to the finite lifespan of the cells 
residing in the tissue, ultimately decreasing the number of resident cells 
within the mandible cultures. This aging of cells over time in culture will also 
leave them more susceptible to stress, particularly to the effects of reactive 
oxygen species (ROS) (Fatokun et al. 2008; Tan et al. 1998). These highly 
reactive molecules are a natural by-product of oxygen metabolism, playing 
important roles in cell signalling, but can cause significant structural damage 
in aged cells which have a declining ability to defend themselves. Cell death 
due to tissue hypoxia may also be a contributing factor to the decrease in cell 
numbers, particularly within the base type cultures, where the mandible slices 
were fully submerged in media and thus not cultured at the liquid-gas 
interface. It is likely that this type of culture technique would lead to a 
reduction in oxygen tension within the mandible tissues, important for 
maintaining essential cellular functions. A number of studies have 
demonstrated that hypoxia can affect cellular behaviour and viability, 
reducing cellular proliferation and viability (Park et al. 2002; Utting et al. 
2006), and decreasing expression of osteoblastic genes (Park et al. 2002). 
The cell death occurring during the extended culture period, observed as a 
decrease in cell numbers, is not apparent within the acridine orange / 
ethidium bromide viability stains, with the 21 day viability stains showing no
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significant increase in cell death. Since the stain only shows clearly the 
surface of the tissue, this is most likely due to the dead cells on the surface of 
the tissue being sloughed off, as previously seen at the beginning of the 
culture period, where damage from slicing was removed over time. H&E 
stains, which represent sections beneath the surface of the tissue, do 
however show some cell death occurring within the tissue. Importantly, 
although there is a decrease in cell numbers, both the viability stain and the 
histology stain demonstrate the presence of a remaining population of highly 
viable cells, even after 21 days of culture.
Two culture methods were utilised in this study: submerged base type 
cultures, where mandible slices are cultured on the base of a culture dish and 
submerged in media, and Trowel type cultures (Trowell 1959), where the 
slices are embedded in a semi-solid agar and cultured at the liquid-gas 
interface. Both methods are widely used in organ culture techniques, but the 
Trowel type culture has been previously reported to promote better viability 
and tissue morphology, both in culture of tooth tissue (Begue-Kirn et al. 1992; 
Sloan et al. 1998) and bone (Nifuji and Noda 1999). In this study, similar 
results have been observed, with Trowel type cultures yielding slightly higher 
cellular viability and maintenance of tissue architecture within the mandible 
slices. These observations are most likely due to the mandible slices being 
cultured at the liquid-gas interface, which allows for gaseous diffusion, 
thereby increasing oxygen tension within the tissues. As mentioned earlier, 
maintaining an appropriate oxygen tension is important for the viability of 
cells and tissues, and within bone cells it has been reported that hypoxia can
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inhibit both osteoblast viability (Utting et al. 2006), and osteogenic 
differentiation by decreasing the expression of the essential transcription 
factor Runx2 (Park et al. 2002). Therefore, a lower oxygen tension, such as 
that which may occur within submerged cultures, may affect both survival 
and differentiation of bone cells. Cell survival may also be affected within 
these submerged cultures due to the mandible slices being positioned on the 
base of the culture dish, resulting in one surface of the slice being in contact 
with plastic during the entire culture period. This may facilitate the out-growth 
of cells onto the tissue culture dish, as seen in classical explant cultures, and 
also may affect viability since the surface in contact with the dish may not be 
receiving suitable nutrient diffusion from the surrounding media. In contrast, 
mandible slices in Trowel type cultures reside in a three-dimensional agar 
medium, allowing for optimum nutrient diffusion into all areas of tissue. 
Another significant advantage of Trowel type cultures is that the system can 
be easily manipulated by addition of components to this semi-solid agar 
media that surrounds the mandible slice. The advantages of the Trowel type 
cultures are such that they were used in all further experiments involving the 
mandible model.
In order to confirm the activity of the cells within the mandible tissue during 
culture, the synthetic and secretory abilities of these cells were assessed 
using a tritiated proline pulse chase experiment. Proline is an amino acid 
essential for the production of collagen, as well as other proteins, albeit to a 
much lesser extent, and by incorporating a radiolabelled form of proline into 
the mandible cultures, it is possible to visualise cellular synthesis and
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secretion of protein (Sloan et al. 1998; Weinstock and Leblond 1974). After 7 
days of culture, the vast majority of protein secretion (as indicated by silver 
grain deposition throughout the tissue) was apparent within, and closely 
surrounding, the cells of the PDL, the matrix of both the PDL and the bone, 
and also within the predentine of the dentine-pulp complex. This suggests 
that the cells residing within the PDL and bone actively synthesise and 
secrete proteins into their surrounding matrix throughout the first 7 days of 
culture, and the odontoblasts present within the pulp secrete proteins into the 
predentine matrix. Since a large proportion of silver grains are closely 
associated with the cells after this time, and a much lesser proportion found 
within the matrix itself, it is likely that over the 7 days of culture the cells have 
taken up the radiolabelled proline, and begun to utilise it to synthesise 
proteins, but secreted only a small proportion. However, after extending the 
culture period to 14 days, a significantly greater proportion of silver grain 
deposition could be observed within the matrix of the PDL and bone (Figure 
2.28), with less being associated with the actual cells themselves. This 
suggests that the proteins synthesised by the cells residing in the PDL and 
bone during the first 7 days, were secreted into the matrix after 14 days of 
culture. These observations provide evidence that the cells present within the 
mandible model are capable of actively synthesising and secreting proteins 
throughout their period in culture, suggesting that the cells are actively 
functioning in culture, rather than simply laying dormant. The distribution of 
radiolabel detected by this autoradiographic method was similar to that 
observed in a similar ex vivo tooth slice model (Sloan et al. 1998), where 
after 7 days silver grain deposition were closely associated with the
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odontoblasts, and after 14 days distribution was predominately observed 
within the predentine.
Immunohistochemical characterisation of the model was carried out to 
investigate cell behaviour in the tissue under ex vivo culture conditions. 
Firstly, cellular proliferation was characterised by investigating the expression 
of PCNA, an established marker of cellular proliferation. PCNA, a co-factor 
for DNA polymerase 5, accumulates during the G1 phase of mitosis and is 
most abundant during the S phase, where DNA replication takes place, while 
little or no PCNA is expressed in resting cells (Celis et al. 1987). This 
temporal specificity of PCNA makes it a good marker for proliferation in cells. 
Within an in vivo situation, PCNA expression would be observed within the 
cells of the PDL, which is comprised predominantly of fibroblasts, which have 
a high proliferative capacity, as well as highly proliferative osteoprogenitor 
cells and mesenchymal stem cells (Lekic and McCulloch 1996; Seo et al. 
2004). These mesenchymal stem cells, which have the capability of 
differentiating down the osteoblastic linage in response to appropriate stimuli, 
are also present within the bone marrow spaces of the mandibular bone 
(Prockop 1997). It could be hypothesised, therefore, that PCNA expression 
within the mandible model would be localised to the cells within these areas 
of the PDL and bone marrow spaces. Immunohistochemistry data from the 
mandible slices confirmed expression of PCNA within these areas, both after 
7 and 14 days of culture. No PCNA expression was observed within the post­
mitotic odontoblast cells within the pulpal area (Arana-Chavez and Massa 
2004), and limited expression was observed within the cells of the pulp itself,
98
where the resident cells have a slow rate of turnover (Casasco et al. 1997; 
Pinzon et al. 1966).
Immunohistochemical localisation of alkaline phosphatase and osteopontin 
was carried out to investigate the type of cells residing within the cultured 
mandible tissue. Alkaline phosphatase is known to be expressed in vivo 
within osteoblasts, as well as their precursors, and as such is a widely 
accepted marker of the presence of differentiating osteoblasts (Kim et al. 
2004). Osteopontin is another protein expressed by cells of an osteoblastic 
lineage, thought to be involved in cell adhesion and matrix mineralisation 
(Merry et al. 1993; Yamate et al. 1997), and as such is also a marker of 
differentiating osteoblasts (Denhardt and Noda 1998; Giachelli and Steitz 
2000). Expression of both of these bone markers has been demonstrated 
within the ex vivo mandible model, within cells residing within the PDL and 
bone marrow spaces, after both 7 and 14 days of culture. The expression 
patterns observed in the model indicate the presence of cells of the 
osteoblastic lineage within the mandible tissues when cultured ex vivo, which 
may be osteoprogenitors, or fully differentiated osteoblast cells. This 
correlates with in vivo studies showing the presence of osteoblasts and their 
progenitors within both the PDL and bone marrow spaces (Isaka et al. 2001; 
Krebsbach et al. 1999; Lekic et al. 1996). However, the presence of these 
cells within the cultured mandible tissue is likely to represent cells remaining 
in the tissue from the start of culture, rather than demonstrating active 
differentiation occurring during culture, as no significant alterations in bone 
marker expression are observed. This data does however indicate that
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osteoblast cells can be maintained within the mandible tissue during 
culturing, within areas that would naturally contain these cells in vivo.
This chapter has demonstrated that intact mandible slices can be cultured for 
up to 21 days in culture, with maintenance of cell and tissue architecture, and 
cellular viability. Resident cells within the tissues were active throughout the 
culture period, secreting proteins into the matrix and predentine. The 
observed expression patterns of PCNA, alkaline phosphatase, and 
osteopontin suggest that the cells residing within the ex vivo model are 
behaving in a similar manner to that seen in vivo, both in terms of their 
cellular proliferation, and the localisation of osteoblast cells within the tissues. 
This suggests that the culture conditions are not significantly altering the 
cellular behaviour within the tissues. The development of this ex vivo 
mandible model has significant advantages over more traditional in vitro and 
in vivo modelling systems. Whereas in vitro models use only one or two cell 
types (Yamaguchi et al. 1996), the ex vivo mandible model enables the 
culture of many cell and tissue types together, allowing many of the complex 
interactions that occur in vivo to be recapitulated, but without the presence of 
the complex systemic influences that can often hinder in vivo 
experimentation. Furthermore, the ex vivo model system can significantly 
reduce costs and ethical objections, with one animal yielding up to eight 
experiments, as opposed to the one animal, one experiment ethos often used 
for in vivo work. The next part of this chapter aims to further develop and 
characterise this mandible culture system, to produce a quantitative model 
for investigating specific processes of bone repair.
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CHAPTER TWO
SECTION B: 
ORGAN CULTURE OF FRACTURED RAT MANDIBLE SLICES
2.5 MATERIALS AND METHODS
2.5.1 Organ culture of fractured mandible slices
Mandibles were dissected from 28 day old male Wistar rats, and slices 
prepared as in section 2.2.2. After preparation, a fracture was introduced into 
the mandible slices by placing pressure onto the central portion of the bone 
of the lingual plate using a sterile scalpel blade. Fractures were prepared in a 
similar location in each mandible slice. Fractured mandible slices were 
placed into Trowel type culture, as described previously (section 2.2.2) using 
prepared culture medium and embedding medium as described in section 
2.2.1. Slices were cultured at 37°C, in an atmosphere of 5% CO2 in air, in a 
humidified incubator, for 7, 14, or 21 days.
2.5.2 Histological examination
After each culture period, mandible slices were fixed, demineralised, 
processed, sectioned and stained for H&E as described in section 2.2.3. Cell 
numbers were automatically counted within 100pm2 areas of the PDL and the 
pulp of H&E stained mandible sections, using Image ProPlus software.
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100|jm2 areas within five random fields of view were counted per section. 
PDL and pulp cell counts were obtained for 7, 14, and 21 day cultures (n=12 
for each time point), and standard errors of the mean were calculated. Mean 
values were analysed using one-way ANOVA and Tukey’s post hoc test, to 
analyse differences between the cell numbers in different culture periods, as 
well as between the fractured and the intact mandible slices.
2.5.3 Cell viability assessment
Cellular viability within fractured mandible slice cultures was assessed with 
an acridine orange / ethidium bromide vital dye stain, as described in section 
2.2.4.
2.5.4 Tritiated proline pulse chase
The synthetic and secretory activity of cells within the fractured mandible 
slice cultures was investigated with tritiated proline pulse chase experiments, 
as described previously in section 2.2.5. Quantification and statistical 
analysis of silver grain deposition was also performed as in section 2.2.5.
2.5.5 Immunohistochemistrv
Fractured mandible slices cultured for 7 or 14 days were stained 
immunohistochemically for the expression of the proliferation marker PCNA, 
and the bone markers alkaline phosphatase and osteopontin, using the
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method described in section 2.2.6. Positive cells for each of the makers were 
automatically counted within 100[jm2 areas of the PDL using Image ProPlus 
software (n=5 for each marker). Positive cells were counted within a 100|jm2 
area of PDL adjacent to the site of fracture, 100pm2 areas of PDL either side 
of the fracture, and a 100pm2 area of PDL from the opposite side to fracture, 
to assess if the fracturing process was influencing the behaviour of the cells 
of the PDL in any way. Standard errors of the mean were calculated, and 
mean values were analysed using one-way ANOVA and Tukey’s post hoc 
test, to analyse differences between areas of PDL adjacent to the fracture 
site, and opposite the fracture site.
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2.6 RESULTS
2.6.1 Histology and viability of fractured mandible slices
Optimum culture conditions were established for the mandible model in 
section A of this chapter. It was observed that Trowel type cultures appeared 
to be more favourable in maintaining tissue architecture and cell viability, 
therefore this Trowel type system was used for all fractured mandible slices.
Mandible slices were firstly prepared and fractured, but not cultured. H&E 
histology of these slices showed maintenance of tissue architecture 
throughout all areas, including the bone, PDL, and dentine (Figure 2.35). 
Cells appeared viable, with darkly stained, round nuclei, and many cell types 
could be observed within the tissue. These included osteoblasts and 
osteocytes within the bone, bone marrow stromal cells, PDL cells, 
odontoblasts and pulp cells. Fractures were of a similar size and position in 
all slices. Cell and tissue architecture adjacent to the fracture site were well 
maintained, with no excess damage caused by the fracturing procedure. 
Acridine orange / ethidium bromide vital dye staining of uncultured tissues 
showed major cell death across the surface of the slice, including around the 
surface of the fracture site indicated by the presence of red fluorescence 
(Figure 2.36). Since H&E histology demonstrated healthy tissue further into 
the mandible slice, this may be due to surface damage due to the slicing 
procedure. Results for both H&E histology, and acridine orange / ethidium 
bromide staining, were comparable with those for uncultured intact slices.
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Figure 2.35: Histology of uncultured fractured mandible slices showing 
maintenance of tissue and cells of the bone (B), periodontal ligament (PDL), 
dentine (D), pulp (P), and around the site of fracture (F).
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Figure 2.36: Acridine orange / ethidium bromide vital dye staining of an uncultured 
fractured mandible slice, showing bone (B), periodontal ligament (PDL), pulp (P), 
dentine (D) and the fracture site (F).
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2.6.1.1 24 hour culture of fractured mandible slices
Mandible slices were prepared from 28 day old male Wistar rats, the bone 
fractured using a sterile scalpel blade, and slices placed into Trowel type 
culture for 24 hrs. H&E histology performed on these slices showed 
maintenance of tissue architecture within all areas of the tissue, including 
areas adjacent to the fracture site, as well as maintenance of cellular viability 
(Figure 2.37). Generally, the morphological appearance of the tissues and 
cells paralleled that of the uncultured control mandible slices. Acridine orange 
/ ethidium bromide staining again demonstrated significant levels of cell 
death throughout the tissue, indicating that surface damage had not been 
resolved after 24 hrs (Figure 2.38). However, there did appear to be an 
increase in the number of viable cells fluorescing green when compared with 
the uncultured control slices, and acridine orange / ethidium bromide staining 
of fractured mandible slices cultured for 4 days showed vastly improved cell 
viability throughout the entire of the surface (Figure 2.39).
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Figure 2.37: Fractured mandible slices after 24 hours culture.
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Figure 2.38: Acridine orange / ethidium bromide vital dye staining of a fractured 
mandible slice cultured for 24 hours.
Figure 2.39: Acridine orange / ethidium bromide vital dye staining of a fractured 
mandible slice cultured for 4 days.
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2.6.1.2 7 day culture of fractured mandible slices
After 7 days in culture, fractured mandible slices stained for H&E histology 
showed maintenance of cell and tissue architecture across the mandibular 
tissue (Figure 2.40). Cells appeared viable within all areas of the mandible 
slices, exhibiting darkly stained round nuclei, and both cell and tissue 
morphology and viability were maintained around the site of fracture. The 
fractured slices appeared morphologically similar to uncultured and 24 hour 
cultured slices. Acridine orange / ethidium bromide vital dye staining 
indicated maintenance of a high level of cellular viability across the surface of 
the tissue (Figure 2.41). The vast majority of cells exhibited green 
fluorescence, indicating their viability, and only a relatively few number of 
cells displayed red fluorescence. A large number of green fluorescing cells 
adjacent to the site of fracture indicated high viability at this area, with no 
increase in cell death associated with the fracturing process. Viability was 
comparable to slices cultured for 4 days.
Automated cell counts using Image ProPlus software were performed on 
H&E stained sections of fractured mandible slices cultured in Trowel type 
cultures for 7 days. The software calculated an average number of 99 ± 2.8 
cells per 100pm2 area within the PDL, and an average number of 126 ± 1.8 
cells per 100pm2 area within the pulp (Figures 2.46 and 2.47).
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Figure 2.40: Fractured mandible slices cultured for 7 days. Maintenance of cell 
and tissue architecture can be observed throughout the bone (B), periodontal 
ligament (PDL), dentine (D) and pulp (P). Cell and tissue architecture is 
maintained around the fracture site (F).
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Figure 2.41: Acridine orange / ethidium bromide vital dye staining of a fractured
mandible slice cultured for 7 days, showing bone (B), periodontal ligament
(PDL), pulp (P), dentine (D) and the fracture site (F).
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2.6.1.3 14 day culture of fractured mandible slices
After 14 days of culture, H&E histology demonstrated maintenance of tissue 
architecture throughout the mandible slice, including around the site of 
fracture (Figure 2.42). Cells appeared viable with darkly stained, round 
nuclei, and results were comparable with those for 7 day cultures. There 
appeared to be a slight decrease in cell numbers in the 14 day fractured 
cultures, when compared with the 7 day fractured cultures, and this was 
confirmed with automated cell counting, with an average of 86 ± 1.5 cells per 
100pm2 area counted within the PDL, and an average of 115 ± 1.7 cells per 
100pm2 within the pulp (Figure 2.46 and 2.47). However, statistical analysis 
did not show this decrease in cell number to be significant (p>0.05). Also, 
acridine orange / ethidium bromide vital dye staining demonstrated high 
cellular viability across the tissue surface (Figure 2.43), indicating that 
although there was a slight decrease in cell numbers, the vast majority of the 
cell population present were still highly viable. There was again a large 
population of viable cells adjacent to the site of fracture, with no increased 
cell death associated with this area, as shown by limited red fluorescence.
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Figure 2.42: Fractured mandible slices cultured for 14 days. Maintenance of cell 
and tissue architecture can be observed throughout the bone (B), periodontal
ligament (PDL), dentine (D) and pulp 
maintained around the site of fracture (F).
(P). Cell and tissue architecture is
Figure 2.43: Acridine orange / ethidium bromide vital dye staining of a fractured
mandible slice cultured for 14 days, showing bone (B), periodontal ligament
(PDL), pulp (P), dentine (D) and the fracture site (F).
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2.6.1.4 21 day culture of fractured mandible slices
Maintenance of cell and tissue architecture could still be observed throughout 
the fractured mandible slices after 21 days of culture (Figure 2.44). Tissue 
structure was well preserved within all areas and cells still appeared viable 
with round, darkly stained nuclei. Cell and tissue architecture were well 
maintained adjacent to the fracture site. Results were comparable with 7 and 
14 day cultures, although cell numbers again appeared to have decreased, 
and this was confirmed with automated cell counting. An average of 52 ± 1.3 
cells per 100pm2 area within the PDL was calculated, and an average of 113 
± 4.3 cells per 100pm2 was calculated within the pulp (Figure 2.46 and 2.47). 
Statistical analysis performed on these cell counts demonstrated that the cell 
numbers within the PDL of 21 day cultures were significantly decreased 
when compared to the 7 day cultures (p<0.001). However, there was no 
significant difference in cell numbers within the pulp. Also, despite the 
decrease in PDL cell number after 21 days of culture, acridine orange / 
ethidium bromide vital dye staining indicated high cellular viability across the 
tissue surface (Figure 2.45). This indicated the presence of a highly viable 
population of cells even after 21 days in culture.
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Figure 2.44: Mandible slices cultured for 21 days. Maintenance of cell and tissue 
architecture can be observed throughout the bone (B), periodontal ligament 
(PDL), dentine (D), pulp (P), and around the site of fracture (F).
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Figure 2.45: Acridine orange / ethidium bromide vital dye staining of a fractured
mandible slice cultured for 21 days, showing bone (B), periodontal ligament
(PDL), dentine (D), pulp (P), and the site of fracture (F).
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Figure 2.46: Average cell numbers per 100pm2 area within the 
periodontal ligament after 7, 14 or 21 days of culture.
*** p<0.001
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Figure 2.47: Average cell numbers per 100pm2 area within the 
pulp after 7, 14 or 21 days of culture.
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2.6.2 Secretory and synthetic activity of fractured mandible slices
2.6.2.1 7 day culture of radiolabelled fractured mandible slices
After a 48 hr exposure to tritiated proline, and subsequent 7 day culture, 
fractured mandible slices exhibited deposition of silver grains throughout the 
tissue (Figure 2.48). In particular, high densities of silver grains were 
deposited within (and closely surrounding) the cells of the PDL, within the 
matrix of both the PDL and the bone, and within the predentine of the 
dentine-pulp complex. Adjacent to the fracture site, silver grain deposition 
could be observed within both the bone matrix and PDL matrix. Unlabelled 
but exposed control cultures, assessing for false-positive signals, 
demonstrated minimum silver grain deposition within the tissue, and did not 
follow any distinctive deposition patterns (Figure 2.49). Automated counts of 
silver grains showed significant increases (p<0.001) in 7 day cultures 
exposed to tritiated proline when compared with unlabelled control cultures, 
both within the matrix of the PDL (Figure 2.52) and the predentine (Figure 
2.53).
2.6.2.2 14 day culture of radiolabelled fractured mandible slices
After a 48 hr exposure to tritiated proline, and extension of the subsequent 
culture period to 14 days, fractured mandible slices again exhibited 
deposition of silver grains throughout the tissue (Figure 2.50). Silver grain 
deposition could again be seen within the bone matrix and PDL matrix
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adjacent to the site of fracture. Higher silver grain density appeared to be 
deposited within the matrix of the PDL, and less associated with the actual 
cells of the PDL; a contrast to the results obtained after 7 days of culture.
There also appeared to be a higher density of silver grains within the
predentine of 14 day cultures, when compared with 7 day cultures. 
Unlabelled, but exposed control cultures, assessing for false-positive signals, 
exhibited minimum deposition of silver grains within the tissue (Figure 2.51). 
The small amount that could be observed did not follow any distinctive 
deposition patterns, and was comparable to 7 day control cultures.
Automated counts of silver grains with Image ProPlus software indicated 
significant increases (p<0.001) in 14 day cultures exposed to tritiated proline, 
when compared with unlabelled control cultures. This was observed both 
within the matrix of the PDL (Figure 2.52) and the predentine (Figure 2.53). 
Comparisons between 7 day cultures and 14 day cultures revealed 
significantly higher silver grain numbers within the PDL matrix of 14 day
cultures (p<0.05). A slightly higher increase in silver grains was also
observed within the predentine of 14 day cultures when compared with 7 day 
cultures, but this increase was not shown to be significant.
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Figure 2.48: Tritiated proline radiolabelled fractured mandible slices cultured for 
7 days. Silver grains can be seen within the cells and matrix of the periodontal 
ligament (PDL), within the predentine (PD) of the dentine-pulp complex, and 
within the matrix around the fracture site (F).
■>. 50um
Figure 2.49: Radiolabel false positive controls. Slices were exposed, but no 
radiolabel was added to the culture.
117
Figure 2.50: Tritiated proline radiolabelled fractured mandible slices cultured for 
14 days. Silver grains can be seen within the cells and matrix of the periodontal 
ligament (PDL), within the predentine (PD) of the dentine-pulp complex, and 
within the matrix surrounding the fracture site (F).
100um
Figure 2.51: Radiolabel false positive controls. Slices were exposed, but no 
radiolabel was added to the culture.
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Figure 2.52: Average number of silver grains per 100pm2 area within 
the periodontal ligament of fractured mandible slices after 7 or 14 days 
of culture.
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Figure 2.53: Average number of silver grains within the pulp of fractured 
mandible slices after 7 or 14 days of culture.
*** p<0.001
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2.6.3 Immunohistochemical characterisation
2.6.3.1 PCNA immunolocalisation
The observed pattern of PCNA expression was similar to that within intact 
mandible slices, with expression localised to cells of the PDL and bone 
marrow space, within slices cultured for both 7 days (Figure 2.54A) and 14 
days (Figure 2.54B). Expression appeared to be associated with PDL cells 
adjacent to the site of fracture, with less immunopositivity at sites further 
away from the site, although this was not shown to be significant (Figure 
2.55). No non-specific staining was observed within negative controls which 
either replaced the primary antibody with a non-immune IgG control (Figure 
2.54C) or omitted the primary antibody altogether (Figure 2.54D).
2.6.3.2 Alkaline phosphatase immunolocalisation
Alkaline phosphatase expression could be detected within cells within the 
PDL, bone marrow spaces, and some osteocytes, in a similar pattern to that 
observed in intact slices. Expression appeared to be localised to PDL cells 
adjacent to the fracture site, with less expression observed further away from 
the fracture site, although this was not shown to be significant (Figure 2.57). 
This expression pattern could be observed in fractured mandible slices 
cultured for both 7 days (Figure 2.56A) and 14 days (Figure 2.56B). Negative 
controls that replaced the primary antibody with a non-immune IgG control
120
(Figure 2.56C), or omitted the primary antibody (Figure 2.56D), showed only 
the methyl green counterstain with no non-specific staining.
2.6.3.3 Osteopontin immunolocalisation
Expression of the bone marker osteopontin could be detected around the 
fracture site, within cells of the PDL and bone marrow spaces, within 
fractured mandible slices cultured for both 7 days (Figure 2.58A) and 14 days 
(Figure 2.58B). Positive expression could also be detected in cells within the 
fracture site itself. In a pattern similar to that of PCNA and alkaline 
phosphatase, osteopontin expression appeared to be localised to PDL cells 
adjacent to the fracture site, and was increased compared to areas opposite 
the site of fracture, although this was not shown to be significant (Figure 
2.59). Negative controls, where the primary antibody was replaced with a 
non-immune IgG control (Figure 2.58C) or where it was omitted (Figure 
2.58D), showed no non-specific staining.
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Figure 2.54: Mandible slices immunohistochemically stained for expression of 
proliferation marker PCNA. Positive cellular expression (examples indicated by 
arrows) can be observed within cells of the periodontal ligament (PDL) and bone 
marrow (BM) within (A) 7 day cultures and (B) 14 day cultures. Negative 
controls using (C) a non-immune IgG or (D) omitting the primary antibody 
exhibits only the methyl green counterstain.
122
PCNA expression within fractured mandible slices
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Region of mandible slice
Figure 2.55: Number of PCNA positive cells within various 100pm2 areas of 
periodontal ligament in fractured mandible slices cultured for 7 or 14 days.
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Figure 2.56: Mandible slices immunohistochemically stained for expression of 
alkaline phosphatase. Positive cellular expression (examples indicated by 
arrows) can be observed within cells of the periodontal ligament (PDL) and some 
cells of the bone marrow (BM), within (A) 7 day cultures and (B) 14 day cultures. 
Negative controls using (C) a non-immune IgG or (D) omitting the primary 
antibody exhibits only the methyl green counterstain.
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Alkaline Phosphatase expression within fractured mandible slices
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Figure 2.57: Number of alkaline phosphatase positive cells within various 100pm2 
areas of periodontal ligament in fractured mandible slices cultured for 7 or 14 days.
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Figure 2.58: Mandible slices immunohistochemically stained for expression of 
osteopontin. Positive cellular expression (examples indicated by arrows) can be 
observed within some cells of the periodontal ligament (PDL) and bone marrow 
(BM), within (A) 7 day cultures and (B) 14 day cultures. Negative controls using 
(C) a non-immune IgG or (D) omitting the primary antibody exhibits only the 
methyl green counterstain.
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Osteopontin expression within fractured mandible slices
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Figure 2.59: Number of osteopontin positive cells within various 100pm2 areas 
of periodontal ligament in fractured mandible slices cultured for 7 or 14 days.
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2.7 DISCUSSION
This second part of this chapter has demonstrated that the ex vivo mandible 
model can be successfully fractured and cultured, without sustaining further 
damage to the tissue or cells. In similar results to those observed within intact 
mandible slices, fractured mandible slices could be successfully cultured for 
up to 21 days, with maintenance of cell and tissue architecture, and cellular 
viability adjacent to the site of fracture. As with the intact slices, cells within 
the fractured slices were shown to be actively synthesising and secreting 
proteins throughout the culture period, and expression of proliferation 
markers and bone markers were observed within various cell types adjacent 
to the site of fracture.
Mandibles that had been initially sliced and fractured, but not cultured, and 
fractured mandible slices cultured for 24 hrs, showed significant cell death 
across the tissue surface. This cell death was present throughout all areas of 
the tissue, including adjacent to the site of fracture. Since histological stains 
indicated healthy viable tissue further into the mandible slice, this damage 
was probably due to initial trauma to the tissue caused by the slicing 
procedure, as was previously observed within the intact slices. 4 day cultures 
of fractured mandible slices demonstrated a recovery in viability of surface 
tissue, again suggesting that by this time surface damage had been resolved, 
probably by damaged cells and tissue being sloughed off to reveal healthy 
viable tissue underneath. After the 4 day culture period, fractured mandible 
slices remained highly viable for up to 21 days in culture. There was very little
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decrease in cellular viability observed across this extended culture period, 
and importantly no decrease in viability was associated with areas of tissue in 
close proximity to the site of fracture. This demonstrates that the mandible 
slices can be successfully fractured without sustaining excessive damage to 
the cells and tissues within adjacent areas, thus providing a healthy and 
viable population of cells adjacent to the site of fracture with which to study 
early repair processes within the model. Automated cell counts of the 
fractured mandible slices did reveal a slight decrease in cell numbers across 
the culture period, both within the PDL and pulp, although statistical analysis 
only revealed a significant difference after 21 days of culture, and only within 
the PDL. This decrease in cell numbers was seen throughout the tissue, and 
was not significantly associated with the site of fracture, thus suggesting that 
the decrease was probably due to cell death caused by the extended time in 
culture, as seen previously in the intact mandible slices, and often 
encountered during cell and tissue culture (Arden and Betenbaugh 2004). 
Despite the decrease in cell numbers after 21 days in culture, both the 
viability stain and the histology stain demonstrate that after 21 days of culture 
there was still a significant presence of a highly viable cell population within 
the tissue, including adjacent to the fracture site.
The synthetic and secretory capabilities of the cells within the fractured 
mandible slices were assessed using a tritiated proline pulse chase 
experiment, to ensure that the fracturing procedure was not affecting the 
activity of the cells. After 7 days of culture, silver grain deposition (indicative 
of protein secretion) could be seen adjacent to the fracture site, both within
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and closely surrounding cells residing in this area. Some silver grain 
deposition could also be observed within the matrix itself, of both the bone 
and the PDL. After extension of the culture period to 14 days, a significantly 
greater proportion of silver grain deposition could be observed within the 
matrix of both the bone and the PDL adjacent to the site of fracture, with less 
being associated with the cells themselves. This suggests that the cells 
residing in the bone and PDL adjacent to the site of fracture synthesise 
proteins during the first 7 days, which remain closely associated with them, 
but by 14 days these proteins are secreted into the matrix. This provides 
evidence that these cells are actively synthesising and secreting proteins, 
showing their functionality. The distribution of radiolabel within the PDL of the 
fractured mandible slices was similar to the distribution observed in intact 
slices, and to that observed in the ex vivo tooth slice model (Sloan et al. 
1998), suggesting that fracturing does not detrimentally affect the activity of 
the cells, and cells can still actively function within the tissue.
Immunohistochemical staining was carried out to characterise the cells 
residing in areas adjacent to the site of fracture, to assess if the fracturing 
procedure was altering cell behaviour. Cellular proliferation was firstly 
assessed by investigating the expression of the cellular proliferation marker 
PCNA, followed by investigation of expression of the bone markers alkaline 
phosphatase and osteopontin. Cells positive for PCNA, alkaline 
phosphatase, and osteopontin could be observed within the PDL and bone 
marrow spaces adjacent to the site of fracture, after both 7 and 14 days of 
culture. Osteopontin positive cells could also be observed within the fracture
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site itself, which may have migrated from the PDL during the culture period, 
or may have been an artefact of the fracturing process which may have 
disrupted cells in the area. There was a slight increase in PCNA, osteopontin 
and alkaline phosphatase positive cells within areas adjacent to the fracture 
site, compared to mandible regions opposite to the site of fracture, although 
this was not shown to be significant. These observed increases, although not 
significant, may indicate stimulation of some early reparative processes 
within the tissue in response to the fracturing process, stimulating migration 
and proliferation of cells within the PDL. However, despite the presence of 
these responsive osteoprogenitors present within the mandible tissue, it is 
unlikely that any further repair mechanisms would be initiated during the 
culture period. The mandible model has a distinct lack of blood supply, and 
therefore lacks the inflammatory and haemopoietic cell lineages that in vivo 
would infiltrate the site of injury and bring about further repair responses, 
including osteoclastic bone resorption (Colnot et al. 2006; Mizuno et al. 1990; 
Oe et al. 2007). Therefore the mandible model probably lacks sufficient 
stimulus for bone repair within the tissue, in response to the fracture alone. 
However, this model provides a valuable tool with which to investigate 
specific early repair processes in bone in the absence of the systemic 
influences seen in vivo, which can often interfere with obtaining clear data 
from such experiments. Stimulation of the model, with growth factors or 
chemical treatments to release bone matrix components, will enable the 
study of the specific roles of these factors in repair processes in bone.
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CHAPTER 3
GROWTH FACTOR STIMULATION OF THE EX VIVO FRACTURED 
MANDIBLE MODEL
3.1 INTRODUCTION
During normal bone repair the processes of intramembranous and 
endochondral ossification will ultimately result in optimal repair of the 
damaged tissue and restoration of function (Vortkamp et al. 1998). Bone 
healing can, however, fail or be severely delayed in clinical situations such as 
fracture non-union and non-healing sockets following tooth extraction. 
Significant research over the last 25 years has sought to develop alternative 
therapies to aid in bone healing processes through the utilisation of 
osseoinductive or osseoconductive factors at the site of injury. The process 
of bone formation may be augmented by the clinical application of bone- 
inducing growth factors, which have long been known to govern successful 
bone healing processes. These have included the BMPs and other members 
of the transforming growth factor family, such as TGF-(31, using a scaffold or 
carrier (Boden et al. 2000; Friedlaender et al. 2001; Ramoshebi et al. 2002; 
Westerhuis et al. 2005). The clinical potential for these bioactive molecules 
is, at present, limited due to the supraphysiological milligram doses of the 
growth factor that are currently needed to elicit an effect in healing small 
bone defects, making them a highly expensive clinical treatment (Simpson et 
al. 2006).
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Recent studies using an ex vivo tooth slice culture system (Sloan et al. 1998) 
have demonstrated that the bioactive growth factor TGF-p1, applied to the 
tooth slice within either alginate hydrogels or agarose beads, has mitogenic 
effects on cells within the subodontoblast layer, and is capable of inducing 
differentiation of odontoblast-like cells within the dentine-pulp complex with 
subsequent upregulation of dentine matrix secretion (Dobie et al. 2002; Sloan 
et al. 1998; Sloan and Smith 1999). TGF-P1, as well as being present in the 
matrix of dentine (Sloan et al. 2000a), is the most abundant growth factor in 
bone (Fox and Lovibond 2005; Kanaan and Kanaan 2006). It is known to 
play key roles in bone repair processes, stimulating recruitment and 
proliferation of mesenchymal stem cells and osteoprogenitor cells at sites of 
injury (Barnes et al. 1999), as well as promoting early stages of differentiation 
within these cells (Bostrom and Asnis 1998; Janssens et al. 2005). It has also 
been demonstrated that serum levels of TGF-p1 are significantly reduced in 
patients displaying delayed fracture healing (Zimmermann et al. 2005). BMP- 
2 is another growth factor that also plays a critical role in the repair of bone, 
as it is capable of stimulating the differentiation of mesenchymal stem cells 
and osteoprogenitor cells into mature, fully functional osteoblast cells, 
capable of laying down new bone (Cheng et al. 2003a; Lieberman et al. 
2002). A substantial amount of research has been conducted into the clinical 
use of BMP-2 in bone repair, and successful clinical trials have led to the 
FDA-approval of BMP-2 in the treatment of non-union in long bones 
(Govender et al. 2002) and in the induction of spinal fusion (Boden et al. 
2000). Thus, it is apparent that these two growth factors are highly involved 
in the bone repair cascade, and it is likely that they work synergistically. TGF-
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(31 stimulates recruitment and proliferation of mesenchymal stem cells and 
osteoprogenitors, providing a pool of osteogenic cells at the site of bone 
injury, while BMP-2 serves to differentiate these cells down an osteoblastic 
lineage, thus providing a population of fully mature osteoblast cells capable 
of producing new bone to repair the damaged area.
The development of an ex vivo mandible slice culture system in this study 
provides a model for investigating specific mechanisms involved in growth 
factor regulation of bone repair processes, particularly within a delayed or 
non-healing clinical setting, and may provide a functional model for testing 
novel therapeutic agents. Thus the aim of this chapter of the study was to 
examine the effects of adding single exogenous TGF-(31 and BMP-2 to the 
fracture site of the mandible model, on the response and behaviour of the 
cells within the PDL during culture, to demonstrate proof of principle of the 
functionality of the model for testing novel therapeutics.
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3.2 MATERIALS AND METHODS
3.2.1 Cellular stimulation of fractured mandible slices with TGF-B1
Human recombinant TGF-|31 (PeproTech EC Ltd, UK) was solubilised in 
10mM citric acid (pH 3) to a concentration of 50(jg/ml, and then further 
diluted to a working concentration in 0.1% BSA in PBS and stored at -20°C. 
150pm sized Affi Gel Blue agarose beads (BioRad Laboratories, UK) were 
divided into 100 bead aliquots and incubated with 50pl 1.6pg/ml TGF-pi in 
0.1% BSA in PBS for 30 min at 37°C. As a control, 100 agarose beads were 
also incubated in 0.1% BSA in PBS without TGF-(31.
Fractured mandible slices were prepared from 28 day old male Wistar rats 
immediately before bead treatment (as described in 2.5.1). Prior to 
embedding in semi-solid agar medium the fracture site was packed with 6 
agarose beads ± TGF-p1 using sterile forceps and needles, with the aid of a 
dissecting microscope (Bausch and Lomb). The numbers of beads used 
were the optimal number that could be placed within the fracture site of the 
mandible slice without overlap. Once the beads were transferred, the 
mandible slices were cultured in Trowel type cultures (as described in 2.2.2) 
for 7 days. Control fractured mandible slices which had no beads transferred 
into the fracture site were also prepared and cultured in Trowel type cultures 
as above.
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3.2.2 Cellular stimulation of fractured mandible slices with BMP-2
Human recombinant BMP-2 (Invitrogen, UK) was solubilised in 20mM acetic 
acid to a concentration of 1 mg/ml, and then further diluted to a working 
concentration in 0.1% BSA in TBS and stored in -20°C. 150|jm sized Affi Gel 
Blue agarose beads (BioRad Laboratories, UK) were divided into 100 bead 
aliquots and incubated with 50|jl 100ng/ml BMP-2 in 0.1% BSA in PBS for 30 
min at 37°C. Control agarose beads were prepared as previously described 
(3.2.1).
Fractured mandible slices were prepared from 28 day old male Wistar rats 
immediately before bead treatment (as described in 2.5.1). Prior to 
embedding in semi-solid agar medium the fracture site was packed with 6 
agarose beads ± BMP-2 using sterile forceps and needles. Once the beads 
were transferred, the mandible slices were cultured in Trowel type cultures 
(as described in 2.2.2) for 7 days. Control fractured mandible slices which 
had no beads transferred into the fracture site were also prepared and 
cultured in Trowel type cultures.
3.2.3 Histological examination
After culture, fractured mandible slices stimulated with TGF-p1 or BMP-2 
(with respective control slices) were prepared for histological staining with 
H&E (as described in section 2.2.3). A total of 10 mandible slices were 
cultured for each treatment type and control type. Cell numbers were
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automatically counted within randomly selected 100pm2 areas of the PDL 
using Image ProPlus software. Cells were counted within the fracture site 
itself, within 100pm2 of the PDL adjacent to the site of fracture, and within 
100|jm2 areas of the PDL to the left and right of the fracture site. A control 
count was also taken within a randomly selected 100pm2 area of the PDL at 
a mandible region opposite the site of stimulation. Standard errors of the 
mean were calculated, and mean values were analysed using one-way 
ANOVA and Tukey’s post hoc test, to analyse differences between treatment 
types and controls. Statistical analysis was also used to compare between 
TGF-pi and BMP-2 stimulation.
3.2.4 Immunohistochemistrv
Fractured mandible slices stimulated with TGF-01 or BMP-2 (with respective 
control slices) were stained immunohistochemically for expression of the 
proliferation marker PCNA, and the bone marker osteopontin, as described in 
section 2.2.6. Expression of an additional bone marker, bone sialoprotein, 
was also examined using the same method as described in 2.2.6 (rabbit anti­
rat BSP, clone LF-87; diluted 1:50) (Fisher et al. 1995). A total of 5 mandible 
slices were cultured for each treatment type and control type, for each 
marker. Cells positive for each of the markers were automatically counted 
within randomly selected 100pm2 areas of the PDL using Image ProPlus 
software. Positive cells were counted within 100pm2 of the PDL adjacent to 
the site of fracture, and within 100pm2 areas of the PDL to the left and right of 
the fracture site. A control count was also taken within a 100pm2 area of the
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PDL at a mandible region opposite the site of stimulation. Standard errors of 
the mean were calculated, and mean values were analysed using one-way 
ANOVA and Tukey’s post hoc test, to analyse differences between treatment 
types and controls. Differences were also analysed between mandible slices 
stimulated with TGF-(31 and BMP-2, for each marker.
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3.3 RESULTS
3.3.1 Histology of TGF-B1 and BMP-2 stimulated mandible slices
Fractured mandible slices stimulated with TGF-(31 and subsequently cultured 
for 7 days showed aggregation of cells within the PDL in close proximity to 
the site of fracture and stimulation (Figure 3.1 A). This aggregation of cells 
was not observed within regions of PDL opposite the site of stimulation 
(Figure 3.1B) or within control mandible slices, either cultured in the presence 
of bead alone (Figure 3.1C) or in the absence of either bead or growth factor 
(Figure 3.1 D). Similar results were observed in fractured slices stimulated 
with BMP-2, with aggregation of cells observed within the PDL in close 
proximity to the BMP-2 soaked bead (Figure 3.2A). As with TGF-(31 
stimulation, regions of PDL opposite the site of BMP-2 stimulation (Figure 
3.2B) or within control mandible slices (Figures 3.2C and 3.2D) did not exhibit 
such increased cell numbers.
Statistical analysis of cell counts within 100pm2 areas of the PDL (Figure 3.3) 
indicated that the increase in cell numbers within the PDL of TGF-01 
stimulated mandible slices was significant, both adjacent to the site of 
fracture (p<0.001), 100pm to the left of the site of fracture (p<0.001) and 
100pm to the right of the site of fracture (p<0.01). These results were 
observed when compared with both control mandible slices. There was no 
significant difference in cell numbers within regions of mandible slices 
opposite the site of TGF-(31 stimulation, when compared to control slices
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(p>0.05). Cell counts within 100pm2 areas of the PDL in BMP-2 stimulated 
slices (Figure 3.4) showed similar significant increases in cell numbers, both 
adjacent to the site of fracture (p<0.001), 100pm to the left of the site of 
fracture (p<0.01) and 100pm to the right of the site of fracture (p<0.05). 
These results were observed when compared with both control mandible 
slices. There was no significant difference in cell numbers within regions of 
mandible slices opposite the site of stimulation, when compared to control 
slices. Statistical analysis of cell counts in TGF-(31 and BMP-2 stimulated 
mandible slices showed a decrease in PDL cell numbers within BMP-2 
treated mandible slices when compared to those treated with TGF-p1, but 
this was not shown to be significant (p>0.05).
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Figure 3.1: Mandible slices cultured for 7 days following stimulation with TGF-(31 
with agarose beads. (A) Aggregation of cells within the periodontal ligament 
(PDL) can be observed within close proximity to the site of fracture (F) in TGF-(31 
stimulated slices. Similar aggregation cannot be observed within (B) regions of 
PDL at the opposite side of stimulation, (C) in control slices cultured in the 
presence of agarose beads alone, or (D) in control slices cultured in the absence 
of either bead or growth factor.
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Figure 3.2: Mandible slices cultured for 7 days following stimulation with BMP-2 
with agarose beads. (A) Aggregation of cells within the periodontal ligament 
(PDL) can be observed within close proximity to the bead in BMP-2 stimulated 
slices. Similar aggregation cannot be observed within (B) regions of PDL at the 
opposite side of stimulation, (C) in control slices cultured in the presence of 
agarose beads alone, or (D) in control slices cultured in the absence of either 
bead or growth factor.
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Fractured mandible slices stimulated with TGF-b1 soaked
agarose beads
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Figure 3.3: Average cell numbers within 100|jm2 areas of periodontal ligament in 
fractured mandible slices stimulated with TGF-(31, compared with control slices 
cultured in the presence of bead alone, or in the absence of bead.
** p<0.01, *** p<0.001
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Fractured mandible slices stimulated with BMP-2 soaked agarose
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Figure 3.4: Average cell numbers within various 100|jm2 areas of periodontal 
ligament in fractured mandible slices stimulated with BMP-2, compared with control 
slices cultured in the presence of bead alone, or in the absence of bead.
* p< 0.05, ** p<0.01, *** pO.001
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3.3.2 Immunohistochemical characterisation of stimulated cells
3.3.2.1 PCNA immunolocalisation
Fractured mandible slices stimulated with TGF-p1 or BMP-2 exhibited higher 
expression of PCNA within cells of the PDL, closely associated with the site 
of stimulation (Figures 3.5A and 3.6A). This could be due to increased 
expression of the PCNA protein, or an increase in the number of cells around 
the stimulation site. There was an observed decrease in the number of PCNA 
positive cells within the PDL of control slices cultured with bead alone 
(Figures 3.5B and 3.6B) or in the absence of bead (Figures 3.5C and 3.6C). 
Statistical analysis indicated that the increase in the number of PCNA 
positive cells in TGF-pi stimulated cultures was significant, within 100pm2 
areas of PDL adjacent to the site of stimulation, and 100pm either side 
(p<0.01) (Figure 3.7). The number of positive cells was also significantly 
increased in BMP-2 stimulated slices, within 100pm2 areas of PDL adjacent 
to the stimulation site, and 100pm either side (p<0.01) (Figure 3.8). Control 
counts from a mandible region opposite the site of stimulation (either with 
TGF-pi or BMP-2) did not reveal any significant changes in PCNA 
expression, when compared with control slices. Statistical comparisons 
between TGF-p1 and BMP-2 stimulated slices indicated a higher number of 
PCNA immunopositive cells within TGF-P1 stimulated slices, but this was not 
shown to be significant (p>0.05). Negative controls replaced the primary 
antibody with a non-immune IgG control and showed the methyl green 
counterstain with no non-specific staining (Figures 3.5D and 3.6D).
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Figure 3.5: Mandible slices immunohistochemically stained for expression of 
PCNA (examples of PCNA immunopositivity indicated by arrows). Increased 
cellular expression can be observed within (A) cells of the periodontal ligament 
(PDL) in mandible slices stimulated with TGF-(31, when compared with (B) control 
mandible slices cultured with bead alone or (C) control mandible slices cultured in 
the absence of bead. (D) Negative controls using a non-immune IgG exhibits only 
the methyl green counterstain.
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Figure 3.6: Mandible slices immunohistochemically stained for expression of 
PCNA (examples of PCNA immunopositivity indicated by arrows). Increased 
cellular expression can be observed within (A) cells of the periodontal ligament 
(PDL) in mandible slices stimulated with BMP-2, when compared with (B) control 
mandible slices cultured with bead alone or (C) control slices cultured in the 
absence of bead. (D) Negative controls using a non-immune IgG exhibits only the 
methyl green counterstain.
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PCNA expression within fractured mandible slices stimulated with TGF-b1
■ No bead □ PBS soaked bead ■ TGFb soaked bead
Adjacent to fracture site Left side of PDL Right side of PDL Opposite fracture site
Region of mandible slice
Figure 3.7: Number of PCNA positive cells within various 100pm2 areas of 
periodontal ligament in fractured mandible slices stimulated with TGF-(31, compared 
with control slices cultured in the presence of bead alone, or in the absence of bead.
** p<0.01
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PCNA expression within fractured mandible slices stimulated with BMP-2
■ No bead □ PBS soaked bead ■ BMP2 soaked bead
Adjacent to fracture site Left side of PDL Right side of PDL Opposite fracture site
Region of mandible slice
Figure 3.8: Number of PCNA positive cells within various 100pm2 areas of 
periodontal ligament in fractured mandible slices stimulated with BMP-2, compared 
with control slices cultured in the presence of bead alone, or in the absence of bead.
** p<0.01
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3.3.2.2 Osteopontin immunolocalisation
Expression of the bone marker osteopontin appeared to be increased in 
mandible slices stimulated with either TGF-p1 or BMP-2, within cells of the 
PDL closely associated with the site of fracture and therefore stimulation 
(Figures 3.9A and 3.10A). Expression was lower within the PDL of control 
slices cultured with bead alone (Figures 3.9B and 3.1 OB) or in the absence of 
bead (Figures 3.9C and 3.10C), although this may be due to a reduction in 
cell number rather than a decrease in expression. Statistical analysis 
demonstrated that the number of osteopontin positive cells was significantly 
increased in mandible cultures stimulated with TGF-p1, within 100pm2 areas 
of PDL adjacent to the site of stimulation, and also 100pm either side 
(p<0.05) (Figure 3.11). Similar significant increases were observed within 
BMP-2 stimulated mandible slices, also within 100pm2 areas of PDL adjacent 
to the site of stimulation, and also 100pm either side (p<0.001) (Figure 3.12). 
Control counts from a mandible region opposite the site of stimulation (either 
with TGF-p1 or BMP-2) did not reveal any significant changes in expression 
of osteopontin. Treatment with BMP-2 appeared to elicit a greater response 
than TGF-p1 treatment, with a greater observed increase in osteopontin 
immunopositivity, but this was not shown to be significant (p>0.05). Negative 
controls (as prepared in 3.3.2.1) showed only the methyl green counterstain 
with no non-specific staining (Figure 3.9D and 3.10D).
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Figure 3.9: Mandible slices immunohistochemically stained for expression of 
osteopontin (examples of osteopontin immunopositivity indicated by arrows). 
Increased cellular expression can be observed within (A) cells of the periodontal 
ligament (PDL) in mandible slices stimulated with TGF-(31, when compared with 
(B) control mandible slices cultured with bead alone or (C) control slices cultured 
in the absence of bead. (D) Negative controls using a non-immune IgG exhibits 
only the methyl green counterstain.
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Figure 3.10: Mandible slices immunohistochemically stained for expression of 
osteopontin. Increased cellular expression (examples indicated by arrows) can be 
observed within (A) cells of the periodontal ligament (PDL) in mandible slices 
stimulated with BMP-2, when compared with (B) control mandible slices cultured 
with bead alone or (C) control slices cultured in the absence of bead. (D) Negative 
controls using a non-immune IgG exhibits only the methyl green counterstain.
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Osteopontin expression within fractured mandible slices stimulated with TGF-b1
■ No bead □ PBS soaked bead ■ TGFb soaked bead
Adjacent to fracture site Left side of PDL Right side of PDL Opposite fracture site
Region of mandible slice
Figure 3.11: Number of osteopontin positive cells within various 100pm2 areas of 
periodontal ligament in fractured mandible slices stimulated with TGF-(31, compared 
with control slices cultured in the presence of bead alone, or in the absence of bead.
* p<0.05
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Osteopontin expression within fractured mandible slices stimulated with
BMP-2
■ No bead □ PBS soaked bead ■ BMP2 soaked bead
* * *
* * *
* * *
Adjacent to fracture site Left side of PDL Right side of PDL Opposite fracture site
Region of mandible slice
Figure 3.12: Number of osteopontin positive cells within various 100pm2 areas of 
periodontal ligament in fractured mandible slices stimulated with BMP-2, compared 
with control slices cultured in the presence of bead alone, or in the absence of bead.
*** p<0.001
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3.3.2.3 Bone sialoprotein immunotocalisation
Localisation of a second bone marker, bone sialoprotein, demonstrated a 
similar expression pattern to osteopontin, with increased expression 
observed in TGF-p1 and BMP-2 stimulated mandible slices, within cells of 
the PDL closely associated with the site of stimulation (Figures 3.13A and 
3.14A). Expression again appeared to be reduced within the PDL of control 
mandible slices cultured with either bead alone (Figures 3.13B and 3.14B) or 
in the absence of bead (Figures 3.13C and 3.14C), although this could again 
be due to a decrease in cell number rather than actual expression. Statistical 
analysis demonstrated that there was a significant increase in the number of 
BSP positive cells in mandible cultures stimulated with TGF-(31, within 
100pm2 areas of PDL adjacent to the site of stimulation, and also 100pm 
either side (p<0.01) (Figure 3.15). The increase within BMP-2 stimulated 
slices was also significant, within 100pm2 areas of PDL adjacent to the site of 
stimulation, and also 100pm either side (p<0.001) (Figure 3.16). Control 
counts from a mandible region opposite the site of stimulation did not reveal 
any significant changes in BSP expression within cultures stimulated with 
either TGF-p1 or BMP-2. BMP-2 treatment appeared to stimulate a greater 
increase in BSP immunopositivity when compared with TGF-p1 stimulated 
mandible slices, in a similar way to osteopontin expression, but this was 
again not shown to be significant. Negative controls (as prepared in 3.3.2.1) 
showed only the methyl green counterstain with no non-specific staining 
(Figure 3.13D and 3.14D).
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Figure 3.13: Mandible slices immunohistochemically stained for expression of 
bone sialoprotein (examples of BSP immunopositivity indicated by arrows). 
Increased cellular expression can be observed within (A) cells of the periodontal 
ligament (PDL) in mandible slices stimulated with TGF-(31, when compared with 
(B) control mandible slices cultured with bead alone or (C) control slices cultured 
in the absence of bead. (D) Negative controls using a non-immune IgG exhibits 
only the methyl green counterstain.
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Figure 3.14: Mandible slices immunohistochemically stained for expression of 
bone sialoprotein. Increased cellular expression (examples indicated by arrows) 
can be observed within (A) cells of the periodontal ligament (PDL) in mandible 
slices stimulated with BMP-2, when compared with (B) control mandible slices 
cultured with bead alone or (C) control slices cultured in the absence of bead. 
(D) Negative controls using a non-immune IgG exhibits only the methyl green 
counterstain.
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BSP expression within fractured mandible slices stimulated with TGFb-1
No bead □ PBS soaked bead ■ TGFb soaked bead
■  I
Adjacent to fracture site Left side of PDL Right side of PDL Opposite fracture site
Region of mandible slice
Figure 3.15: Number of bone sialoprotein positive cells within various 100pm2 areas 
of periodontal ligament in fractured mandible slices stimulated with TGF-(31, 
compared with control slices cultured in the presence of bead alone.
** p<0.01
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BSP expression within fractured mandible slices stimulated with BMP2
■ No bead □ PBS soaked bead ■ BMP2 soaked bead
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Figure 3.16: Number of BSP positive cells within various 100pm2 areas of 
periodontal ligament in fractured mandible slices stimulated with BMP-2, compared 
with control slices cultured in the presence of bead alone, or in the absence of bead.
*** p<0.001
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3.4 DISCUSSION
This study has demonstrated the responsiveness of the ex vivo fractured 
mandible model to exogenously applied growth factors. Both TGF-|31 and 
BMP-2, key players in bone repair, were capable of affecting cellular 
behaviour within the model, influencing proliferation, migration, and / or 
differentiation. Treatment of mandible slices with either growth factor 
stimulated an aggregation of cells within the PDL adjacent to the site of 
stimulation, and an increase in both cell number and PCNA immunopositivity 
within this area. The increase in cell number observed after stimulation with 
TGF-p1 or BMP-2 could be due to an increase in cell migration towards the 
site of stimulation; TGF-p1 in particular is known to act as a chemoattractant 
for osteogenic cells (Lucas 1989). Alternatively, as the PCNA data may 
suggest, the growth factors may be initiating intracellular signalling cascades 
to increase cellular proliferation, thus increasing cell numbers (Centrella et al. 
1994; Jueren et al. 1999). This increase in cell number and PCNA 
immunopositivity was closely associated with the agarose bead, as 
demonstrated in Figures 3.2A and 3.6A, with aggregation of cells, and 
increased numbers of PCNA immunopositive cells, observed around the 
edge of the bead. It could be hypothesised that this was simply an edge 
effect due to the bead being present, but slices cultured in the presence of 
bead alone (as demonstrated in figure 3.2C) did not show a similar 
aggregation of cells associated with the bead. This observation was 
reproducible within each mandible slice. Results suggest that the effects 
observed are due to the effects of the growth factor, rather than just the
160
physical presence of the bead itself. Comparisons between TGF-(31 
stimulated slices and BMP-2 stimulated slices exposed some differences in 
both cell number and PCNA immunopositivity, with TGF-pi appearing to 
elicit a greater response than BMP-2. Adjacent to the fracture site, an 
average number of 97 ± 2 cells were counted within TGF-(31 stimulated 
slices, an increase to the 89 ± 3 cells counted within BMP-2 stimulated slices, 
with similar differences also observed 100pm2 either side of the fracture site. 
Similar differences in PCNA immunopositivity were also observed, with an 
average increase of 3 PCNA positive cells per 100pm2 area observed in 
TGF-pi stimulated cultures when compared with BMP-2 stimulated cultures, 
both adjacent to the site of fracture and 100pm either side. Although this 
difference was not shown to be significant by statistical analysis, it may still 
indicate a difference in the cellular effects induced by the two growth factors. 
TGF-p1 is known to be a potent stimulator of both migration and proliferation 
of mesenchymal stem cells and osteoprogenitors in bone repair (Barnes et 
al. 1999), and while BMP-2 has also been shown to stimulate proliferation of 
osteoprogenitors (Shui-bing et al. 2009; Yamaguchi et al. 1991), its main 
function is to drive the differentiation of these cells in repair processes 
(Hughes et al. 2006; Lieberman et al. 2002). This may explain the increase in 
cell numbers and PCNA immunopositivity observed in TGF-pi stimulated 
mandible slices compared with slices stimulated with BMP-2. Studies using 
TGF-pi in an ex vivo tooth slice culture system (Sloan et al. 1998) 
demonstrated similar results to those presented here, with exogenously 
applied TGF-pi having mitogenic effects on subodontoblast cells within the 
dentine-pulp complex (Dobie et al. 2002; Sloan and Smith 1999).
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To assess the effects of TGF-pi and BMP-2 on the behaviour of the cells 
within the mandible model, the expression of two bone matrix proteins were 
investigated: osteopontin, and bone sialoprotein. Expression patterns were 
similar for both markers, with TGF-|31 and BMP-2 increasing 
immunopositivity within PDL cells adjacent to the site of stimulation, as well 
as 100pm either side, probably due to the growth factors diffusing through 
the tissue from the beads placed within the fracture site. Importantly, no 
increase in immunopositive cells could be detected within PDL areas 
opposite to the site of stimulation, or within control slices cultured in the 
presence of bead alone, indicating that the observed results on cell 
behaviour were due to the presence of the growth factors, rather than the 
presence of the bead itself. This data correlates with previous studies 
demonstrating that TGF-p1 and BMP-2 can upregulate expression of both 
osteopontin and bone sialoprotein in vitro (Hullinger et al. 2001; Lecanda et 
al. 1997; Ogata et al. 1997), although within the mandible model it is not yet 
elucidated whether the increase in immunopositivity is due to the growth 
factors increasing expression of the proteins within target cells, or due to an 
increased number of cells present within the site of stimulation, thus 
increasing the immunopositivity observed. Future work could aim to further 
investigate the cause of this increase in immunopositivity, perhaps using 
laser capture microdissection to isolate PDL cells from within the mandible 
tissue. Osteopontin and bone sialoprotein gene levels could then be 
analysed in the presence or absence of growth factors, to elucidate if these 
molecules are causing increased expression.
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Comparison of immunopositive cell numbers between slices treated with 
TGF-pi and BMP-2 indicated an increase in the number of cells positive for 
both osteopontin and BSP within the PDL of slices stimulated with BMP-2; 
this increase was not proved to be significant with statistical analysis, but this 
may be due to the small numbers of immunopositive cells present, so any 
changes observed may not necessarily be statistically significant. The 
increase, even though not significant, may still be indicative that within the 
mandible model BMP-2 is more capable of stimulating osteoblast 
differentiation than TGF-p1. This hypothesis correlates with published data, 
since although TGF-p1 is also thought to be involved in stimulating some 
early stages of osteoblast differentiation (Bostrom and Asnis 1998; Janssens 
et al. 2005), it is the BMPs which are the most potent stimulators of 
osteoblast differentiation, with a unique ability to independently induce 
ectopic bone formation (Cheng et al. 2003a; Katagiri and Takahashi 2002; 
Phimphilai et al. 2006; Wozney and Rosen 1998).
This study has demonstrated that the ex vivo mandible culture model is 
suitable for investigating the role of specific growth factors in repair 
processes in bone. The results obtained were reproducible, in terms of both 
histology and immunohistochemical characterisation, and similar patterns 
and results were observed within the mandible slices during each 
experiment. The data obtained from this study correlates with the hypothesis 
that TGF-pi and BMP-2 work synergistically together, with TGF-pi being 
involved in the recruitment and proliferation of mesenchymal stem cells and 
osteoprogenitors, and BMP-2 driving the differentiation of these cells down
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an osteoblastic lineage. Although only a small selection of proliferation / 
differentiation markers have been investigated, future work should investigate 
a larger group of markers, especially downstream markers of TGF-(31 and 
BMP-2, such as the signalling transducing Smad proteins (Miyazawa et al. 
2002), transcription factors such as Runx2, Msx2, and Dlx5, and other 
proteins such as osteocalcin (Bostrom and Asnis 1998; Janssens et al. 2005; 
Matsubara et al. 2008; Phimphilai et al. 2006). Expression of TGF-p1 and 
BMP-2 receptors, known to alter at different stages of osteoblast 
differentiation and bone repair (Centrella et al. 1995; Onishi et al. 1998; 
Yamashita et al. 1996), should also be investigated to allow for full validation 
of the ex vivo model, of its responsiveness and functionality.
This study has investigated the effects of exogenous growth factors, added to 
the model alone; the basis behind growth factor therapies currently in 
practice (Boden et al. 2000; Friedlaender et al. 2001; Govender et al. 2002; 
Vaccaro et al. 2003). The reproducibility of the results obtained from the 
model may make it a valuable tool for testing future novel therapeutics, such 
as bioactive materials, for clinical use. However, the synergy apparent 
between these various bioactive factors means that investigation of the many 
endogenous growth factors present in vivo within the bone matrix itself may 
be essential in advancing these therapies.
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CHAPTER 4
GROWTH FACTOR EXPOSURE FROM BONE SURFACES BY CHEMICAL
TREATMENT MODALITIES
4.1 INTRODUCTION
The extracellular matrix of bone is known to contain stores of endogenous 
growth factors bound within it (Frolik et al. 1988; Hauschka et al. 1986; 
Taipale and Keski-Oja 1997). Release of these molecules following bone 
injury or trauma allows presentation of these factors to target cells, and 
subsequent cellular signalling to initiate reparative processes at these sites, 
leading to optimal repair and regeneration of the bone (Ramirez and Rifkin 
2003; Schonherr and Hausser 2000). Interactions between growth factors 
and the ECM can be mediated by proteins such as collagen (Reddi 2000), 
binding protein antagonists such as noggin and chordin in the case of the 
BMPs (Reddi 2001), or by proteoglycans; macromolecules comprised of at 
least one glycosaminoglycan (GAG) chain attached to a core protein. 
Cytokines and growth factors can interact with either the GAG moieties of the 
proteoglycans, or their core proteins, and different cytokines bind to different 
proteoglycans (Baker et al. 2009; Bernfield et al. 1999; Ruoslahti 1989; 
Ruoslahti and Yamaguchi 1991). For example, it has been widely shown that 
the small leucine-rich proteoglycans decorin and biglycan can bind TGF-pi 
with high affinity, and that this interaction is mediated via the core protein 
(Hildebrand et al. 1994; Imai et al. 1997; Yamaguchi et al. 1990). Such
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immobilisation of growth factors within the bone matrix provides an 
accessible reservoir of molecules crucial in repair processes, and may also 
protect the growth factors from degradation (Ruoslahti and Yamaguchi 1991).
Release of matrix-bound growth factors, via osteoclastic resorption in 
response to bone injury, results in the presence of a ‘cocktail’ of bioactive 
molecules at the site of trauma (Dallas et al. 2002). This enables the growth 
factors to work synergistically, activating a complex network of signalling 
pathways and stimulating optimal repair processes within the damaged bone 
(Hughes et al. 2006; Lieberman et al. 2002). This in vivo situation contrasts 
to current clinical therapies utilising bioactive growth factors, where 
treatments usually contain only a single growth factor (Gautschi et al. 2007). 
These growth factor therapies face problems due to the massive milligram 
doses required to elicit a therapeutic response in humans, doses which are in 
stark contrast to the natural in vivo situation (Reddi 1998). Future clinical 
treatments may benefit from utilising the array of growth factors already 
residing in vivo within the bone matrix, rather than addition of exogenous 
growth factors. There are several chemical treatments that have been 
demonstrated to solubilise growth factors such as TGF-p1 from within the 
mineralised matrix of dentine, including acids, ethylenediaminetetraacetic 
acid (EDTA), and calcium hydroxide (Graham et al. 2006; Zhao et al. 2000). 
Acids, including EDTA, solubilise growth factors by matrix demineralisation, 
by local matrix dissolution or by chelating calcium ions present within the 
mineralised matrix (De-Deus et al. 2008). It is, however, unclear whether this 
simply releases bound growth factors, or if a more complex mechanism is
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responsible for the release of the matrix-bound bioactive molecules. Calcium 
hydroxide appears to solubilise growth factors via a unique mechanism, since 
other alkaline agents have not previously been reported to solubilise matrix 
components from dentine, and the proteins released after matrix dissolution 
with calcium hydroxide differ from those released with EDTA (Graham et al. 
2006). This may suggest that interaction of growth factors and proteins with 
the ECM is more complex than simple mineral binding, although currently the 
mechanism for growth factor solubilisation by calcium hydroxide is unknown.
This thesis chapter aims to further investigate the actions of these chemical 
treatment modalities, by developing an in vitro bone slab model to analyse 
the release of growth factors from within bone matrix. Chemical treatments 
will include EDTA, citric acid, and calcium hydroxide, known to release 
growth factors as mentioned above. Slabs will also be treated with sodium 
hydroxide, an alkaline not previously shown to release bioactive molecules, 
to compare with the alkaline calcium hydroxide. In particular, the release of 
TGF-pi will be analysed, since this growth factor plays a pivotal role in bone 
repair, stimulating migration and proliferation of osteoprogenitors (Barnes et 
al. 1999; Bostrom and Asnis 1998; Janssens et al. 2005). Reduced serum 
levels of TGF-pi have also been demonstrated in patients exhibiting delayed 
bone healing (Zimmermann et al. 2005). Release of TGF-pi from the matrix 
may therefore be of clinical relevance in the treatment of impaired bone 
healing. By developing and utilising this model, the aim is also to analyse the 
effects of the released bioactive molecules on bone marrow stromal cell 
behaviour, in terms of both proliferation and differentiation.
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4.2 MATERIALS AND METHODS
4.2.1 Preparation of tissue culture reagents
Washing Medium
Washing medium of alpha-modified Minimum Essential Medium (a-MEM) 
(Invitrogen, UK) was prepared containing 10% concentration of a penicillin / 
streptomycin / amphotericin solution (containing 10,000 units of penicillin, 
10mg/ml of streptomycin, and 25pg/ml amphotericin B) (Invitrogen, UK).
Culture Medium
Mineralising culture medium of a-MEM (Invitrogen, UK) was prepared 
containing 15% heat inactivated FCS (Invitrogen, UK), 1% concentration of a 
penicillin / streptomycin / amphotericin solution (containing 10,000 units of 
penicillin, 10mg/ml of streptomycin, and 25pg/ml amphotericin B) (Invitrogen, 
UK), 10mM (3-glycerophosphate (Invitrogen, UK), 10nM dexamethasone 
(Sigma Chemical Co, UK), and 50pg/ml ascorbic acid (Invitrogen, UK).
4.2.2 Preparation and chemical treatment of bone slabs
Bone slabs were prepared from the femurs of 28 day old male Wistar rats, 
freshly sacrificed by CO2 asphyxiation. Femurs were dissected and cut in 
half, longitudinally. The marrow was removed from the marrow cavity and the 
remaining bone was then cut into 2mm slabs using a sterile scalpel. The 
femur bone slabs were incubated in 1 mg/ml collagenase / dispase (Sigma
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Chemical Co, UK) for 30 min to enzymatically disrupt cellular bonds, washed 
thoroughly in 70% ethanol and PBS, and freeze-thawed three times to 
remove all residual cells from the bone surface. Bone slabs were either left 
untreated, or treated with chemical agents known to solubilise growth factors 
from the bone matrix; 17% EDTA (pH 7.2), 0.02M calcium hydroxide (pH 
11.7, saturated solution), 0.2M sodium hydroxide (pH 11.7), 10% citric acid 
(pH 3), or as a negative control, PBS (pH 7.4). Bone slabs were treated for 5 
min, 10 min, or 15 min, gently rinsed in distilled water, and air-fixed for 48 
hrs, in sterile conditions. A total of six bone slabs were used per treatment, 
for each time point.
4.2.3 Immunogold labelling of released TGF-B1 from bone surfaces
Treated femur bone slabs were immunostained for TGF-01 using an 
immunogold procedure with scanning electron microscope (SEM) imaging 
(de Harven et al. 1984; Zhao et al. 2000). After fixation, bone slabs were 
blocked for 1 hr with 5% goat serum and 10% BSA in TBS, followed by a 15 
min buffer wash (1% goat serum, 1% BSA, 0.1% Tween 20 in TBS). Bone 
slabs were then incubated with the primary antibody, a polyclonal rabbit anti­
human TGF-p1 antibody (Santa Cruz Biotech) diluted 1:100 in buffer, for 2 
hrs. Following incubation with primary antibody, bone slabs were washed 
twice in buffer, and incubated with a gold-labelled goat anti-rabbit secondary 
antibody (British Biocell International, particle diameter 30nm, protein 
3.6pg/ml) diluted 1:100, for 1 hr. As a negative control, staining was inhibited 
by preincubation with a 10-fold excess of specific blocking peptide (Santa
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Cruz Biotech). Following a further two washes in buffer and two washes in 
distilled water, bone slabs were incubated with silver enhancing agent (British 
Biocell International) for 15 min. All bone slabs were then immediately 
washed in distilled water for 2 x 15 min, air dried for 24 hrs, and examined 
under an EBT1 scanning electron microscope (SEMTech Ltd, Derbyshire, 
UK) at a magnification of x 550. The number of gold particles were 
automatically counted within 20pm2 areas of bone per slab, within five 
random fields of view, using Image ProPlus software. A total of 6 bone slabs 
were used for each time point, for each treatment. Standard errors of the 
mean were calculated, and mean values were analysed using one-way 
ANOVA and Tukey’s post hoc test. Differences in TGF-(31 release were 
analysed between the time points of each treatment, as well as between 
different chemical treatment types.
4.2.4 Isolation and culture of bone marrow stromal cells
Femurs were dissected from 28 day old male Wistar rats, freshly sacrificed 
by CO2 asphyxiation, soft tissue removed with a sterile scalpel blade, and 
placed into sterile washing medium. Bone marrow stromal cells were 
collected from each femur by inserting a 21 gauge syringe needle containing 
15ml of culture media into the marrow cavity and flushing out the contents 
into a T75 culture flask (Greiner Bio-One). Cells were cultured at 37°C, in an 
atmosphere of 5% CO2 in air, in a humidified incubator, for 5 days. After five 
days culture media was removed and the cells incubated with 5ml trypsin- 
EDTA (Invitrogen, UK) at 37°C for 5 min to detach cells from their monolayer.
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Cells were then resuspended in 1ml culture medium, counted using a 
haemocytometer, and seeded onto individual bone slabs in a 96-well tissue 
culture plate (Greiner Bio-One) at a density of 1x104 cells/cm2. Bone slabs 
were either pre-treated with EDTA for 15 min, calcium hydroxide for 5 min, as 
described in 4.2.2, or were left untreated as a negative control. Cells were 
cultured at 37°C, in an atmosphere of 5% CO2 in air, for 7 days, with media 
changes every 48 hrs.
4.2.5 Visualisation of cellular cvtoskeleton
After 7 days of culture, media was removed from the bone slabs and the cells 
were fixed in 2% paraformaldehyde for 30 min. Cells were then washed in 
TBS for 3 x 10 min. To visualise the actin cytoskeleton with phalloidin, cells 
were permeabilised in 3% Triton-X 100 for 30 min. To prevent non-specific 
binding, cells were blocked with 1% BSA for 1 hr. Cells were incubated for 2 
hrs at 4°C in the dark with 0.2ml of phalloidin-FITC (diluted 1:16) (Sigma 
Chemical Co, UK), followed by a 1 hr incubation at room temperature in the 
dark with the nuclear counterstain bisbenzimide (Sigma Chemical Co, UK). 
Following a final wash in 0.5% Tween 20 in TBS, bone slabs were removed 
from the 96-well plate and mounted onto glass microscope slides. Cells were 
viewed under an Olympus AX70 fluorescence microscope and photographed 
with a Nikon DXM digital camera and ACT-1 imaging software. A total of five 
bone slabs were used for each treatment. Cell numbers were automatically 
counted within 200pm2 areas of bone stained with phalloidin, using Image 
ProPlus software. 200pm2 areas within five random fields of view were
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counted per slab, and standard errors of the mean calculated. Mean values 
were analysed using one-way ANOVA and Tukey’s post hoc test. Each 
treatment type was compared with untreated bone slabs, to statistically 
analyse differences in cell numbers in response to each chemical treatment. 
Comparisons were also made between the different treatment types, to 
statistically analyse any cell number differences between chemical treatment 
types.
4.2.6 Immunocvtochemical characterisation of cells
After 7 days of culture, media was removed from the bone slabs and the cells 
were fixed in 2% paraformaldehyde for 30 min. Cells were then washed in 
TBS for 3 x 10 min. To prevent non-specific binding, cells were blocked with 
1% BSA for 1 hr, then incubated overnight at room temperature with 0.2ml of 
the primary antibody for osteopontin (clone LF-124) (Fisher et al. 1995) or 
alkaline phosphatase (Santa Cruz Biotech), diluted appropriately in 1% BSA 
in TBS (Table 4.1). For negative controls, a nonimmunogenic control 
antibody (IgG isotype control; Sigma Chemical Co, UK) was used instead of 
the primary, along with a primary exclusion.
Following incubation with primary antibody, the cells were washed in 0.5% 
Tween 20 in TBS for 3 x 10 min and incubated in the presence of 0.2ml of 
the appropriate secondary antibody (Table 4.1), diluted in 1% BSA in TBS. A 
nuclear counterstain, bisbenzimide (Sigma Chemical Co), was included with 
the secondary antibody at a dilution of 1:50. Cells were incubated at room
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temperature for 1 hr in the dark. Following a final wash in 0.5% Tween 20 in 
TBS, bone slabs were removed from the 96-well plate and mounted onto 
glass microscope slides. Cells were viewed under an Olympus AX70 
fluorescence microscope and photographed with a Nikon DXM digital camera 
and ACT-1 imaging software. Image ProPlus software was used to 
automatically count the number of cell nuclei (stained blue by bisbenzimide), 
as well as the number of cells expressing either alkaline phosphatase or 
osteopontin (stained green with FITC), within five random 200pm2 fields of 
view per bone slab. This enabled a percentage of positive cells to be 
calculated. A total number of 5 bone slabs were cultured for each treatment, 
for each marker.
Primary
antibody
Source of 
primary 
antibody
Primary 
antibody 
source / 
species 
reactivity
Primary
antibody
dilution
Secondary
antibody
Secondary
antibody
dilution
Osteo­
pontin
Larry Fisher 
(Fisher et al. 
1995)
Monoclonal 
mouse anti­
human
1:50 Goat anti­
mouse IgG 
FITC- 
conjugated
1:50
Alkaline
Phos­
phatase
Santa Cruz 
Biotech
Polyclonal 
rabbit anti­
human
1:50 Goat anti­
rabbit IgG 
FITC- 
conjugated
1:50
Table 4.1. Immunocytochemistry antibodies.
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4.3 RESULTS
4.3.1 Immunogold labelling of released TGF-B1 from bone surfaces
4.3.1.1 EDTA treated bone surfaces
SEM examination of bone surfaces treated with 17% EDTA (pH 7.2) for 5 min 
(Figure 4.1 A) and 10 min (Figure 4.1B) yielded few TGF-(31 molecules, with 
an average of 6 ± 1.3 immunogold particles counted per 20pm2 area of bone 
surface for each treatment time (Figure 4.5). However, after extension of the 
treatment time to 15 min (Figure 4.1C), the number of released TGF-pi 
molecules increased to an average of 27 ± 4.4 immunogold particles per 
20pm2 area of bone surface (Figure 4.5). Statistical analysis showed this 
increase to be highly significant (p<0.001). Negative control bone surfaces 
treated with PBS (Figure 4.1D) showed negligible TGF-pi after all treatment 
times (Figure 4.5), while negative controls incubated with an excess of 
specific peptide to TGF-p1 showed no immunogold labelling (Figure 4.1 E).
4.3.1.2 Calcium hydroxide treated bone surfaces
SEM examination of bone surfaces treated with 0.02M calcium hydroxide (pH 
11.7) revealed a pattern of TGF-p1 release different from that observed with 
EDTA treatment. A treatment time of 5 min (Figure 4.2A) released an 
average number of 39 ± 8.6 TGF-p1 labelled immunogold particles per 
20pm2 area of bone surface (Figure 4.5). Subsequent treatment times of 10
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min (Figure 4.2B) and 15 min (Figure 4.2C) revealed a decline in TGF-p1, 
with an average of 11 ± 1.6 and 6 ± 0.9 immunogold particles counted per 
20pm2 area of bone surface respectively (Figure 4.5). Statistical analysis 
showed the number of immunogold particles to be significantly higher after a 
treatment time of 5 min, when compared to either 10 min or 15 min 
treatments (p<0.001). The maximum number of released TGF-|31 particles 
after calcium hydroxide treatment (39 ± 8.6) was larger than the maximum 
released after EDTA treatment (27 ± 4.4). Negligible TGF-pi was observed 
after all treatment times on negative control bone surfaces treated with PBS 
(Figures 4.2D and 4.5). Negative controls incubated with an excess of 
specific peptide to TGF-pi showed no immunogold labelling (Figure 4.2E).
4.3.1.3 Citric acid treated bone surfaces
SEM examination of bone surfaces treated with 10% citric acid (pH 3) yielded 
a similar pattern of immunogold labelling to bone surfaces treated with EDTA, 
with release of TGF-p1 increasing with treatment time. Treatment times of 5 
min (Figure 4.3A) and 10 min (Figure 4.3B) yielded average immunogold 
counts of 11 ±1.5 and 13 ± 0.8 particles per 20pm2 area of bone surface, 
respectively. Extending the treatment time to 15 min (Figure 4.3C) increased 
the average number of gold particles per 20pm2 area of bone surface to 23 ± 
0.9 (Figure 4.5), although this increase was not shown to be significant 
(p>0.05). The increase after 15 min was, however, significant when 
compared with PBS treated control surfaces (p<0.05) (Figure 4.3D), which 
showed negligible TGF-p1 after all treatment times (Figure 4.5). Comparison
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between citric acid and EDTA revealed a higher number of released 
immunogold particles after EDTA treatment; 27 ± 4.4 particles compared to 
23 ± 0.9. No immunogold labelling was observed on negative controls 
incubated with an excess of specific peptide to TGF-p1 (Figure 4.3E).
4.3.1.4 Sodium hydroxide treated bone surfaces
Treatment of bone surfaces with 0.2M sodium hydroxide (pH 11.7) produced 
a pattern of TGF-p1 immunogold labelling different from all other treatment 
types, including calcium hydroxide. Treatment with sodium hydroxide for 5 
min (Figure 4.4A) yielded an average number of 12 ± 2.2 immunogold 
particles per 20pm2 area of bone surface, which was increased to 21 ±3.1 
particles after extension of the treatment time to 10 min (Figure 4.4B). 
Further extension of the treatment time to 15 min led to a decrease in 
immunogold particles, with an average of 17 ± 1.4 particles counted per 
20um2 area of bone surface (Figure 4.4C). The increase in immunogold 
particles after 10 min treatment was not statistically significant when 
compared to 5 min or 15 min treatment times (p>0.05), but it was significantly 
higher than PBS treated control surfaces (p<0.05) (Figure 4.4D), which 
showed negligible TGF-p1 after all treatment times (Figure 4.5). The 
maximum number of TGF-p1 immunogold particles released after 10 min 
sodium hydroxide treatment (21 ± 3.1) was significantly lower than the 
maximum number released after 5 min calcium hydroxide treatment (39 ± 
8.6) (p<0.05). Negative controls which were incubated with an excess of 
specific peptide to TGF-p1 showed no immunogold labelling (Figure 4.4E).
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Figure 4.1: Immunogold labelling of TGF-(31 (as indicated by arrows) 
released from bone surfaces treated with 17% EDTA for (A) 5 min, (B) 10 
min, or (C) 15 min. Negative controls were treated with (D) PBS or (E) 
incubated with a 10-fold excess of specific peptide to block TGF-(31 staining.
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Figure 4.2: Immunogold labelling of TGF-(31 (indicated by arrows) released 
from bone surfaces treated with 0.02M Ca(OH)2 for (A) 5 min, (B) 10 min, or 
(C) 15 min. Negative controls were treated with (D) PBS or (E) incubated 
with a 10-fold excess of specific peptide to block TGF-(31 staining.
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Figure 4.3: Immunogold labelling of TGF-(31 (indicated by arrows) released 
from bone surfaces treated with 10% citric acid for (A) 5 min, (B) 10 min, or 
(C) 15 min. Negative controls were treated with (D) PBS or (E) incubated 
with a 10-fold excess of specific peptide to block TGF-(31 staining.
179
HT=10Kv, WD=9.3, MAG=250
50pmHT=10Kv. WD=6.5. MAG=275
Figure 4.4: Immunogold labelling of TGF-(31 (indicated by arrows) released 
from bone surfaces treated with 0.2M NaOH for (A) 5 min, (B) 10 min, or (C) 
15 min. Negative controls were treated with (D) PBS or (E) incubated with a 
10-fold excess of specific peptide to block TGF-(31 staining.
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Figure 4.5: Number of TGF-(31 labelled immunogold particles per 20pm2 area of 
treated bone surface.
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4.3.2 Immunocvtochemical characterisation of cultured cells
4.3.2.1 Cells cultured on untreated surfaces
Phalloidin staining of cells cultured on untreated bone surfaces showed
visible actin cytoskeletons of cells adhered to the bone surface (Figure 4.6A).
Cells appeared to have an elongated morphology, and did not adhere to the 
whole surface of the bone, but appeared in small clusters in different areas 
across the surface. The adherent cells expressed the bone markers alkaline 
phosphatase (Figure 4.6B) and osteopontin (Figure 4.6C), although this 
expression was only observed in a proportion of the cells, with an average of 
22% of adherent cells expressing alkaline phosphatase and 20% expressing 
osteopontin (Figure 4.10).
4.3.2.2 Cells cultured on EDTA treated surfaces
Bone slabs were treated with 17% EDTA for 15 min, a time period shown 
previously (4.3.1.1) to be optimum for release of growth factors. Phalloidin 
staining of cells cultured on these EDTA treated bone surfaces showed 
visible actin cytoskeletons of cells adhered to the bone surface (Figure 4.7A). 
In contrast to untreated bone surface, cells had a more cuboidal morphology 
and appeared to adhere across the entire surface of the bone slab, rather 
than in discrete areas. Cell numbers appeared to be higher on EDTA treated 
surfaces when compared with untreated surfaces, which was confirmed with 
automated cell counting. The average number of cells on EDTA treated bone
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was calculated to be 34 ± 7.5 cells per 200pm2 area, a significant increase 
from the average number of cells on untreated bone, calculated as 9 ± 0.5 
cells per 200pm2 area of bone (p<0.01) (Figure 4.9). There appeared to be a 
higher number of cells expressing the bone markers alkaline phosphatase 
and osteopontin on EDTA treated bone slabs (Figures 4.7A and B) when 
compared with untreated bone slabs, with an average of 81% of adherent 
cells expressing alkaline phosphatase and 72% expressing osteopontin 
(Figure 4.10). Whether this increase was due to increased cellular expression 
or rather an increase in cell numbers remains to be elucidated.
4.3.2.3 Cells cultured on calcium hydroxide treated surfaces
Bone slabs were treated with 0.02M calcium hydroxide for 5 min, a time 
period shown previously (4.3.1.2) to be optimum for release of growth 
factors. Phalloidin staining showed cells with visible actin cytoskeletons 
adhered across the surface of these calcium hydroxide treated bone slabs 
(Figure 4.8A). Adherence of cells to the calcium hydroxide treated bone 
slabs, and their morphology, was very similar to those cultured on EDTA 
treated surfaces, with cells having a more cuboidal morphology than those 
cultured on untreated surfaces and adhering across the entire bone surface. 
Cell numbers again appeared increased when compared to cells cultured on 
untreated bone surfaces, which was confirmed with automated cell counting. 
The average number of cells adhered to calcium hydroxide treated bone 
surfaces was calculated to be 29 ± 3.7 cells per 200pm2 area of bone, a 
significant increase from the 9 ± 0.5 cells per 200pm2 area adhered to
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untreated bone (p<0.05) (Figure 4.9). Statistical analysis indicated that there 
was no significant difference in cell numbers adhered to calcium hydroxide 
treated bone surfaces and EDTA treated surfaces (p>0.05). Similarly to 
EDTA treatment, a higher proportion of cells appeared to be expressing 
alkaline phosphatase and osteopontin within calcium hydroxide treated bone 
slabs (Figures 4.7B and C) when compared with untreated bone slabs, with 
an average of 80% of adherent cells expressing alkaline phosphatase and 
75% expressing osteopontin (Figure 4.10). Again this could be due to an 
increase of cell number rather than an actual increase in protein expression.
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Figure 4.6: Immunocytochemical characterisation of cells cultured on untreated 
bone slabs. (A) Phalloidin staining demonstrated adherence of cells to the bone. 
(B) Adherent cells expressed the bone markers alkaline phosphatase and (C) 
osteopontin (examples indicated by arrows). (D) Negative controls using a non- 
immune IgG showed only the nuclear counterstain.
Figure 4.7: Immunocytochemical characterisation of cells cultured on bone 
slabs treated with 17% EDTA. (A) Phalloidin staining demonstrated increased 
adherence of cells to the treated bone and a more cuboidal morphology. (B) 
Adherent cells expressed the bone markers alkaline phosphatase and (C) 
osteopontin (examples indicated by arrows). (D) Negative controls using a non- 
immune IgG showed only the nuclear counterstain.
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Figure 4.8: Immunocytochemical characterisation of cells cultured on bone 
slabs treated with 0.02M Ca(OH)2. (A) Phalloidin staining demonstrated 
increased adherence of cells to the treated bone and a more cuboidal 
morphology. (B) Adherent cells expressed the bone markers alkaline 
phosphatase and (C) osteopontin (examples indicated by arrows). (D) Negative 
controls using a non-immune IgG showed only the nuclear counterstain.
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Figure 4.9: Average number of phalloidin stained cells cultured on bone 
surfaces left untreated, treated with EDTA, or treated with Ca(OH)2
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Figure 4.10: Average % positive cell nuclei for alkaline phosphatase or 
osteopontin expression on bone surfaces left untreated, treated with EDTA, 
or treated with Ca(OH)2
188
4.4 DISCUSSION
This in vitro bone slab model system was developed in order to demonstrate 
proof of principle that growth factors can be released from bone matrix by 
chemical treatment modalities, and that release of such molecules can affect 
cellular behaviour. The development of such an in vitro model provides a 
simplified system which can demonstrate these principles before progressing 
the work into the ex vivo mandible model, a system of increased complexity 
due to the presence of different cells and tissues within a three-dimensional 
microenvironment.
Release of growth factors by chemical treatment modalities has been shown 
extensively in dentine, in particular using EDTA or calcium hydroxide 
(Graham et al. 2006; Zhao et al. 2000). The results obtained in this study 
provide evidence that such chemical treatment modalities may also release 
growth factors from within the matrix of bone, thus exposing them on the 
bone surface, and that different chemical treatments appear to employ 
different mechanisms of release. Release of growth factors by the varying 
chemical treatments was demonstrated by immunogold labelling of one such 
growth factor, TGF-(31. All chemical treatments used in this study were 
capable of releasing TGF-(31 from within the matrix of the femur bone slab, 
although differences were observed in the release between treatment types. 
EDTA, as well as other acids including citric acid, are known to demineralise 
both bone and dentine matrix (De-Deus et al. 2008; Walsh and Christiansen 
1995; Yamaguchi et al. 1996). They accomplish this by either local
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dissolution of mineralised matrix, releasing calcium ions, or by acting as 
chelating agents capable of binding and sequestering calcium ions within the 
mineralised matrix, thus reducing their activity (De-Deus et al. 2008; 
Dorozhkin 1997; O'Connell et al. 2000; Yamaguchi et al. 1996). Both of these 
treatments displayed a similar pattern of TGF-p1 solubilisation, with the 
majority of solubilisation occurring only after a treatment time of 15 min. 
There were a small number of TGF-(31 particles released after 5 min and 10 
min treatment, which may indicate an initial gradual release by the chemicals. 
However, the number of particles released after these earlier treatment times 
were similar to those observed from PBS treated control slabs, and may 
therefore be residual TGF-p1 particles that have remained on the bone 
surface, rather than particles released by the treatments. The similar 
solubilisation patterns observed with EDTA and citric acid treatment suggests 
that both chemicals release growth factors by a similar mechanism. EDTA 
did however release increased quantities of TGF-(31 from the bone when 
compared with citric acid, suggesting that although the mechanism of release 
is similar for both chemicals, EDTA may be more efficient at solubilising the 
matrix. This may be due to EDTA being a stronger acid, having pKa values of 
1.99, 2.67, 6.16 and 10.26 (Inoue et al. 1995), compared to higher pKa 
values of 3.13, 4.76 and 6.40 for citric acid (Silva et al. 2009), which may 
confer a greater ability for matrix dissolution to EDTA. It could also be due to 
EDTA being a more potent chelating agent, due to the presence of six 
binding sites within the chemical that may associate with calcium ions, 
sequestering them and reducing their activity (Barnett and Uchtman 1979). It 
is also possible that citric acid, at a 10% solution (far more concentrated than
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the 10mM citric acid used to activate recombinant TGF-p1 used previously in 
section 3.2.1) with a pH of 3, is capable of denaturing proteins (including 
TGF-pi), whereas EDTA which is optimum at a physiological pH of 7.2, may 
not have such an effect. This is supported by evidence from previous studies 
demonstrating that EDTA is capable of releasing bioactive molecules from 
dentine. Graham and colleagues (Graham et al. 2006) demonstrated that 
application of EDTA-extracted dentine matrix proteins to an odontoblast-like 
cell line induced TGF-pi expression in a dose-dependent manner, while 
Tomson and colleagues (Tomson et al. 2007) used ELISA methodology to 
demonstrate the presence of active TGF-p1 in dentine matrix proteins 
extracted with EDTA. These studies suggest that EDTA treatment, at least in 
part, is not denaturing the growth factors it releases. This hypothesis is also 
supported in our study, since EDTA treatment (and subsequent growth factor 
release) is capable of eliciting effects on cells cultured upon such treated 
surfaces. If time had permitted, and perhaps an experiment to consider for 
future work, it may have been constructive to culture bone marrow stromal 
cells on citric acid treated surfaces, to determine if growth factors released 
with this chemical treatment were capable of affecting cellular behaviour. It 
may be hypothesised that if citric acid denatured growth factors, thus 
releasing fewer bioactive molecules, there may be a decrease in the cellular 
effects observed with this treatment compared with EDTA.
The TGF-pi release observed with EDTA and citric acid was in contrast to 
the pattern of release observed with calcium hydroxide treatment, which 
solubilised the greatest quantity of TGF-p1 after a treatment time of only 5
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min, with very little release observed with extended treatment times. 
Interestingly, treatment of the bone slabs with sodium hydroxide, an alkaline 
with the same pH as calcium hydroxide, showed a pattern of release that 
differed from all other treatment types, including calcium hydroxide. 
Solubilisation of growth factors from the mineralised matrix of bone or dentine 
by alkaline agents other than calcium hydroxide has not previously been 
reported, but the results displayed in this study demonstrate that sodium 
hydroxide is capable of releasing TGF-(31 from within the matrix of bone. The 
majority of TGF-p1 was released after a 10 min treatment time with sodium 
hydroxide, although the quantity released was significantly lower than the 
maximum quantity released with calcium hydroxide after a treatment time of 
5 min (p<0.05). As yet, the mechanism for growth factor solubilisation by 
alkaline treatments such as calcium hydroxide remains elusive. One possible 
hypothesis is that the alkaline agents alter the charge of growth factors within 
the mineralised matrix of the bone, since an amino acid placed in alkaline 
conditions will favour its negatively charged anion form. This may alter the 
interaction of the growth factor with the matrix, facilitating release of the 
protein and exposure on the bone surface. Alternatively, it may be that the 
alkaline reagents affect the matrix proteins that keep the growth factors within 
their bound state, again perhaps by influencing their charge, by the 
disassociated molecules of the base binding or interacting with these 
proteins. Both calcium hydroxide and sodium hydroxide are strong bases, 
used within this study at the same pH of 11.2, although sodium hydroxide is a 
slightly stronger base with a lower pKb value of 0.2, compared to values of 
2.43 and 1.4 for calcium hydroxide. Thus the differences observed in the
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release of TGF-(31 by these two chemicals may be attributed to their 
composition. Calcium hydroxide has two hydroxyl groups available for 
interaction with matrix proteins and / or growth factors, affecting the charge of 
such proteins and thus possibly affecting the release of growth factors from 
the matrix. Sodium hydroxide, however, has only a single hydroxyl group, so 
may therefore interact to a lesser degree with sequestered growth factors or 
matrix proteins, as it may have a reduced capacity to alter the protein charge. 
Thus it may be hypothesised that calcium hydroxide has a greater efficacy for 
altering protein charge and thus growth factor release. An alternative 
hypothesis to alkaline chemicals facilitating actual release of growth factors 
may be that interaction of these treatments with matrix proteins could be 
having an effect on the antigens of the growth factors, making the antibody- 
recognised epitope more accessible and thus increasing the number of 
immunogold particles observed. However, this study has also shown that 
cellular behaviour is significantly affected by calcium hydroxide treatment of 
bone slabs, suggesting that bioactive growth factors are being released by 
this treatment, rather than simply the antigenicity of the growth factors being 
affected.
Release of growth factors from within the mineralised matrix of bone by 
chemical treatment modalities can only be considered clinically relevant if the 
molecules released are active, and thus capable of affecting cell behaviour at 
a site of bone injury. Culture of primary bone marrow stromal cells on treated 
and untreated bone slab surfaces provided a model system to investigate cell 
growth and differentiation in response to such chemical treatments. The bone
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marrow contains a crucial store of mesenchymal stem cells and 
osteoprogenitor cells that are capable of migrating towards a site of bone 
injury, responding to growth factors and signals once there which stimulate 
differentiation of these cells down the osteoblastic lineage (Bielby et al. 
2007). Cultured cells were first stained with phalloidin, to visualise the actin 
cytoskeleton of the cells and their adherence to the bone slabs, to determine 
if chemical treatments were affecting the morphology, growth or adhesion of 
cells to the bone slabs. Cells cultured on untreated bone slabs did not adhere 
to the whole surface of the bone, but were present in small clusters in 
different areas across the surface, and had a more elongated morphology, 
more like that of a fibroblast cell. This correlates with previous studies which 
have demonstrated such a fibroblast-like morphology of bone marrow stromal 
cells when cultured on plastic surfaces for up to 7 days of culture (Ciapetti et 
al. 2006; ter Brugge and Jansen 2002), suggesting that untreated bone slabs 
may have similar characteristics to smooth surfaces in terms of their effects 
on cell morphology. Once the bone slabs had been treated however, with 
either EDTA (for 15 min) or calcium hydroxide (for 5 min), the cells appeared 
to adhere across the whole surface of the bone slab, and cell numbers were 
significantly increased when compared with untreated bone slabs. Cells also 
appeared more cuboidal than those cultured on untreated surfaces, with 
morphology more resembling mature cells of the osteoblast lineage. For 
EDTA treatment, one hypothesis for the increase in cell numbers and change 
in morphology may be the alteration of surface topography. It is well 
documented that surface topography can markedly affect the behaviour of 
osteoblast progenitors, with rougher surfaces facilitating attachment of cells,
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as well as their differentiation down the osteoblast lineage (Anselme 2000; 
Boyan et al. 1998; Boyan et al. 1996; Deligianni et al. 2001b; Hatano et al. 
1999). It is possible that treatment of the bone slabs with EDTA alters the 
surface topography; it has already been demonstrated in dentine that EDTA 
treatment can remove the smear layer and roughen the dentine surface 
(Buchalla et al. 2007; Eldeniz et al. 2005; Zhao et al. 2000). Thus EDTA may 
be having a similar effect on the bone slabs, roughening their surface by 
demineralising the matrix and facilitating the adhesion of bone marrow 
stromal cells (Deligianni et al. 2001b). There is conflicting evidence regarding 
the effects of surface topography on cellular proliferation, but some previous 
studies have shown an increase in proliferation of bone marrow stromal cells 
and osteoblasts cultured upon roughened surfaces (Deligianni et al. 2001a; 
Kamal et al. 2001; Kim et al. 2007; Naoki et al. 2008). In conjunction with 
EDTA treatment releasing growth factors that may increase cellular 
proliferation, including the FGFs (Mansukhani et al. 2000), IGFs (Hughes et 
al. 2006), and TGF-(31 (Barnes et al. 1999), it is possible that EDTA 
treatment is both facilitating adhesion of cells onto the bone surface, and 
increasing their proliferation, thus increasing cell numbers.
Calcium hydroxide, which also significantly increased cell numbers, is 
unlikely to alter surface topography as EDTA treatment may do, as it is not 
involved in surface demineralisation, but instead may alter the charge of 
proteins and growth factors within the bone matrix. This may cause an 
increase in the hydrophillicity of the bone surface, which previous studies 
have shown to increase proliferation and differentiation of bone marrow
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stromal cells (Anselme 2000; Kim et al. 2007; Naoki et al. 2008; Wall et al. 
2009). Thus alteration of hydrophillicity, together with the released growth 
factors mentioned above, may explain the increased cell numbers observed 
upon bone slabs after treatment with calcium hydroxide.
Cells cultured on the bone slabs were also stained for two markers of 
osteoblast differentiation, osteopontin and alkaline phosphatase, to 
investigate the differentiation state of the adherent cells. Cells adherent to 
untreated bone slabs did express both osteopontin and alkaline 
phosphatase, although the expression was observed in only a proportion of 
the cells, with 22% expressing alkaline phosphatase and 20% expressing 
osteopontin. This observation would perhaps be expected, due to the culture 
of the cells in a supplemented media including dexamethasone that promotes 
differentiation down an osteoblastic lineage. However, treatment of the bone 
surfaces with either EDTA or calcium hydroxide appeared to further stimulate 
expression of these bone markers when compared with untreated slabs, with 
an apparent increase in the number of cells expressing osteopontin and 
alkaline phosphatase: 81% of cells were positive for alkaline phosphatase 
and 72% positive for osteopontin after treatment with EDTA, while 80% of 
cells were positive for alkaline phosphatase and 75% positive for osteopontin 
after calcium hydroxide treatment. This observed increase may be due to the 
chemical treatments stimulating an increase in cellular expression of the 
proteins, or may be due to the increased number of cells already positive for 
alkaline phosphatase and osteopontin adhering to the treated bone surfaces 
(Hatano et al. 1999; Schwartz et al. 1999). Growth factors released by both
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EDTA and calcium hydroxide, such as the BMPs (Cheng et al. 2003a; 
Wozney 1992) and the IGFs (Celil and Campbell 2005), may stimulate 
osteoblast differentiation of the bone marrow stromal cells. As mentioned 
previously, EDTA alteration of surface topography may also influence the 
differentiation of the cultured bone marrow stromal cells, with previous 
studies demonstrating an increase in alkaline phosphatase and osteocalcin 
on rougher surfaces (Deligianni et al. 2001a; Hatano et al. 1999), while 
calcium hydroxide may affect differentiation via its effects on hydrophillicity 
(Anselme 2000; Wall et al. 2009).
The results presented in this study appear to demonstrate that growth factors 
can be released from within the mineralised matrix of bone, and that these 
factors can actively influence the behaviour of cells cultured on the bone 
surface. The data presented here may suggest that development of future 
clinical therapies for treating cases of impaired bone repair may benefit from 
utilising chemical treatments to release bioactive growth factors already 
residing in vivo within the matrix of the bone, rather than adding in 
exogenous growth factors. In this way, a ‘cocktail’ of bioactive molecules may 
be released into the site of injury, enabling these factors to work 
synergistically, and ultimately stimulating optimal repair processes within the 
injured bone.
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CHAPTER 5
STIMULATION OF THE EX VIVO FRACTURED MANDIBLE MODEL WITH 
CHEMICALLY RELEASED ENDOGENOUS GROWTH FACTORS
5.1 INTRODUCTION
The previous chapter demonstrated that the bone matrix contains many 
endogenous growth factors that can be released in vitro by chemical 
treatment modalities, including EDTA and calcium hydroxide. It also 
demonstrated that release of these bioactive growth factors in vitro may 
affect cellular behaviour, by influencing proliferation and differentiation of 
osteoprogenitor cells. Following this demonstration of proof of principle within 
an in vitro bone slab cell culture system, the aim of this chapter was to 
develop this further into an ex vivo system, to examine the effects of these 
growth factor-releasing chemical treatments on the cells residing with the ex 
vivo mandible model. While the in vitro cell culture system developed in the 
previous chapter was a useful model to demonstrate growth factor release, 
and to gain some insight into the release mechanisms of the various 
chemical treatments, the culture of a single cell type does not represent the 
many interactions that occur between cell and tissue types during bone repair 
in vivo (Arnold 1987; Hughes et al. 2006; Schindeler et al. 2008). The ex vivo 
model contains a range of different cell and tissue types cultured in situ, in a 
three-dimensional environment as opposed to the monolayer of in vitro cell 
culture, and therefore allows examination of the effects of the chemical
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treatments in a situation far more representative of an in vivo situation. The 
presence of the fracture site within the model allows the chemical treatments 
to be tested in a situation representative of bone repair in vivo, without the 
complicating systemic influences, and the ethical and cost implications 
associated with in vivo studies.
This study may also be compared with the previous results acquired from 
treatment of the mandible model with TGF-p1 and BMP-2, to determine if 
releasing a ‘cocktail’ of endogenous growth factors from within the bone 
matrix elicits a greater response than adding single exogenous growth 
factors. As mentioned previously, application of single exogenous bioactive 
factors is the basis behind current growth factor clinical therapies 
(Friedlaender et al. 2001; Gautschi et al. 2007; Govender et al. 2002), but the 
limited success that these treatments have had may be addressed by 
utilising endogenous growth factors already bound within the matrix of bone. 
Previous studies have demonstrated that the use of combinations of different 
growth factors can improve both wound healing (Lynch et al. 1989; Lynch et 
al. 1987) and bone regeneration (Meraw et al. 2000). The possibility of 
releasing combinations of endogenous growth factors within an in vivo 
situation may therefore provide a promising alternative clinical treatment for 
bone repair. In dentistry applications calcium hydroxide-based materials such 
as Dycal® are widely used to drive release of growth factors from dentine 
matrix, facilitating formation of a dentine bridge to repair the dentine-pulp 
complex after injury (Graham et al. 2006; Horsted-Bindslev et al. 2003; 
Tziafas et al. 2000). Emdogain, a purified enamel matrix protein product, is
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also used in clinical periodontal treatment to aid tissue regeneration, 
increasing growth factor release and inducing formation of cementum and 
alveolar bone (He et al. 2004; Nakamura et al. 2001). Expansion of such 
dental-based treatments, or development of novel treatments that can 
facilitate growth factor release, for use in bone injury therapeutics may 
overcome some of the problems associated with current growth factor 
therapies using exogenously added bioactive molecules. Development of the 
ex vivo mandible organ culture system may provide an ideal model system 
with which to test such therapeutics.
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5.2 MATERIALS AND METHODS
5.2.1 Preparation and chemical treatment of fractured mandible slices
Fractured mandible slices were prepared from 28 day old male Wistar rats 
immediately before chemical treatment (as described in 2.5.1). Prior to 
embedding in semi-solid agar medium, 10pl of either 17% EDTA (pH 7.2), 
0.02M calcium hydroxide (pH 11.7, saturated solution), or a control solution 
of PBS (pH 7.4) was applied to the fracture site with a 2mm microbrush 
(Microbrush International) under a dissecting microscope (Bausch and 
Lomb). The microbrush was used to ensure that each chemical treatment 
was applied to the whole surface of the fracture site, in the same amount of 
10pl. Slices were treated for 15 min (EDTA), or 5 min (calcium hydroxide and 
PBS), and slices were partially submerged in media during treatment times, 
so that the slice remained hydrated but the chemical treatment did not wash 
away from the site of application at the fracture site. After each treatment 
time, slices were gently washed in PBS for 3 x 2 min to remove the chemical 
treatment, and transferred into Trowel type cultures (as described in 2.2.2) 
for 7 days.
5.2.2 Histological examination
After culture, fractured mandible slices stimulated with EDTA / calcium 
hydroxide (plus respective control slices) were prepared for histological H&E 
staining (as described in section 2.2.3). A total of 5 mandible slices were
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cultured for each treatment type and each control. Cell numbers were 
automatically counted within randomly selected 100pm2 areas of the PDL 
using Image ProPlus software. Cells were counted within the fracture site 
itself, within 100pm2 of the PDL adjacent to the site of fracture, and within 
100pm2 areas of the PDL to the left and right of the fracture site. A control 
count was also taken within a 100pm2 area of the PDL at a mandible region 
opposite the site of stimulation. Standard errors of the mean were calculated, 
and values analysed using one-way ANOVA and Tukey’s post hoc test, to 
analyse differences between treatment types and controls.
5.2.3 Immunohistochemistrv
Fractured mandible slices stimulated with EDTA / calcium hydroxide, plus 
respective control slices, were stained immunohistochemically for expression 
of the proliferation marker PCNA, and the bone markers osteopontin and 
bone sialoprotein, as described in sections 2.2.6 and 3.2.4. A total of 5 
mandible slices were cultured for each treatment type and control, for each 
marker. Cells positive for each of the markers were automatically counted 
within randomly selected 100pm2 areas of the PDL, both adjacent to the site 
of fracture, and to the left and right of the fracture site, using Image ProPlus 
software. A control count was also taken within a 100pm2 area of the PDL at 
a mandible region opposite the site of stimulation. Standard errors of the 
mean were calculated, and mean values were analysed using one-way 
ANOVA and Tukey’s post hoc test, to analyse differences between treatment 
types and controls.
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5.3 RESULTS
5.3.1 Histology of pre-treated mandible slices
Mandible slices pre-treated with either EDTA (Figure 5.1 A) or calcium 
hydroxide (Figure 5.1B) and cultured for 7 days demonstrated an increase in 
the number of PDL cells close to the site of fracture and stimulation, when 
compared with areas opposite the stimulation site (Figure 5.1C) or with 
control PBS treated slices (Figure 5.1D). Automated cell counts (Figure 5.2) 
showed this increase in cell number to be significant in EDTA and calcium 
hydroxide treated slices, both adjacent to the site of fracture (p<0.001), and 
100pm either side (p<0.01). No differences were observed in cell number 
between mandible slices pre-treated with EDTA and slices pre-treated with 
calcium hydroxide.
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Figure 5.1: Fractured mandible slices cultured for 7 days following pre-treatment 
with (A) 17% EDTA or (B) 0.02M Ca(OH)2. Aggregation of cells within the 
periodontal ligament (PDL) can be observed within close proximity to the site of 
fracture (F) after both treatments. Similar aggregation cannot be observed within 
(C) regions of PDL at the opposite side of stimulation, or (D) in control slices 
treated with PBS.
Fractured mandible slices treated with EDTA or calcium hydroxide
PBS □  EDTA ■  CaOH
' 1 . -----1* * * * * * * *  ’
Within 
fracture site
near far
Adjacent to fracture site Left side of Right side of Opposite
PDL PDL fracture site
Region of m and ib le  slice
Figure 5.2: Average cell numbers within various 100pm2 areas of periodontal 
ligament in fractured mandible slices treated with EDTA or Ca(OH)2, compared with 
control slices treated with PBS.
** p<0.01 *** p<0.001
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5.3.2 Immunohistochemical characterisation of pre-treated mandible
slices 
5.3.2.1 PCNA immunolocalisation
An increase in the number of PCNA positive cells could be observed within 
the PDL of mandible slices pre-treated with EDTA (Figure 5.3A) or calcium 
hydroxide (Fi gure 5.3B), closely associated with the site of fracture, when 
compared with control PBS treated slices (Figure 5.3C). This increase in 
PCNA immunopositivity was proved to be highly significant by statistical 
analysis (Figure 5.4), with both treatment types, both adjacent to the site of 
fracture and 100pm either side (p<0.001). Since an increase in cell number 
was observed within the H&E sections, it is possible that the increase in 
immunopositivity is due to these higher numbers of cells, rather than being 
due to an increase in expression. EDTA and calcium hydroxide pre-treatment 
gave similar results, with no significant differences in immunopositivity 
observed between them (p>0.05). Negative controls using a non-immune IgG 
showed no immunoreactivity (Figure 5.3D).
5.3.2.2 Osteopontin immunolocalisation
Pre-treatment of mandible slices with EDTA (Figure 5.5A) or calcium 
hydroxide (Figure 5.5B) resulted in an increase in cells immunopositive for 
osteopontin within the PDL in close proximity to the site of fracture, compared 
with control slices treated with PBS (Figure 5.5C). Statistical analysis of
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automated cell counts (Figure 5.6) proved this increase to be significant in 
slices treated with both chemicals, adjacent to the site of treatment 
(p<0.001), and 100pm either side. EDTA pre-treatment did appear to have a 
greater effect than calcium hydroxide, with a higher number of osteopontin 
positive cells observed adjacent to the site of fracture, although this increase 
was not shown to be significant (p>0.05). No immunoreactivity was observed 
within negative controls where the primary antibody was replaced with a non- 
immune IgG (Figure 5.5D).
5.3.2.3 Bone sialoprotein immunolocalisation
The expression pattern of bone sialoprotein was similar to that of 
osteopontin, with an increase in the number of immunopositive cells 
observed in the PDL of mandible slices pre-treated with EDTA (Figure 5.7A) 
or calcium hydroxide (Figure 5.7B) when compared with PBS control slices 
(Figure 5.7C). Statistical analysis of automated counts (Figure 5.8) proved 
the increase observed within both EDTA and calcium hydroxide pre-treated 
slices to be significant, both adjacent to the site of treatment (p<0.001) and 
100pm either side (p<0.001). Adjacent to the site of fracture, EDTA appeared 
to induce a greater response than calcium hydroxide, with a slightly higher 
number of bone sialoprotein positive cells observed in EDTA pre-treated 
mandible slices, but this difference was not shown to be significant (p>0.05). 
Negative controls replaced the primary antibody with a non-immune IgG and 
showed no immunoreactivity (Figure 5.7D).
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Figure 5.3: Fractured mandible slices immunohistochemically stained for 
expression of PCNA. Increased cellular expression (examples indicated by 
arrows) can be observed within cells of the periodontal ligament (PDL) in 
mandible slices treated with (A) EDTA or (B) Ca(OH)2, when compared with (C) 
control mandible slices treated with PBS. (D) Negative controls using a non- 
immune IgG exhibits only the methyl green counterstain.
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PCNA expression within fractured mandible slices treated with 
EDTA or calcium hydroxide
* * *
Adjacent to fracture site Left side of PDL Right side of PDL Opposite fracture site
Region of mandible slice
Figure 5.4: Number of PCNA positive cells within various 100pm2 areas of 
periodontal ligament in fractured mandible slices treated with EDTA or CA(OH)2, 
compared with control slices treated with PBS.
*** p<0.001
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Figure 5.5: Mandible slices immunohistochemically stained for expression of 
osteopontin. Increased cellular expression (examples indicated by arrows) can be 
observed within cells of the periodontal ligament (PDL) adjacent to the fracture site 
(F) in mandible slices treated with (A) EDTA or (B) Ca(OH)2 when compared with 
(C) control mandible slices treated with PBS. (D) Negative controls using a non- 
immune IgG exhibits only the methyl green counterstain.
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Osteopontin expression within fractured mandible slices treated with EDTA or
calcium hydroxide
PBS □ EDTA ■ CaOH
2  10 -
Adjacent to fracture site Left side of PDL Right side of PDL Opposite fracture site
Region of mandible slice
Figure 5.6: Number of osteopontin positive cells within various 100pm2 areas of 
periodontal ligament in fractured mandible slices treated with EDTA or Ca(OH)2, 
compared with control slices treated with PBS.
* p<0.05, *** p<0.001
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Figure 5.7: Mandible slices immunohistochemically stained for expression of 
bone sialoprotein. Increased cellular expression (examples indicated by arrows) 
can be observed within cells of the periodontal ligament (PDL) adjacent to the 
site of fracture (F) in mandible slices treated with (A) EDTA or (B) Ca(OH)2 when 
compared with (C) control slices treated with PBS. (D) Negative controls using a 
non-immune IgG exhibits only the methyl green counterstain.
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BSP expression within fractured mandible slices treated with EDTA or calcium
hydroxide
16
PBS □ EDTA ■ CaOH
***
* * *
* * *  * * *
Adjacent to fracture site Left side of PDL Right side of PDL Opposite fracture site
Region of mandible slice
Figure 5.8: Number of bone sialoprotein positive cells within various 100pm2 areas 
of periodontal ligament in fractured mandible slices treated with EDTA or CA(OH)2 
compared with PBS treated control slices.
*** p<0.001
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5.4 DISCUSSION
The previous chapter of work demonstrated that both EDTA and calcium 
hydroxide were capable of releasing growth factors from within the matrix of 
bone, and influencing the behaviour of primary cells cultured on these 
surfaces. This study further developed this work, by demonstrating that 
release of growth factors in response to both EDTA and calcium hydroxide 
could influence cellular behaviour in an ex vivo mandible model system, a 
dynamic system more representative of an in vivo situation. Since both 
chemicals were applied as a pre-treatment, and were subsequently washed 
away from the mandible tissue, it is likely that the findings from this study are 
a result of the released growth factors initiating cellular signalling within the 
tissue, rather than a direct effect of the chemical treatment itself.
Both EDTA and calcium hydroxide pre-treatment significantly increased the 
number of cells within the PDL of mandible slices, adjacent to the site of 
fracture, and also 100pm either side, although to a lesser extent, probably 
due to diffusion of released growth factors through the tissue from the 
fracture site. The increase in cell numbers could be due to an increase in 
migration, or proliferation, or both processes. A number of different growth 
factors may be being released due to the chemical treatments (Finkelman et 
al. 1990; Graham et al. 2006; Zhao et al. 2000), so it is possible that they are 
functioning synergistically to influence cell behaviour (Bolander 1992; 
Bourque et al. 1993; Taipale and Keski-Oja 1997). Immunohistochemistry 
data showed that pre-treatment with both EDTA and calcium hydroxide
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increased the number of PCNA immunopositive cells adjacent to the site of 
fracture, suggesting that proliferation was being influenced by the 
endogenous growth factors. There are a number of growth factors that are 
capable of driving such proliferation of osteoprogenitors, including the FGFs 
(Mansukhani et al. 2000), IGFs (Hughes et al. 2006), and TGF-pi; shown in 
the previous chapter to be released from the matrix after treatment with both 
EDTA and calcium hydroxide, and known to be involved in stimulating 
proliferation of mesenchymal stem cells and osteoprogenitors (Barnes et al. 
1999; Bostrom and Asnis 1998; Centrella et al. 1994). Expression of two 
bone markers, osteopontin and bone sialoprotein, was also significantly 
increased in response to EDTA and calcium hydroxide pre-treatment, 
adjacent to the site of treatment and 100pm either side. This increase in the 
number of immunopositive cells could be due to migration of osteoblastic 
cells expressing these proteins towards the treatment site, or could also be 
due to the released growth factors inducing differentiation of cells residing 
within the PDL close to the site of fracture, increasing protein expression 
(Barnes et al. 1999; Lieberman et al. 2002). The evidence from the histology 
and cell counts, which show a significant increase in cell numbers in 
response to EDTA and calcium hydroxide pre-treatment, may suggest that 
the increase in immunopositivity for PCNA, osteopontin and bone sialoprotein 
is due to these increased cell numbers within the area. However, there was a 
difference in the expression of osteopontin and bone sialoprotein between 
mandible slices pre-treated with EDTA and calcium hydroxide, with a higher 
number of immunopositive cells observed within the PDL of EDTA pre­
treated mandible slices. This difference was not shown to be significant by
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statistical analysis, but this may be because of the small numbers of 
immunopositive cells that are present; any changes observed may not be 
large enough to necessarily be statistically significant. Despite the differences 
in immunopositivity not being significant, it may still indicate that the two 
treatment types have differential effects on cells within the mandible model, 
and may therefore suggest that it is not only an increase in cell numbers that 
is affecting immunopositivity, but that the growth factors released in response 
to chemical treatments are affecting cellular expression of proteins within the 
area. This hypothesis may also support the results found in the previous 
chapter, with EDTA and calcium hydroxide hypothesised to release growth 
factors by a different mechanism: EDTA by chelating calcium ions and thus 
demineralising the matrix, while calcium hydroxide may affect interactions of 
growth factors with the matrix by altering protein charge. It may also support 
the hypothesis that EDTA and calcium hydroxide release a different protein 
profile from bone matrix, as previously shown by Graham and colleagues 
(2006), which may affect the influence each treatment has on cellular 
behaviour; release of different combinations of growth factors or in different 
concentrations may have marked effects on the ability of the treatment to 
affect proliferation, migration and differentiation. For example, a higher 
concentration of released TGF-(31 may induce proliferation and migration of 
osteoprogenitor cells (Barnes et al. 1999), whereas higher concentrations of 
the BMPs may induce differentiation within these cells (Cheng et al. 2003a). 
Within the study by Graham and colleagues, EDTA was shown to be more 
efficient at solubilising growth factors than calcium hydroxide. This may 
explain the slightly higher cellular expression of osteopontin and bone
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sialoprotein observed in response to EDTA within our study. Future work 
could further investigate the effects that these chemical treatments have on 
migration and differentiation, perhaps by utilising microinjection of labelled 
osteoprogenitors into the PDL of mandible slices (Taylor et al. 2008), 
enabling cells to be tracked and giving some indication of their migratory 
paths and differentiation states in response to the different chemical 
treatments.
Comparison of results observed in this chapter with those previously 
obtained from treatment with a single growth factor (either TGF-(31 or BMP-2) 
showed some interesting differences. Treatment with EDTA / calcium 
hydroxide and TGF-p1 / BMP-2 yielded similar results in terms of cell 
numbers and proliferation (PCNA expression). However, pre-treatment with 
EDTA and calcium hydroxide induced a greater increase in osteopontin and 
bone sialoprotein immunopositivity than treatment with either of the single 
growth factors (p<0.001). This may be due to the chemical treatments 
releasing a cocktail of growth factors from the matrix, enabling them to act in 
a synergistic manner and thus eliciting a greater cellular effect than addition 
of single exogenous growth factors (Lieberman et al. 2002; Meraw et al. 
2000; Taipale and Keski-Oja 1997). The half-life of the released growth 
factors may also be different to the single exogenously added growth factors. 
The exogenous growth factors are activated before administration into the 
tissue, via citric acid. The endogenous growth factors released from the bone 
matrix may also be active, if bound to ECM components such as decorin and 
biglycan (Hildebrand et al. 1994). However it is also possible that growth
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factors may be bound and subsequently released in a latent form, requiring 
activation by, for example, proteases within the tissue (Dallas et al. 2002; 
Janssens et al. 2005; Taipale et al. 1992; Todorovic et al. 2005). Since such 
proteases may remain within the ex vivo tissue during culture, it is possible 
that cleavage of growth factor from latent binding proteins could occur within 
the system. The treatments themselves may also participate in the cleavage 
and activation, since previous studies have demonstrated that both strong 
acids and strong alkalis can activate growth factors (Lawrence et al. 1985; 
Lyons et al. 1988). Latent TGF-pi has been shown to have an extended half- 
life compared to active TGF-p1 (Wakefield et al. 1990), and therefore release 
of latent TGF-pi by chemical treatments may explain the greater cellular 
effects seen in terms of osteopontin and bone sialoprotein expression. This 
difference in immunopositivity was only observed immediately adjacent to the 
site of fracture. Immunopositive counts taken from 100pm either side of the 
fracture site yielded no significant differences between slices pre-treated with 
chemicals and those treated with single exogenous growth factors. 
Interestingly, while treatment with TGF-pi or BMP-2 yielded similar 
immunopositive counts both adjacent to the site of fracture and 100pm either 
side, chemically treated slices showed a decrease in immunopositivity further 
away from the fracture site. There may be several reasons for this 
observation. Firstly, it may be due to the method of delivery of the exogenous 
growth factors via agarose beads. The beads, once placed within the fracture 
site and cultured, allow diffusion of the growth factors from within the bead 
into the surrounding tissue. The placement of the beads within the fracture 
site itself enables slight protrusion of the beads into the PDL tissue, and may
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therefore facilitate wider diffusion of soluble growth factors throughout the 
tissue, further away from the site of fracture. Such diffusion of growth factors 
from agarose beads has also been shown in previous studies, both in the 
tooth slice model (Sloan and Smith 1999), and in models investigating the 
role of growth factors in developmental processes (Dudas et al. 2006; Moore 
et al. 2002). It is also possible that the agarose beads may offer a certain 
degree of protection to the growth factors from degradation, keeping the 
growth factors within the bead itself until they diffuse out into the tissue. It 
may also be that the concentration of exogenous growth factors used in this 
study is higher than the concentration of endogenous growth factors that the 
chemical treatments can release from the matrix, allowing the effects to be 
elicited over a greater area. TGF-(31, for example, has been shown to be 
present in vivo in the ng/ml range (Finkelman et al. 1990), significantly lower 
than the pg/ml concentrations of exogenous growth factors required to elicit a 
response within this study. Taken together, these results may suggest that 
the chemical treatments elicit a greater response adjacent to the site of 
fracture in terms of osteoblast differentiation, due to the combination of 
synergistic growth factors they release (Meraw et al. 2000), as indicated by 
an increase in the osteopontin and bone sialoprotein bone markers. 
However, it appears that the agarose bead delivery method allows for greater 
diffusion of the bioactive molecules through the tissue, and may confer some 
degree of protection to the growth factors. It may therefore be beneficial for 
future clinical treatments to investigate either different delivery mechanisms 
of chemical treatments, or to look at a combination of chemical treatment with 
exogenous growth factors, to elicit the greatest cellular response.
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CHAPTER 6
GENERAL DISCUSSION
The main aim of this thesis was to develop and validate an ex vivo rat 
mandible fracture model for investigation of specific cellular and molecular 
processes of bone repair, and to provide a functional model for testing novel 
therapeutic agents for clinical use. Proliferation, migration, activity, and 
differentiation of resident cell types within the model were investigated, 
including the responses of osteoblasts and their progeny, and the effect that 
growth factors have on the responses of these cells. Finally an in vitro bone 
slab cell culture model was developed to demonstrate release of bioactive 
growth factors from within the matrix of bone, and the effect of these 
molecules on primary bone marrow stromal cells.
Central to this thesis was the successful establishment of an ex wVo organ 
culture model, utilising excised slices of rat mandibular tissue, both intact and 
fractured, and subsequent validation of this model system, to establish cell 
behaviour within the cultured tissue. Between 8 and 10 mandible slices could 
be isolated per animal, enabling significant reduction of costs and ethical 
objections over the one animal, one experiment ethos often used for in vivo 
work, and thus central to the 3Rs aim of replacing, refining and reducing 
animal use in scientific research. Intact and fractured mandible slices were 
successfully cultured for up to 21 days, and tissues were shown to remain 
viable after this time period, with maintenance of tissue architecture and
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cellular morphology. The fracturing process did not cause excessive cell or 
tissue damage, and viable populations of cells remained adjacent to the site 
of fracture, with which it would be possible to study early repair processes 
within the model system. Two different culture methods were utilised within 
this study; submerged base type cultures, and Trowel type cultures. While 
both methods are used widely in organ culture techniques, the results 
obtained from this study correlated with previous work suggesting that Trowel 
type culture systems promote viability and tissue morphology, probably due 
to an increased oxygen tension from culture at the liquid-gas interface, and 
optimum nutrient diffusion into all tissues areas from within the three 
dimensional agar medium (Begue-Kirn et al. 1992; Nifuji and Noda 1999; 
Sloan et al. 1998). Resident cells within the mandible tissue slices were 
shown to be actively synthesising and secreting proteins, and cells of the 
osteoblast lineage were shown to survive throughout the culture period, 
essential for future development of the mandible model as an experimental 
system for investigating bone repair processes and for testing novel 
therapeutics. Fracturing of the mandible slices did not significantly alter 
cellular behaviour, suggesting that the mandible model may lack sufficient 
stimulus for initiating repair processes within the bone tissue, in response to 
the fracture alone. However, this thesis has demonstrated that the fractured 
mandible model can respond to stimulation with exogenous growth factors, or 
with chemical treatments to release endogenous growth factors from within 
the matrix, significantly altering the behaviour of cells resident within the 
model.
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In order to develop the ex vivo mandible model as a viable system for testing 
novel therapeutics, it was essential to demonstrate the responsiveness and 
functionality of the model. Mandible slices were firstly stimulated with 
exogenous growth factors TGF-p1 and BMP-2. These were chosen due to 
their role as key players in bone repair processes, but this model could be 
used to investigate any of the wide range of bioactive molecules involved in 
these repair processes (Barnes et al. 1999; Cheng et al. 2003a; Janssens et 
al. 2005; Tsiridis et al. 2007). Both TGF-p1 and BMP-2 were capable of 
affecting the cells within the PDL of the mandible tissue, increasing migration 
/ proliferation, and expression of bone matrix proteins osteopontin and bone 
sialoprotein. TGF-pi however, appeared to have a greater effect on 
migration and proliferation, whereas BMP-2 appeared to have a greater 
effect on osteoblast differentiation, demonstrating that the ex vivo system is 
capable of responding to individual bioactive molecules in different ways. The 
experimental techniques used to establish the model enabled the generation 
of mandible slices of a consistent shape and size, and histology indicated 
that tissue architecture was consistently maintained within slices. The 
experimental results obtained from the model were also highly reproducible, 
with experiments performed on multiple slices yielding consistently similar 
results. This may make the system a valuable tool for both developing 
current therapeutics and testing future ones. These may include biomaterials 
(Benke et al. 2001; Neovius and Engstrand In Press) such as calcium 
phosphate bone cements used in dentistry and orthopaedic surgery (Bohner 
et al. 2005; Ooms et al. 2002), recombinant growth factor therapies 
(Luginbuehl et al. 2004; Malafaya et al. 2002), and novel drug compounds.
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Application of such materials and compounds could be directly to the site of 
fracture, or, as in this study, could be applied using a bead delivery system. 
Alternatively, the materials and compounds could be applied to other areas of 
the mandible tissue, for example directly into the PDL.
Along with the ex vivo mandible model, this study also aimed to develop a 
second model system; an in vitro bone slab culture system, with which to 
analyse release of endogenous growth factors from within the bone matrix, 
and the effects these molecules can have on osteogenic cells. During in vivo 
bone repair, a cocktail of endogenous growth factors are released, 
synergistically eliciting optimal repair processes (Dallas et al. 2002; Hughes 
et al. 2006; Lieberman et al. 2002). It may therefore be beneficial for future 
clinical therapeutics to recapitulate this in vivo process of growth factor 
release. The simplified in vitro system developed was an ideal model to 
demonstrate these principles of growth factor release, before progression of 
this work into the more complex ex vivo mandible system. Using the bone 
slab culture model, this study demonstrated that chemical treatments such as 
EDTA and calcium hydroxide, widely known to solubilise growth factors from 
dentine matrix (Graham et al. 2006; Zhao et al. 2000), can also release 
growth factors from the matrix of bone. Another alkaline agent, sodium 
hydroxide, which has not previously been reported to solubilise growth 
factors, was also shown to facilitate TGF-(31 release. The differences in 
release kinetics between the chemical treatments suggested that the 
treatments may utilise different mechanisms to facilitate growth factor 
release. This study hypothesised that EDTA, together with citric acid, may
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induce local dissolution of mineralised matrix, or act as chelating agents to 
bind calcium ions within the matrix, reducing their activity (De-Deus et al. 
2008). The alkaline agents may alter protein charge, either the charge of the 
growth factors themselves, thus altering their interaction with the matrix, or 
the charge of the matrix proteins that keep the growth factors within their 
bound state. Differences in chemical composition between the alkaline 
agents may account for the differences in their release kinetics. Growth 
factors released by chemical treatments were shown to be capable of 
actively influencing the behaviour of osteogenic cells. Cell number was 
increased through either an increase in adhesion or proliferation, and cells 
appeared cuboidal, with a morphology more resembling mature cells of the 
osteoblast lineage. Expression of the bone markers osteopontin and alkaline 
phosphatase were also increased. When carried out in the ex vivo mandible 
model, treatment of the fracture site revealed similar results to the in vitro 
study, with both EDTA and calcium hydroxide pre-treatment increasing cell 
number, proliferation, and bone matrix protein expression. The release of a 
‘cocktail’ of growth factors by these chemical treatments appeared to elicit 
different effects on cellular behaviour than those seen with single 
exogenously applied TGF-p1 or BMP-2. Chemical treatments appeared to 
have a greater effect on osteoblast differentiation adjacent to the site of 
fracture, suggesting that synergy between various growth factors may be 
important in eliciting optimal repair processes. However, the delivery of 
exogenous growth factors via agarose beads may help protect the growth 
factors from degradation, and appeared to allow greater diffusion of the 
bioactive molecules through the tissue. This may suggest that future clinical
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therapies could benefit from investigating different delivery mechanisms of 
chemical treatments, or combining chemical treatments with exogenous 
growth factors, to elicit the greatest cellular response and stimulate optimal 
healing processes.
The ex wVo model, with cells and tissues cultured in situ in a three 
dimensional microenvironment, is a far more complex system than in vitro 
cell culture, and thus is more representative of an in vivo situation without the 
ethical and financial disadvantages associated with such experiments. 
Therefore the ex vivo model may represent a promising alternative to in vivo 
testing of novel clinical therapeutics, as well as an ideal system for answering 
specific questions about bone repair processes without the complex systemic 
influences found in an in vivo experimental system. The versatility of the 
model also enables further development for a range of uses, for example as 
a system to investigate the processes of bone loss associated with 
inflammatory bone diseases (Taylor et al. 2008), or to assess changes in 
bone remodelling caused by orthodontic forces. The model also allows for 
co-culture with other cell types, for example microinjection of cells into the 
mandible PDL, which will further widen the potential uses of the model. 
Microinjection of preosteoclasts or inflammatory cells, for example, would 
allow investigation of resorptive or inflammatory processes that would in vivo 
be facilitated via the vasculature. The development of this ex vivo mandible 
model may therefore be a useful tool in a wide range of investigations.
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